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Cancer has become one of the biggest threats to human health.  In most 
cases, cancer cells can be differentiated from normal tissues via the 
overexpression of certain cellular membrane proteins.  Improved therapeutic 
effects can be achieved by targeting these specific receptors.  Compared to 
antibody targeting, small molecule targeting strategies have the advantages of 
efficient diffusion and delivery of theranostic agents into tumor tissue.  This 
dissertation focuses on developing novel active targeting small molecule agents 
for cancer diagnosis and therapy.   
The focus of the first study is unique small molecules that bind the TrkC 
receptor, which is overexpressed in metastatic breast cancer (as well as 
gliobastoma, neuroblastoma, and melanoma).  A conjugate of a TrkC ligand and 
the highly cytotoxic alkaloid, maytansinoid, was prepared.  Cellular studies 
featuring TrkC+ and TrkC- human breast cancer cells indicated this conjugate 
might have a better therapeutic effect than the maytansinoid alone.  It emerged 
that the conjugate was very efficacious in vivo, completely ablating orthotopic 
4T1 breast tumor in one case, and dramatically reducing the tumor size in four 
other mice.   
The second study is based on a small sub-set of heptamethine (Cy7) 
dyes that are preferentially uptaken into tumors, then, in some cases, retained 




(above 750 nm), and deliver cargoes to various tumor models in vivo, offering 
theranostic effect.  This study describes how four heptamethines were 
synthesized, all having the gemcitabine fragment attached to the meso-position 
of the Cy7 core.  One theranostic agent localized in glioblastoma tumor cells 
with absorption maxima in NIR region and showed similar therapeutic effect to 
gemcitabine, but at one-third the molar dose.   
The third study describes work aimed at discovering a novel targeted 
small molecule from a one-bead one-compound (OBOC) combinatorial library.  
Two different screening protocols were established and the on-bead compounds 
were effectively decoded with an extended linker and step-wise partial capping 
strategy.   
Some other efforts related to developing novel theranostic agents by 
targeting cancer cell surface receptors are also recorded.  These either did not 
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CHAPTER I  
INTRODUCTION  
 
1.1 Characterizing, locating, then treating primary and metastatic tumors is 
crucial in oncology.   
Tumors are usually characterized by the overexpression of certain 
proteins on cancer cell surfaces.  One example featured in this dissertation is 
the tropomyosin receptor kinase (Trk) proteins.  There are three main sub-types 
of Trk proteins (TrkA – C), each having a preferential natural ligand 
(neurotrophin).  TrkA, B and C binds preferably to nerve growth factor (NGF), 
brain derived neurotrophic factor (BDNF), and neurotrophin-3 (NT-3) 
respectively.1-3  Interaction of neurotrophins with cells expressing the Trk 
receptors is associated with cell proliferation and survival.4,5   
Targeting probes that specifically recognize and bind to specific cell 
surface proteins can help with active delivery of diagnostic and therapeutic 
agents into cancer cells.  This active targeting6 strategy is useful in 
characterizing, locating and treating cancer.  Active targeting can be achieved by 
small molecules that bind receptors or large molecules (i.e. antibodies).   
Monoclonal antibodies (mAbs) are commonly used as targeting probes in 
cancer diagnosis and treatment, because of their high binding affinity and 
selectivity to the targeted protein on cancer cell surface.  Four antibody-drug 




(FDA) and are commercially available in the US for cancer treatment: 
brentuximab vedotin (Adcetris®, Seattle Genetics),7,8 ado-trastuzumab 
emtansine (Kadcyla®, Genetech/Roche),9 inotuzumab ozogamicin (Besponsa®, 
Wyeth Pharmaceuticals),7,10   and  gemtuzumab ozogamicin (Mylotarg®, Wyeth 
Pharmaceuticals).10,11  More ADCs are being tested in clinical trials.12,13   
Active targeting with mAbs has obvious limitations.  Solid stress in tumors 
compresses blood vessels within them, which makes it particularly hard for large 
biomolecules to permeate.14  Tumor vasculature tends to be immature, leading 
to reduced pressure gradients and heterogeneous blood flow15,16 while tumor 
hydrostatic pressure is high, disfavoring convective drug transfer from blood 
vessels.  Most mAbs do not penetrate tumors with efficient diffusion.  MAbs that 
do diffuse into tumor tissue tend to be trapped by antigens located on the 
perivascular tumor cells,17 an “antigen barrier”,18-20 even around 
micrometastases.18  Moreover, slow clearance of mAbs from the body results in 
high normal tissue exposure15,16,21 leading to accumulation in the excretory 
organs; this can lead to toxicity effects and reduces the dose that reaches the 
target.22,23  However, small molecules that bind specifically to cell surface 
receptors can diffuse into tumor tissue easily and have a negligible influence by 
the antigen barrier.24  Small molecules are also non-immunogenic, accessible 






1.2 Small molecule therapeutic drugs applied in research and clinical use 
Many small molecule compounds have been approved by FDA for 
chemotherapy of solid tumor and metastasis, and some of them are suitable for 
conjugation with targeting moieties to act as a therapy “warhead”.  They possess 
different mechanisms to inhibit cancer cell proliferation and migration, increasing 
the diversity of targeted chemotherapy.  A few examples are highlighted here 




Figure I.1. Chemical structures of illustrative small molecule therapeutic drugs.  
 
Doxorubicin intercalates between two base pairs of the DNA double helix, 
and inhibits the progression of topoisomerase II, which disrupts DNA replication 
and transcription.25-27  Docetaxel is a semi-synthetic analogue of paclitaxel.  It 




preventing mitotic cell division.28  Gefitinib, trade name Iressa, is an inhibitor of 
the epidermal growth factor receptor (EGFR), which selectively inhibits its 
tyrosine kinase domain.29  EGFR is overexpressed in most human cancers, 
including lung and breast. Anti-apoptotic pathways are activated by 
overexpressed EGFR, and induce cell proliferation.  Gefitinib can selectively 
inhibit EGFR, hence cause apoptosis in tumor cells.  Other small molecule 
therapeutic agents are under investigation in clinical trials and research.   
Another way to kill cancer cells is by phototherapy that requires light, 
photosensitizers and singlet oxygen generation.  Iodinated BODIPY,30 a 
photodynamic therapy (PDT) sensitizer, can generate toxic reactive oxygen 
species (ROS) and result in cell apoptosis after proper light illumination.  It first 
absorbs light to reach the singlet excited state.  Intersystem crossing (ISC) 
occurs to turn the sensitizer into triplet excited state.  Energy transfer (ET) 
between the PDT sensitizer in triplet state and triplet oxygen produces singlet 
oxygen, which can oxidize cell components and induce cell death.   
 
1.3 Active targeting molecules for proteins on cancer cell surface 
Typical small molecule targeting agents (e.g. androgen,31 folate,32-34 and 
biotin35) are of natural origins.  Relatively few synthetic small molecules have 
been discovered for active targeting (Figure I.2).  Arginylglycylaspartic acid 
(RGD) peptide analogues recognize various integrins on cancer cell surface.36-39  




overexpressing carbonic anhydrase IX (CAIX).40  Previous work in our group 
also revealed a synthetic bivalent small molecule targeting moiety IY-IY that 
selectively binds to TrkC on metastatic breast cancer cells.41,42   
If we expand the scope to larger peptides and peptidomimetics, some 
other interesting targeting ligands have been discovered via high throughput 
screening (HTS) of combinatorial libraries.  AE105, a selective binder to 
urokinase receptor (uPAR), was discovered from a phage display peptide 
combinatorial library.  A modified derivative, AE147, has improved aqueous 
solubility but has slightly weaker binding affinity.43-45  Peptidomimetic LLP2A 
specifically interacts with α4β1 integrin, and accumulates in α4β1 expressing 
tumors in vivo.46  Peptoids GU40C and GU40E bind to vascular endothelial 
growth factor receptor 2 (VEGFR2) with dissociation constants in the low micro 
molar region.47   
Most of small molecule targeting fragments have good binding affinity to 
their protein targets, but compared with mAbs, there are relatively few of them.  
The diversity of protein expression on cancer cell surface requires more efforts 
to discover novel small molecules that bind to protein targets with improved 








Figure I.2. Chemical structures of featured active targeting molecules and their 








Figure I.2. Continued.   
 
Computational analyses can be useful in designing novel small molecules 
for active targeting.  A computational strategy created by our group, exploring 
key orientations on secondary structures (EKOS),48 is developed to compare 




ideal secondary structures.  Once a virtual fit is found, Glide and CombiGlide49-52 
can guide the backbone modification and fragment extension in molecule design.   
In Chapter II and III of this dissertation, novel targeting small molecule 
drug conjugates for treatment of metastatic breast cancer and glioblastoma were 
synthesized.  Therapeutic effects have been successfully applied in vitro and in 
vivo.  Moreover, in Chapter IV, a small molecule combinatorial library has been 
prepared and screened to discover novel small molecules that selectively bind to 






CHAPTER II  
TARGETED MAYTANSINOID CONJUGATE IMPROVES THERAPEUTIC 
INDEX FOR METASTATIC BREAST CANCER CELLS* 
 
2.1 Introduction 
Cancer is not a single disease.  Primary tumors originating from the same 
organ but in different individuals express different profiles of cell-surface 
receptors, and those fingerprints indicate prognoses and treatment strategies for 
personalized care.53  Breast cancer, for instance, can be classified in terms of 
expression of the ER, PR, and HER2.54,55 If all three of these receptors are not 
expressed (triple negative), the tumor has a high tendency for metastatic spread 
and the prognoses is relatively poor.  It is unlikely that profiling for just these 
three receptors, however, is optimal for all breast cancer types.   
Cell surface receptors overexpressed on breast (and other) types of 
cancers can be used to favorably skew the pharmacokinetics of drug binding, to 
increase the local concentration of chemotherapeutics around the tumor, 
minimize damage to surrounding healthy tissues, and thereby increase 
therapeutic index (Figure II.1).  This is important because therapeutic windows 
for cytotoxic substances that are not directly targeted to tumor cells are 
 
*Reprinted with permission from Jiang, Z.;  Yang, Z.;  Li, F.;  Li, Z.;  Fishkin, N.; 
Burgess, K., Targeted Maytansinoid Conjugate Improves Therapeutic Index for 
Metastatic Breast Cancer Cells. Bioconjugate Chem. 2018, 29, 2920-2926. 




notoriously narrow, and this severely limits dose levels that can be administered 
to patients without serious side effects.  Directing cytotoxic drugs to cancer cells 
via cell surface receptors is “active targeting”, which in this article we abbreviate 
to “targeting”.   
 
 
Figure II.1. Active targeting can increase therapeutic indices by increasing the 
potency and decreasing the toxicity of a warhead in a conjugate.  Reprinted with 
permission from [217].  
 
Humanized monoclonal antibodies (humAb) raised to receptors 
expressed on the surface of cancer cells have proven therapeutic value.  For 
instance, one of the first FDA approved humAb’s for breast cancer, trastuzumab 
(Herceptin®), binds HER2 extracellular domain and downregulates cell signaling 
pathways that lead to proliferation.56,57   This development paved the way to the 
first mAb-drug conjugates to be FDA approved for solid tumors: ado-
trastuzumab emtansine (Kadcyla®) which is typical of a now-broader class of 
antibody drug conjugates (ADCs) that are used to treat patients today for various 
forms of cancer.58  Ado-trastuzumab emtansine has a dual function: the mAb 
part binds HER2 and inhibits proliferation, while the emtansine cargo (emtansine 




maytansinoid13,60) is preferentially delivered to tumors over healthy tissue.9,61  
Thus ado-trastuzumab emtansine localizes the maytansinoid in tumors, 
decreasing the therapeutic dose of that cargo relative to the free macrolide, 
increasing the maximum tolerated dose by suppressing the cytotoxicity of the 
cargo until it is liberated, thus raising the therapeutic index of the ADC relative to 
the parent maytansinoid.    
There are intrinsic advantages and disadvantages to ADCs.  One major 
attribute is that methods to generate mAbs to cell surface receptors, and others 
to humanize them, have high success rates.62  A second advantage is that 
mAbs have high affinities for the targeted receptors.  Paradoxically, those high 
affinities (and the size of Abs) mean that mAbs tend to accumulate around the 
surface of tumor cells where they first encountered receptor antigens and 
compressed vascular structure prevents permeation to the tumor core.17  Thus 
solid tumors are said to possess “antigen barriers”.18-20  Secondly, relatively slow 
in vivo clearances of mAbs mean that ADCs tend to remain in circulation outside 
tumors where they can damage healthy tissues, decreasing their therapeutic 
indices.15,16,21  A third major limitation originates in the difficulties encountered 
when attempting to obtain batch-to-batch reproducibility with the same Ab to 
cargo payload.   
Maytansine alkaloids (like that in ado-trastuzumab emtansine) are one of 
the extremely cytotoxic cargoes favored in development of ADCs.58  In cells, 




inhibiting cell division.63  Free maytansinoids tend to be too toxic for 
chemotherapy; in clinical trials from 1977 to 1984, they were evaluated in 35 
different types of tumor in over 800 patients, but complete response was only 
found in one case and partial response in a few others.13  Maytansinoids are too 
destructive to healthy tissue to be used safely without conjugation, but they are 
ideal for targeted approaches.   
Small molecule targeting agents have entirely different, and 
complementary, disadvantages and advantages relative to ADCs.64  First, the 
pool of molecules that bind appropriate cell surface receptors is relatively small, 
hence the number of appropriate targets is limited.65,66  Affinities of small 
molecules for cell surface receptors tend to be lower than mAbs binding the 
same targets, but this, and the fact that their lower molecular masses lead to 
more rapid and extensive distribution in vivo, and allow them to cross antigen 
barriers and permeate throughout tumor interiors.24  Moreover, small molecules 
having targeting and cytotoxic fragments tend to be more rapidly cleared in vivo 
than ADCs hence minimizing their relative damage to healthy tissues.  Other 
factors that also favor use of small molecule targeting groups include cost, shelf-
life, batch-to-batch reproducibility, lack of ambiguity when conjugating cytotoxic 
cargoes,67 and the fact that even Abs can cause side-effects related to residual 
immunogenicity.   
Folate,68 carbonic anhydrase IX,40,69 and prostate-specific antigen ligands 




maytansinoid derivatives.  However, for breast cancer, prostate-specific antigen 
ligands are not applicable, the levels of folate receptor expression tend to be 
low,71 and small molecules that target other receptor types may have useful 
complementary properties.   
Some work from our laboratories have focused on using the tropomyosin 
kinase receptor C (TrkC) to target breast cancer3,72 (and melanoma73).42,74  More 
particularly, there is a good correlation between overexpression of TrkC and 
metastatic breast cancer.1,75-80  Throughout we have used a bivalent dipeptide 
mimic designed in these laboratories to bind TrkC; these are the blue parts of 
structure 1.81  An isomer of 1 that has the Ile- and Tyr-like side chains reversed 
(green fragments in 2) does not bind TrkC and is therefore a useful control for 
non-specific binding.  All our previous work features photodynamic therapy 
(PDT).82,83  Active targeting in PDT involves accumulation of the ligand in tumors, 
and illumination of those regions; areas that are not illuminated incur less tissue 
damage, hence there is overall a double targeting effect74 that increases the 
therapeutic index.   
Research reported in this paper describes, for the first time, use of the 
TrkC-targeting ligands to deliver a conventional cytotoxic compound in vivo, i.e. 
without PDT.  Specifically, the cargo used is the maytansinoid DM4 (DM1 and 
DM4 differ only in that the thiol is connected directly to a methylene, or an 
extended CMe2 group, where disulfides from the latter have more favorable 




TrkC receptors are found on healthy tissues in the nervous system; (ii) 
maytansinoids are extremely toxic as discussed above; and, (iii) there would be 
no double targeting effect (unlike our work on active targeting in PDT).  In the 
worse possible case, TrkC-targeted maytansinoids might negotiate the blood 
brain barrier and cause catastrophic neurotoxicity issues.  In the event, however, 
the data collected here reveals that was not the case, and a significant reduction 
in the size of orthotopic TrkC+ tumors was observed in mice treated with agent 1.   
 
 
   
 
2.2 Results and Discussion 
Initial experiments were performed to establish the affinity of the TrkC 




the fluorescently labeled derivative A3 on live NIH3T3 cells stably transfected 
with TrkC (Figure II.2).   Fluorescence labeling of the cells was measured in the 
absence (blue line) and presence (red) of a large excess of the unlabeled TrkC-
targeting group B.41,81,85  Extent of specific binding in these experiments is 
revealed by subtraction of fluorescence with the blocking group B from the 
corresponding data without it.  Analysis of the data revealed a Kd value of 112 ± 
74 nM.  A lower Kd value would have been preferable for active targeting, but we 
decided this affinity was sufficient to justify synthesis of the key compound.    
 
     
 
Figure II.2. Cell-based compound dissociation constant measurements 
indicated Kd = 112 ± 74 nM, based on three parallel experiments, calculated 




Scheme II.1 outlines how a known amino disulfide86 was added to 
cyanuric chloride in the first of three SNAr displacements, wherein the last two 
involved coupling of the TrkC targeting groups C.41 Comparison of NMR data for 
DM4 and the conjugate 1 indicated the coupling step had proceeded without 





Scheme II.1. Synthesis of the cleavable targeted DM4 conjugate.  Reprinted 























































Experiments were then performed to assess the solubility and stability of 
the conjugate 1 in pertinent aqueous media.  Maytansinoid DM4 is hydrophobic 
hence it was impossible to dissolve 1 in buffer at the required concentrations.  
Consequently, following literature precedent87 the solubility of the maytansinoid 
derivative 1 was measured in pH 7.40 phosphate-buffered saline (PBS) with 9% 
ethanol, 1% DMSO and 0.5% cremophor EL (CrEL).  Thus, using a UV-plate 
reader assay88 gave data (Figure II.3a) indicating a solubility of 67 M.  Figure 
II.3b indicates that conjugate 1 has a half-life of over 40 h in DMEM culture 
medium or pH 7.40 PBS at 37 °C.    
 
 
Figure II.3. a Solubility of 1 in pH 7.40 PBS with 9% ethanol, 1% DMSO and 0.5% 
CrEL.  b Stability of 1 in either DMEM culture medium or pH 7.40 PBS at 37 °C 
as evidenced by analytical HPLC (initial concentration 20 μM).  Reprinted with 
permission from [217].    
 
Cell assays were performed on 1 and 2, to determine if in vivo studies 
were clearly justified.  Data collected for these experiments are shown in Figure 





respectively).  Throughout, DM4 was the most toxic compound, hence the types 
of conjugates featured here (1 and 2) have reduced cytotoxicity relative to DM4.  
To our surprise, the isomeric control 2 was marginally more toxic, even for TrkC+ 
cells (IC50 values for: 1, 28.1 ± 1.9 nM; and, 2, 23.0 ± 2.5 nM).  However, Figure 
II.4c shows that the reduction of cytotoxicity for conjugate 1 was sufficient to 
outweigh its less absolute cytotoxicity affording it a superior therapeutic index in 




Figure II.4. Cytotoxicity and cellular therapeutic index comparison.  a and b 
Dose responses of DM4, 1 and 2 on human breast cancer cell lines Hs578t 







material.  c Calculated in vitro therapeutic index based on IC50 values {IC50 
(MCF-7) / IC50 (Hs578t)}.  Reprinted with permission from [217].   
 
After binding to TrkC proteins on a cell surface, the conjugate 1 is 
uptaken into lysosomes via endocytosis,74  then free DM4 can be released via 
intracellular reduction of the disulfide bond.61  Released maytansinoid DM4 
inhibits microtubule function in targeted tumor cells, causes cell cycle arrest, and 
eventually causes cell death by apoptosis.89  In any event, cellular therapeutic 
indices are determined in static systems, whereas pharmacokinetic effects 
involve dynamic flow of fluids around tumors.  In other words, cellular 
therapeutic indices do not reflect the positive effects active targeting has on 
pharmacokinetics in vivo.  For these reasons, an in vivo study was initiated.   
 
 
Figure II.5. Body weight changes after single i.v. injection of DM4 and 1 (n = 3).  







Figure II.6. In vivo therapy study of maytansinoid conjugates 1 and 2.  a Tumor 
growth curves of 4T1 xenograft bearing mice injected with 7 x 30 nmol 1 as 
therapy group and 2 as control group.  Data represent mean ± SD (n = 5 per 
group).  * indicates one mice of the five tested was cured of tumor in the therapy 
group.  b Weight change of mice shown in a.  No animals were observed with 
weight loss >15% throughout the therapy study.  c Tumors collected from in vivo 





each arrow marked injection day, the compounds were reconstituted into PBS 
buffer and injected into mice via tail vein.)  Reprinted with permission from [217].  
 
In vivo toxicity study was carried out using Balb/C mice to compare 
maytansinoid DM4 and TrkC targeted maytansinoid conjugate 1 at dose of 30 
nmol and 100 nmol per mouse (n = 3) via a single intravenous (i.v.) injection.  
We found that mice lost about 10% of body weight at 30 nmol and over 20% of 
body weight at 100 nmol in DM4 group, whereas no significant weight loss in 1 
group at both doses was observed (Figure II.5).  This result demonstrated that 
TrkC targeted delivery of toxic compound DM4 dramatically reduced systemic 
toxicity as we expected.   
Therapeutic efficacy of targeted maytansinoid conjugate 1 was 
investigated using 4T1 tumor bearing mice.  A scrambled non-targeted 
maytansinoid conjugate 2, which does not bind to TrkC, was synthesized and 
used as a control comparison.  As shown in Figure II.6a, the administration of 1 
efficiently suppressed tumor growth comparing to the control conjugate 2, which 
was evidenced by the outcomes that one tumor out of five was cured and the 
other four were significantly decreased compared with the control group.  It 
strongly supported our hypothesis that conjugating toxic agent such DM4 with 
targeting agent IY significantly promoted therapeutic efficacy in tumor targeting 
therapy.  Meanwhile, animal body weight was also monitored throughout the 




of its initial weight throughout the study.  It suggests that the administration of 
the therapeutic conjugate 1 was well-tolerated by the animals.   
 
2.3 Conclusions 
Expression of ER, PR and HER2 are usually applied to classify breast 
cancers.  This is convenient for predicting prognoses and guiding some 
treatment strategies.  However, that does not mean active targeting of other cell 
surface receptors in breast cancers is not viable.  This work establishes that a 
TrkC ligand with a modest receptor affinity (~112 nM) can be used to deliver a 
cytotoxic cargo.  Unlike our previous studies featuring PDT, this strategy does 
not have the advantages of double targeting, but nevertheless it is effective 
against orthotopic 4T1 tumors in mice.  The approach outlined here is 
complementary to active targeting of ER, PR and/or HER2, and, based on the 
literature outlined here, probably also to mAb approaches in terms of tumor 




CHAPTER III  
CYANINE-GEMCITABINE CONJUGATES AS TARGETED THERANOSTIC 
AGENTS FOR GLIOBLASTOMA TUMOR CELLS 
 
3.1 Introduction 
Glioblastoma multiforme (GBM) forms aggressive malignant tumors, and 
patients with this disease have a five-year survival rate of only 5.1%.90  There 
are only four FDA approved drugs for brain tumor therapy: temozolomide (TMZ 
or Temodar®, 2005),91 lomustine (Gleostine®), carmustine (BiCNU®), and 
bevacizumab (Avastin®, 2017).92  Combination of TMZ and radiotherapy is the 
standard of care for GBM, but more effective therapies need to be established 
since the median survival is 14.6 months, and this requires new strategies to 
generate pre-clinical leads.93,94   
Gemcitabine (dFdC, or gem) acts against a wide range of solid tumors 
(FDA approved for breast, non-small cell lung, ovarian, and pancreatic).93,95  In 
cells, a triphosphate is formed from this nucleoside, i.e. dFdCTP; that 
triphosphate competes with deoxycytidine triphosphate (dCTP) hence acts as a 
DNA chain-terminator.  Simultaneously, the corresponding diphosphate 
(dFdCDP) inhibits ribonucleotide reductase (RNR) leading to more favorable 
gemcitabine:dCTP ratios in cells, improving gemcitabine’s efficacy.  
Nevertheless, the efficacy of gemcitabine could be improved, especially for 




for GBM,93,98 but the in vivo therapeutic response tends to be relatively poor for 
several reasons.93  First, penetration through the blood-brain barrier (BBB) is low; 
even in the brain-tumor-bearing animals where the BBB may be leaky.99,100  
Secondly, gemcitabine has a short half-life due to enzyme metabolism.95,96  
Third, gemcitabine is not actively targeted101 to tumors versus healthy tissue.   
A small set of heptamethine cyanine dyes localize in tumors (MHI-148, A; 
IR-783, B; DZ-1, C; and, IR-780, D).102-107  The literature on actively targeted101 
small molecule gemcitabine derivatives108-110 features an example of a conjugate 
to one of these tumor-seeking fluorophores (C) tested on GBM, i.e. NIRG, E.104  
In mouse models, both E and its parent fluorophore C localized in intracranial 











Figure III.1. Continued.  
 
All four fluorophores A – D that show the remarkable tumor-seeking effect 
described above have a meso-chloride.  This led us to wonder if a gemcitabine 
conjugate formed by displacing this chloride thereby rendering the conjugate 
unable to form a covalent complex with albumin, would also localize into tumors 
in vivo, and, if so, if it would persist there.  To test these ideas, the meso-
gemcitabine adducts 1 were designed here.  We hypothesized these conjugates 




important for short term uptake, but unlike A, they would not persist in tumors in 
vivo for long periods because they cannot form covalent adducts with albumin.  
Consequently, we set out to test if these assertions were true, and to 
simultaneously probe therapeutic effects of 1 in a mouse subcutaneous 
xenograft model.   
 
3.2 Results and Discussion 
3.2.1 Synthesis, Ex Vivo Stabilities, and Cellular Studies 
Conjugates 1a – d were prepared by substitution of the meso-Cl in their 
parent heptamethine cyanine dyes A – D111 using the gemcitabine derivative 
F108 (Scheme III.1 and E.1) as nucleophile.  Parent dyes A – D and their 
corresponding conjugates 1a – d showed similar fluorescence quantum yield 
and UV absorption characteristics (Table E.1 and Figure E.1); consequently, 
they have maximal absorbance at good wavelengths, around 795 nm, and 
sufficient brightness for in vivo diagnostic imaging.    
 
 











heptamethine A - D







Literature evidence indicates gemcitabine modifications at the exocyclic 
amine group do not adversely reduce its cytotoxicity.95,118  To verify this in the 
current study, we measured the cytotoxicities of gemcitabine and intermediate F 
with respect to U87 glioblastoma cells.  The data obtained in these experiments 
were very similar (IC50: gem, 8.2 ± 1.7; F, 11.0 ± 1.4 nM; Figure E.7a) indicating 
formation of the conjugate did not significantly impact the efficacy of the 
gemcitabine component.    
Several experiments were undertaken to test the stabilities of an 
illustrative conjugate, 1a, when incubated in physiological media.  Thus, U87 
tumor tissue from control mice (featured in the in vivo experiments described 
below) was cut into small pieces, homogenized (1 g tumor per mL RIPA buffer) 
then mixed with 1a; the stability of 1a was followed by analytical HPLC using 
detection at 780 nm corresponding to the fluorophore absorption maxima.  
Under these conditions the compound had a half-life of around 60 h at 37 °C 
(Figure III.2a).  The half-life of 1a was even longer when it was incubated with 
tumor cell lysate (4 million cells lysed with 1 mL RIPA buffer).  These data imply 







Figure III.2. Conjugate stability of 1a in physiological conditions.  Tumor tissue 
or cultured U87 cells were homogenized with RIPA buffer on ice before 
centrifuging down to collect supernatant.  Conjugates were incubated at 50 μM 
at 37 °C for up to 72 h.  % Compound remaining was calculated based on area 
under curve from the analytical HPLC trace through a C4 column (Figure E.4).  a 
Conjugate stability of 1a in U87 tumor homogenate and U87 cell lysate; b in 
serum in vitro at 37 °C, conjugate 1a was metabolized to a new compound in ~3 
h; and, c half-life of 1a in mouse serum at 37 °C was determined to be ~1 h.  









Figure III.2. Continued.  
 
The relevance of experiments featuring cell lysates and tumor 
homogenates to pharmacokinetics is tenuous, but in vitro stability tests in serum 
at 37 °C probably have more physiological relevance.  These experiments show 
the conjugate was metabolized to a new compound in 3 h with relatively high 
fidelity (Figure III.2b), via a process that was inhibited by a mixture of proteases 
and phosphatases (Figure E.5b), and was also inhibited at lower temperature 
(Figure E.5c).  Mass spec analyses (Figure E.6b) showed the metabolite had a 
molecular mass corresponding to the amide hydrolysis product 5.  That 
assertion was proven by HPLC analyses involving “spiking” the metabolite 





Thus the amide bond in 1 that connects gemcitabine to the rest of the conjugate 
is vulnerable to proteolysis in serum in vitro giving it a half-life of approximately 1 
h at 37 °C (Figure III.2c).   
Overall, we concluded that short-term intracellular confocal imaging 
experiments featuring compounds 1 would be indicative of intracellular 
localization of the conjugates, and not simply track free fluorophore liberated 
from the nucleoside.   
 
 
Figure III.3. Conjugate 1a uptake and subcellular localization in U87 cells at 
37 °C.  Pearson’s correlation coefficient (PCC) for co-localization between red 
(1a) and green (organelle stain) fluorescence was 0.74 with mitochondria, and 
0.62 with lysosomes.   
 
Data collected from confocal imaging of 1a is illustrative of that obtained 
for all the samples in the series 1a – d (Figures III.3 and E.2).  Throughout, 
colocalization in the lysosome and mitochondria was uniformly observed (just as 











accumulation in the mitochondria.  Mitochondrial localization, and, by inference, 
escape from the lysosome, is probably favorable with respect to cytotoxicity, so 
conjugates 1a, 1b, and 1d only were considered beyond this point, and 1c was 
excluded because it did not appear to escape from the lysosome.   
Cytotoxicity data for 1a, 1b, and 1d were measured, and comparisons 
made with reference compounds 2 which were specifically prepared for this 
purpose (Scheme E.2).  Conjugates 2 feature the same dye as the key 




Cytotoxicity data for the gemcitabine-derivative 1d relative to its cytidine 
control 2d led us to exclude this compound from further studies, for the following 
reasons.  Both the free dye D and the control 2d are cytotoxic at <10 μM, 
whereas none of the other dyes A – C are at these levels (Figures E.7b and 
III.4a).  Moreover, compounds 1a and b proved to be significantly more toxic 




(Figures III.4b and c).  Conjugates 1a and b were less cytotoxic than 
gemcitabine, but the difference was not great because all three of those 
compounds were observed to have IC50 values in the 0.01 – 0.02 μM range.  
The cytotoxicity of gemcitabine on U87 cells has some variance,119 and often 
stabilizes at certain values before 100 % apparent cell death;98 consequently, for 
the purposes of this study, the IC50 values quoted throughout are calibrated 
relative to the lowest concentration beyond which no further cell death appears 
to occur.  On the basis of these data either compound 1a or b could have been 
selected for in vivo studies; conjugate 1a was in fact chosen because there is 
literature120 that indicates A has a superior tumor-to-muscle imaging contrast 
index relative to B.   
 
 
Figure III.4. Cytotoxicity of conjugates 1, their cytidine analogs 2, and their 
parent dyes.  a Compounds 2d and D were shown to be significantly toxic below 
10 μM (IC50: 2d, 3.4 ± 0.4; D, 7.1 ± 1.7 μM).  Conversely, in the sets 1a, 2a, and 
A, and 1b, 2b, and B, gemcitabine and compounds 1 are significantly more 
cytotoxic than the controls 2 and the free dyes (Figure III.4, parts b and c, 







Figure III.4. Continued.   
 
3.2.2 In Vivo Studies 
A xenograft mouse model was used to examine the effects of lead 
compound 1a on tumor growth in vivo. U87 glioma cells stably expressing 
luciferase and RFP reporters (U87-luc-RFP) were injected subcutaneously into 
the flanks of Fox1nu mice.  In the key experiments, the test compound (1a or 
gem, 10 mg/kg) or vehicle control were administered intravenously via retro-






6 injections.  No significant body weight loss was observed among mice in all 
treatment groups (Figure E.10).  Tumor burden was evaluated using weekly 
bioluminescent imaging of mice 1 – 5 weeks after drug or vehicle administration.  
Administration of 1a or gem significantly reduced tumor burden (Figure III.5).  
There was no significant difference in tumor size in mice injected with gem or 1a 
on mg/kg basis, but in terms of moles of drugs delivered, 1a afforded the similar 
effect at under a third of the dose of gem (molecular weight of 1a, 1034.6, is 
3.45 times greater than gemcitabine hydrochloride, 299.66).   
 
 
Figure III.5. Therapeutic effect of 1a.  a Luminescence images of mice harboring 
U87-RFP-Luc subcutaneous tumors and treated with indicated compounds were 
acquired with an IVIS Spectrum in vivo imaging system (Perkin Elmer®) at 2 and 
5 weeks post drug administration.  b Mean tumor size (cm2) with SEM over a 5-
week period post drug administration (n = 3).  Two-way ANOVA with Bonferroni 
posttest shows statistically significant differences between 1a (or gem) and 
vehicle control group at 4 weeks (**p < 0.01) and 5 weeks (***p < 0.001).  c 
Mean tumor luminescence (photons per second, p/s) with SEM over a week 
period (n = 3).  Two-way ANOVA with Bonferroni posttest shows statistically 
significant differences between 1a or gem and the vehicle group at 5 weeks (p < 
0.001).   










Figure III.5. Continued.   
 
Localization of 1a in vivo was monitored by fluorescence imaging of 
tumor-bearing mice at different time post-injection.  Cyanine fluorescence was 
observed throughout the mice 30 min after drug injection, with maximal signal in 
the liver and tumor, and at the site of injection (retro-orbital vein; Figure III.6a, 
mice 1 – 4).  Conjugate 1a mostly cleared from the mouse after 24 h (Figure 






signal that was ~10-fold lower than the signal observed at 30 min post-injection 




Figure III.6. Localization/clearance of 1a in vivo.  a Mice were injected with 10 
mg/kg 1a with an uninjected control (last mouse in each view); images were 
taken at 0.5, 1, 2, 24, 48, and 144 h after intravenous injection, and their 
fluorescence intensities are normalized to be on the same scale.  b Images at 
10x lower scale show persistence of fluorescence in 1a-treated mice indicating 
residual drug localization over extended periods.   
 
Tumor tissue and organs of the mice injected with 1a were dissected and 
imaged to further visualize the localization of the drug conjugated to the 
fluorescent dye.  One of the 1a-treated mice was analyzed 2 h after intravenous 
injection; the fluorophore had localized to the tumor as well as the intestines, 
kidneys, liver, and lungs (Figure III.7a).  Two days after injecting 1a, some signal 
a
0.5 h 1 h 2 h
24 h 48 h 144 h
b




was still detected in the tumor, and significant signal was also observed in the 




Figure III.7. Localization of 1a postmortem via fluorescence imaging on tissues: 
a  dissected 2 h after intravenous injection of 1a; and, b removed from 1a-, gem- 
and vehicle-injected mice 2 d after intravenous injection.   
 
3.3 Conclusions 
Data presented for above indicate the conjugate 1a hydrolyzes with a 











































































fluorophore 5.  However, fluorescence in the tumor implant is near maximal 
around 30 min after intravenous injection, indicating that some of conjugate 1a is 
imported into tumor cells in vivo.  This assertion is consistent with the 
observation that the molar efficacy of the conjugate is significantly greater than 
gemcitabine with respect to reduction of tumor burden in these models.  
Conjugate 1a is cleared from the tumor more quickly than the literature 
conjugate E104 and other fluorophores like MHI-148 that feature a meso-Cl,121 
consistent with our original hypothesis.   
Conjugate 1a comprises a Cy7 dye framework; a similar compound, but 
based on a Cy5 core, has been reported: G.  Conjugate G localized in tumors 
(from SGC7901 gastric carcinoma cells and decreased their volume), but the 
decrease does not appear to have been compared to a gemcitabine control.122  
Conjugates such as these based on a Cy5 core (max em
 ~655 nm) are more 







In related studies, we111 and others117 have found Cy7 dyes with a meso-
chloride react with albumin (t1/2 ~30 min at 37 °C) to give a covalent adduct.  
Displacement of meso-chloride is impossible for conjugates 1 (they do not have 
a meso-Cl) but it can for structure E.  In previous work we have shown that dyes 
in this series that have a meso-chloride can form conjugates with serum albumin, 
and the albumin adducts persists in tumors for extended periods.112,117 Thus the 
presence of a meso-Cl, covalent albumin binding or not, manifests itself in this 
study by the residence time of the fluorophore in the tumor.  Data here also 
shows that the amide bond connecting the dye and gemcitabine in 1a are 
vulnerable to proteolysis in serum.  It seems likely that similar amide bonds, as 
in E, are similarly labile.  Overall, it is advantageous to conjugate gemcitabine 
with tumor seeking dyes like A at meso-position if relatively quick clearance is 
important to reduce the off-target effect and toxicity to normal organs, and this 
approach was shown here to give greater molar efficacy of 1a relative to 
gemcitabine.  Alternatively, if the goal is to increase the residency time in tumors, 
then a better strategy might be via conjugates like E that we strongly suspect 





CHAPTER IV  
OBOC LIBRARY SCREENING TO DISCOVER NEW TUMOR-TARGETING 
SMALL MOLECULE AS THERAPEUTIC CANDIDATE 
 
4.1 Introduction 
One-bead-one-compound (OBOC) combinatorial libraries, developed by 
Kit Lam and others,123,124 has been used for searching oligomers and small 
molecules with unique biological or medicinal properties.125,126  Various efforts 
have been made to expand the accessible chemical space of the library127,128 
and the dimension of its applications129-132 via high-throughput screening (HTS).  
Libraries of peptides,133 peptoids,134 and small molecules135,136 can be screened 
against proteins, intact cells or phage display libraries.137   
The construction of OBOC libraries follows a “split and combine” strategy 
in solid-phase synthesis (Figure IV.1).  A compound library with enormous 
combination of building blocks can be obtained easily with less number of steps 
in synthesis.  At the same time, each solid bead contains only one specific 
fragment combination, which simplifies the characterization (decoding) process 






Figure IV.1. Concept scheme of OBOC library construction.  Using only two 
fragment units X & Y, a library of 2N molecules with N sequential units is 
obtained with only 2N number of synthesis.   
 
Two strategies are commonly used to search OBOC libraries for tumor 
targeting bio-markers.  If the targeted bio-markers are well known and tagged 
with biotin or fluorescence label, a protein-based assay124 can be used to 
identify strong binder.  If the bio-markers are unknown, a cell-based assay138 
can be used to select molecules with high binding potential.  The latter strategy 
is potentially useful in cancer research where the pertinent cell surface receptors 
are uncharacterized.   
Screening an OBOC combinatorial library for biological active molecules 
usually involves three stages: (i) library design and preparation, (ii) library 
screening, and (iii) active compound decoding.   
Library design and preparation is the fundamental stage that directs the 
later strategies.  For a specific target bio-marker, a large and diverse library of 
molecules based on molecular scaffold of interest is designed.  After on-bead hit 




typically via mass spectrometry (MS).  Hence, an optimized cleavable linker has 
to be added to the design to segregate the molecule core and cleavage spot on 
bead surface.  Various linkers have been developed to serve different cleavage 
conditions (e.g. nucleophilic, electrophilic, reductive, oxidative or photo-
cleavable), while being stable during library construction. 139-144  Encoding 
systems can be incorporated to the library design as well to characterize the 
molecule on hit beads.135,145,146  A topologically segregated bilayer/multilayer 
bead with test molecule on the surface and coding molecule buried inside 
(referred as one bead two compound (OB2C) assay147,148) is often used for 
coding various library designs.  Partial Alloc-deprotection149 and partial Fmoc-
protection150 approaches are major techniques for this approach, an enzyme-
mediated spatial segregation151 of bead surface is also feasible.  Polymer beads 
can also be marked with colors or barcodes126,152,153 to simplify decoding 
procedure.  A halogen tag is also a good marker during MS analysis.136  
Apparently, the synthetic efficiency of the library molecule is also crucial; 
otherwise, the one-bead-one/two-compound concept is violated.   
TentaGel resin, a polystyrene and polyethylene glycol (PEG) crosslinked 
polymer bead, provides good swelling during organic phase synthesis as well as 
possibilities for aqueous phase screening.154  Thus, it is widely applied to OBOC 
combinatorial library preparation and screening.  Yet, the auto-fluorescence of 




Auto-fluorescence of the beads can be reduced by coupling an internal 
quencher156 on the bead or by performing image background subtraction.154,157   
For the ease of observing cells adhered on the bead surface, quantum 
dots (QDs) are diffused into the cells that show bright color during library 
screening under fluorescence microscope.158-161  During the primary screening 
of the compound library, molecule that binds to the cancer cells may not interact 
preferably with the targeted cell surface protein.  Usually the non-specific binding 
molecules are eliminated by a secondary screening of the library with a control 
cell line which does not express the targeted protein.  By labeling the targeted 
and control cells with two different colors of QDs, both types of cells can be 
screened with the OBOC library at the same time.  The beads with single color 
(targeted) cells adhered are specific for the target protein, and the beads with 
two colors will be eliminated as non-specific binders.   
Decreasing surface ligand density162 and utilizing redundant libraries163 
(selecting only repeat hits from multiple identical libraries for re-synthesis and re-
screening) can also eliminate non-specific (or false positive) binding molecules 
from library screening.   
Manual screening of OBOC combinatorial libraries are time-consuming 
and laborious due to the large number of molecules in the library, and picking 
positive beads with micro-pipette is inefficient.  This hurdle can be overcome by 
automated equipment, like Complex Object Parametric Analyzer and Sorter 




Active compound decoding from a single bead is easier as mass 
spectrometer evolves with lower detection limit and higher resolution.   Matrix-
assisted laser desorption/ionization (MALDI) mass spectrometry is a prime 
example of this technological advancement that requires less amount (1 – 2 μL) 
of test sample.  This is extremely helpful in making concentrated samples from 
one single bead167 assisting in deciphering the chemical structure of the 
compound by the mass of coding tag.168,169  Tandem mass spectrometry 
(MS/MS) can improve accuracy of decoding.170,171   
In this chapter, synthetic non-peptide libraries were designed based on 
the OBOC concept and screened against various types of cells to develop novel 
tumor-targeting small molecules.   
 
4.2 Results and Discussion 
A peptidomimetic A-based small molecule was revealed by our group to 
perturb protein-protein interactions (unpublished results).  Both the triazole and 
hydantoin fragments in A showed high potentials in mimicking side chain 
orientations of peptide secondary structures via computational overlay by 
exploring key orientations on secondary structures (EKOS) program with low 
root mean square deviation (RMSD) values.172  A synthetic combinatorial OBOC 
library 1 was designed with various amino acid side chains on R1 – R3 to explore 
and expand the application of construct A, especially for cancer cell targeting 




this first library design, but it is possible to get more options for R2 since 




4.2.1 Design and preparation of library 1 
The complex properties of the molecule fragments used for building 
library 1 required investigation to find an appropriate encoding system (details 
explained in experimental methods).  Eventually, step-wise partial capping135 
(Scheme IV.2) incorporated with bromine isotope label136 (Scheme IV.1) was 
applied for efficient synthesis (Figure IV.2a).   
In the linker design (Figure IV.2b), methionine served as the cleaving site 
of the molecule after treating with BrCN solution.173  Lysine linked with 4-
bromobenzoic acid introduced a bromine atom offering a unique MS signal 
pattern {fragments of (M + 1):(M + 3) = 1:1, where M is the exact mass of the 
fragment} to assist in compound decoding.  Moreover, lysine provided a 
potential positive charge to ease MALDI-MS detection.  The extended linker 
acted as a spacer between the library molecule and the molecule cleavage site 
and guaranteed the molecular weight of all library compounds are above 600 to 






Figure IV.2. Featured structure of OBOC library 1.  a Partial capping coding 
construct of OBOC library 1; b linker structure used in the library 1.   
 
When constructing the combinatorial library 1, 20% mole of capping 
reagent was added together with the defined molecule fragment resulting in a 
“one-bead-three-compound” library.  On the bead, the largest and most 
abundant molecule is the designed compound that is used to test cell-adherence; 
the smaller and less abundant molecules are the “codes” for compound 






4.2.2 Preliminary test with modified screening protocol  
While preparing library 1, a known on-bead cyclic peptide B174 (with 
sequence of cNGRGEQc, c represent D-Cysteine) was used to explore and 
adjust the screening protocol to fit our instrument settings.  B was reported to 
bind the α3β1 integrin expressed on the cellular membrane of A549 cancer cells.  
Screening of cyclic peptide B against A549 cells was performed with modified 
protocol (details in experimental method section).  Significant number of cells 
adhered on the beads with B, while nearly no cells were observed on the 




Figure IV.3. TentaGel beads images after equilibrium with A549 cells.  a Beads 





The proper concentration of Bovine Serum Albumin (BSA) in the culture 
medium during cell-bead equilibrium was proven to be important.  With no BSA 
in the medium, cells do not adhere well to the bead surface.  If high 
concentrations of BSA are used, cells tend to clump together resulting in less 
cell-to-bead interaction.  During trial experiments for B, 4% BSA gave the best 
cell adherence ratio (Figure IV.4).   
 
 
Figure IV.4. Images of cells on beads at different concentrations of BSA in the 
culture medium.   
 
4.2.3 Preliminary screening with library C  
To further validate screening protocol, an OBOC small molecule library 
C175 prepared by Dr. Dongyue Xin (previous group member) was used to screen 
against A549 cells.  Library C possesses three variable arms featuring all natural 
amino acid side chains (except proline, 19 x 19 x 19 = 6859 compounds).  In 




(Figure IV.5)  However, without a proper linker segregating the library compound 
and bead surface, most of the molecules cleaved from bead after screening had 
low molecular weight (<600, MS background is high135) resulting in reduced 
signal-to-noise ratio in MS signal.  Lacking of a proper encoding system also 




Figure IV.5. Library C screening results.  a One intact view with one bead (in red 
circle) covered by A549 cells; b featured examples of “positive” beads with 
noticeable number of A549 cells on surface.   
 
4.2.4 OBOC library 1 screening and analysis based on capping strategy  
Tropomyosin kinase receptor C (TrkC)1,2,75,80,176 was chosen as the 
screening target.  Wild-type (TrkC-) and TrkC-transfected (TrkC+) NIH3T3 cells 









Figure IV.6. Protocols applied for OBOC combinatorial library screening with 
NIH3T3 cells.  a Protocol I consumes less beads and cells, yet need longer 
incubation; b protocol II consumes more beads and cells, but involves much 
shorter incubation times.  Protocol II can be applied in single color mode if 
needed.   
 
There are different ways to perform the library screening against cancer 




different protocols for screening against cancer cells.47,128,178  Based on this 
literature we designed and tested several protocols, but only two of them 
showed promising results.  Protocol I was directly derived from Dr. Lam’s 
method,174 screening one cell type at a time.  Protocol II was based on Dr. 
Kodadek’s procedure177 in which both TrkC+ and TrkC- cells can be screened 
simultaneously using different QD labeling (Figure IV.6).   
 
4.2.5 Compound characterization after screening  
Once potential “hit” beads were picked from the library, they were 
thoroughly washed177 to remove cells, and each bead was treated with BrCN 
solution for compound cleavage.  Three sequential MS signals (S1 – 3, high to 
low, Figure IV.7b), featuring MS signal of (M + 1):(M + 3) = 1:1, will be detected 
by MALDI-MS.  The molecular weight of the representative amino acids for R1 – 
R3 can be calculated easily by the following equations (*calculated value equal 
to free amino acid molecular mass):   
R3 = S3 – 847.25* 
R2 = S2 – S3 + 48.07* 
R1 = S1 – S2 + 34.15* 
In a preliminary screening, only one “hit” bead resulted in good quality MS 
signal (1-vlf, Figure IV.7a).  The low characterization rate indicates towards a 
low synthesis efficiency of the library.  To overcome the synthesis hurdle, the 




library (collaborator: Mr. Jonathan Whisenant) was resynthesized on a larger 
TentaGel resin (300 μm diameter, Rapp Polymere® #300002).  
 
 
Figure IV.7. Mass spectrometry analysis of the isolated “hit” bead.  a Chemical 
structure of the three cleaved compounds, with calculated and detected MS 
signal; b zoom-in MS signal patterns of S1 – 3 and corresponding amino acid 
side chains for a “hit” bead.  R3 = 1012.9 (S3) – 847.2 = 165.7 (Phe); R2 = 
1096.1 (S2) – 1012.9 (S3) + 48.1 = 131.3 (Leu); R1 = 1178.5 (S1) – 1096.1 (S2) 








Figure IV.7. Continued.   
 
The new library was screened via protocol I to give eight positive beads.  
Out of these, six beads showed MS ions with the unique isotope pattern in 
MALDI-MS (data not shown).  After much experimentation, we were able to 




Redundant library screening is crucial to eliminate false positive 
results.163  Multiple occurrences of a single molecule signal from repeated 
screening can significantly increase the possibility of a true “hit” compound that 
selectively binds to the targeted cells.  Unfortunately, no identical hit has been 
identified from repeated library screenings with TrkC+/- NIH3T3 and A549 cells.  
This indicates that the library may not contain a molecule with high affinity to the 
proteins overexpressed on these cell surfaces.   
 
4.3 Conclusions 
A peptidomimetic OBOC combinatorial library 1 was established and 
screened against different types of cells.  The screening protocols were adjusted 
to fit specific needs.  Beads picked from library 1 were reliably decodable by 
MALDI-MS, with the help of a properly designed linker.  No repeated sequence 
was discovered from redundant combinatorial library for either TrkC+ NIH3T3 or 
A549 cells.  To overcome the challenge, two parallel strategies will be applied: (i) 
significantly increasing the number of compounds in the library, and (ii) 
screening the library against more cancer cell lines.  These improvements will 
increase the chances of finding a strong binding molecule to the cancer cell 







4.4 Experimental Methods 
Computational overlays of hydantoin and triazole dipeptide mimics on 
common peptide secondary structures (RMSD values included) are in Appendix 
B.172  Synthesis of the featured azido acids (with R3) and alkynes (with R2) were 
previously described.41   
 
4.4.1 Synthesis of B on bead and modified screening protocol 
Synthesis of B is assisted by Liberty Blue peptide synthesizer following 
the protocol reported on TentaGel S NH2 resin (130 m diameter, 0.26 mmol/g, 
ChemImpex® #04773).  B-loaded beads as well as blank beads were swelled 
well in PBS buffer and equilibrated with single suspended A549 cells.   
With efforts adapting the reported protocol to the instrument set-up in our 
lab, a modified screening protocol was finalized with following conditions: 33 mg 
(~25,000) of either blank beads or B-loaded beads were mixed with 0.6 million 
A549 cells in 2.5 mL DMEM buffer (0 – 4% BSA, in a 30 mm petri dish) on an 
orbital shaker for 10 min (50 rpm), then steadily set in a CO2 incubator at 37 
oC 
for 3 d.  After careful wash with fresh DMEM buffer, beads were transferred to a 
clean 30 mm petri dish and observed under EVOS2 microscope (10X objective, 







4.4.2 Preparation of library 1 
Library 1 was prepared via solid-phase synthesis on TentaGel resin 
beads (Scheme IV.1 and 2).  General protocols frequently used during the 





Scheme IV.1. Preparation of the linker on TentaGel resins before library 





(i) carboxylic acid coupling condition: 4.0 equiv. carboxylic acids, 8.0 
equiv. N,N-Diisopropylethylamine (iPr2NEt) and 0.25 M 1-[Bis (dimethylamino) 
methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate 
(HATU) in 2.0 mL DMF solution were added to the swelled resin beads and 
microwaved (400 W) at 75 oC for 10 min.  Solvent was drained and beads were 
washed with fresh DMF twice.   
(ii) Fmoc deprotection: 2.0 mL 20% piperidine in DMF was added to the 
beads and microwaved (400 W) at 75 oC for 3 min.  Solvent was drained and 
beads were washed with fresh DMF twice.   
(iii) Boc and other acid labile protecting group removal: 2 mL of 95:2.5:2.5 
trifluoroacetic acid (TFA):triisopropylsilane (TIPS):H2O mixture was added to 
resin and shaken vigorously for 1 h, followed by thorough washing with DMF.   
TentaGel S NH2 resin (600 mg, 130 m dia.) was swelled well in CH2Cl2 
and N,N-dimethylformamide (DMF) in a 5 mL syringe reaction vessel (Torviq® 
#SF-0500).  Fmoc-Met-OH coupling was performed on a bead surface, followed 
by Fmoc deprotection.  After Fmoc-Lys(Boc)-OH coupling, Boc protecting group 
was removed.  4-bromobenzoic acid coupling added the isotope marker.  The 
Fmoc deprotection led to a second Fmoc-Lys(Boc)-OH coupling.  Fmoc 
deprotection was carried out again and an N-Fmoc-protected ethylene glycol 








Scheme IV.2. Synthesis of OBOC library 1 with step-wise partial capping.   
 
Following routine Fmoc deprotection, the TentaGel resin was equally 
separated into 11 fractions.  In each fraction, one specific azido acid (with R3) 
was coupled to the beads.  All fractions were combined and mixed well after a 




The resin was equally separated into seven fractions.  In each fraction, 
1.6 equiv. Fmoc amino alkyne (with R2) and 0.4 equiv. methyl propargyl ether 
was added along with 0.2 equiv. CuSO4, 0.2 equiv. sodium ascorbate, and 8.0 
equiv.  iPr2NEt in 1.0 mL DMF and stirred at 25 
oC for 12 h.  After removing 
reaction solutions, beads were washed with DMF twice.  All fractions were 
combined followed by Fmoc deprotection.   
TentaGel resin was then equally separated into 16 fractions.  In each 
fraction, 3.2 equiv. Fmoc amino acid (with R1) and 0.8 equiv. acetic acid were 
coupled via carboxylic acid coupling protocol.  All fractions were combined 
followed by Fmoc deprotection, then 3.0 equiv. 4-nitrophenyl chloroformate, and 
6.0 equiv. triethylamine (Et3N) in 2.0 mL acetonitrile (MeCN) were added and 
stirred at 25 oC for 6 h to form hydantoin.  Protecting groups of R1 – R3 (all acid 
labile) were removed (performed twice to completely remove Pbf protecting 
group on arginine) in the end to get encoded library 1.   
 
4.4.3 Cell culture.  
A549 (ATCC®) cells were cultured on 75 cm2 tissue culture flasks in 
RPMI-1640 medium (ATCC®) with 10% fetal bovine serum (FBS).  TrkC 
transfected NIH3T3 cells were cultured on 75 cm2 tissue culture flasks in 
DMEM/F12 supplement with 10% FBS including 400 mg/mL G418 (GIBCO®).  
All cells were cultured in a humidified incubator at 37 °C with 5% CO2 and 95% 




4.4.4 Screening protocol for library C 
The OBOC library beads (30 mg, ~24,000 beads with average three 
copies of each compound in the library) were swelled thoroughly in CH2Cl2, and 
equilibrated in DMF overnight.  The next day, the beads were washed in the 
following sequence: water, PBS buffer and phenol red free DMEM buffer, twice 
at each step.  Beads were kept in equilibrium in DMEM buffer for at least 1 h 
before mixing them with suspended A549 cells (as described below).   
Cultured A549 cells were digested with trypsin solution and resuspended 
in DMEM buffer with 10% FBS. The suspended cells were filtered through a cell 
strainer (40 μm pore size, VWR® #10199-654) to get single suspended cells.  
Filtered cells were prepared in 0.3 million/mL with 2 mL phenol red free DMEM 
(10% FBS) and mixed with the library beads in a 30 mm diameter petri dish.  
The mixture was incubated on an orbital shaker at 37 oC, 60 rpm for 10 min, 
then steadily in a humidified incubator at 37 °C with 5% CO2 for 3 d.  The beads 
were then carefully transferred to a 5 mL tube, and gently washed twice with 
DMEM buffer (no phenol red) to remove the suspended cells.  All library beads 
were observed carefully under microscope (EVOS2 microscope, 10X objective, 
bright field), and beads with significant number of cells adhered were picked up 
manually with a micropipette.   
Positive hit beads were picked and kept individually in Eppendorf tubes 
while the rest of library beads collected in a 3 mL syringe with filter.  Both sets of 




beads were suspended in 1% sodium dodecyl sulfate (SDS) aqueous buffer and 
boiled for 1 h, washed with water twice afterwards.  Then beads were shaken in 
enzyme free cell dissociation buffer (Thermo Scientific® #13151-014) for 30 min, 
and washed with 1:1 MeCN:water, DMF and CH2Cl2 twice.  Library beads were 
kept under vacuum for future use, and compounds on the single “hit” bead were 
cleaved off with 30 mg/mL BrCN in 5:4:1 MeCN:acetic acid:water mixture 
overnight.  After air-drying the cleavage buffer, concentrated sample in 1:1 
MeCN:water (5 μL) were sent for MALDI-MS analysis.   
 
4.4.5 Screening protocol for library A 
Protocol I:  
General protocol is the same as the one for screening library C, only 
difference lies in the density of beads and numbers of NIH3T3 cells.  The library 
beads (30 mg 130 μm dia. or 50 mg 300 μm dia.) were equilibrated with 0.2 
million/mL NIH3T3 cells with 2 mL phenol red free DMEM (10% FBS).   
 
Protocol II:  
The OBOC library beads (90 mg 130 μm dia. or 120 mg 300 μm dia.) 
were swelled thoroughly in CH2Cl2, and equilibrated in DMF overnight.  On the 
next day, the beads were washed in the following sequence: water, PBS buffer 




equilibrium in DMEM buffer for at least 1 h before mixing them with the 
suspended NIH3T3 TrkC+/- cells.   
Cultured NIH3T3 cells were digested with enzyme free cell dissociation 
buffer and resuspended in DMEM buffer with 10% FBS.  The cell density was 
adjusted to 1.0 million/mL, and TrkC-transfected NIH3T3 cells were stained with 
red Qdot 655 (Thermo Scientific® #Q25021MP) while wild type NIH3T3 cells 
were stained with green Qdot 565 (Thermo Scientific® #Q25031MP) in a 
humidified incubator at 37 °C with 5% CO2 for 1 h (detailed protocol was same 
as ref177).  After washing with DMEM buffer, the suspended cells were filtered 
through a cell strainer (40 m pore size) to give single suspended cells.   
Each type of filtered cells was prepared in 2.0 million/mL with 1 mL 
phenol red free DMEM (0.1% BSA) and mixed together with the library beads in 
a 5 mL tube (Torviq® #SF-0500, 1.0 million/mL red or green cells).  The mixture 
was incubated on an orbital shaker at 37 oC, 60 rpm for 1 h.   
The beads were then gently washed twice with DMEM buffer (no phenol 
red) to remove the suspended cells.  All library beads were observed carefully 
under microscope (EVOS2 microscope, blue light excitation with long-pass filter, 
fluorescence under color camera), and beads with only red cells adhered were 
picked up manually with a micropipette.  Bead cleaning and cleavage 
procedures were same as described in library C.   
While preparing suspended NIH3T3 cells for library screening in protocol 




NIH3T3 cells were digested again with enzyme free cell dissociation buffer right 
after QD staining before cell strainer filtration.   
Original MALDI-MS data of the bead analyzed in Figure IV.7 above is 








CHAPTER V  
CONCLUSIONS 
 
This dissertation explores some potential applications of small molecules 
in active targeting of cancer cells, especially metastatic breast cancer and 
glioblastoma.   
A TrkC-targeted small molecule with modest binding affinity (~112 nM) 
was used to deliver maytansinoid, a toxic cargo, to metastatic breast cancer 
cells.  The small molecule conjugate showed improved therapeutic index 
between TrkC+ and TrkC- cells in vitro.  In vivo, the targeted conjugate showed 
better tumor suppression against orthotopic 4T1 tumors in mice than the non-
targeted control group.  This approach offers an alternative way to actively target 
breast cancer cells in addition to the commonly used ER, PR and HER2 
targeting strategies.   
Moreover, four meso-substituted heptamethine gemcitabine conjugates 
were prepared and screened for targeted theranostic effect against glioblastoma 
cells.  These conjugates generally (all except one) had similar organelle 
localization compared to their parent dyes in vitro.  One lead compound was 
tested in vivo, and it showed good tumor accumulation and greater molar 
efficacy in therapy relative to free gemcitabine.   
Furthermore, OBOC combinatorial library screening strategy was used to 




The screening and coding protocols were successfully established after various 
attempts.  Several modifications, including synthesizing an expanded small 
molecule library and screening with diverse cancer cell types, are required to 
discover the targeted synthetic compound with strong affinity to specific protein 
on cancer cell surface.   
Other trials of developing small molecule with active targeting property in 
cancer characterization and treatment were attempted but the results were 
negative.   
In summary, targeted small molecules have potential advantages in 
cancer targeting and therapy.  Although the process is challenging but the ability 
to explore diverse synthetic combinatorial libraries to discover high affinity 
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POTENTIAL THERANOSTIC SMALL MOLECULE DESIGNED AND TESTED 
AGAINST PANCREATIC CANCER CELLS 
 
A.1 Introduction 
Pancreatic ductal adenocarcinoma (PDAC) is one of the most deadly 
types of cancer that has threatened human health for years.  It is the 12th most 
commonly diagnosed cancer and 4th leading cause of cancer related death 
among all types of cancers in the United States.179-181  The overall 5-year 
survival rate for PDAC is less than 8%, with more than 50% of the patients 
diagnosed in the late stage of disease,182 due to its varied or even asymptomatic 
early stage.179,180 In the last few decades, although death rates associated with 
many major types of cancer has reduced, mortality by pancreatic cancer has 
increased.182  Moreover, PDAC is predicted to be one of the top 3 life-
threatening types of cancer by 2030.183,184   
Surgery is considered to be the best strategy to treat PDAC.  There are a 
few FDA approved drugs available to inhibit the progress of PDAC (as listed in 
Figure A.1), but they showed insignificant increase of the five-year survival rate 
of the patients.179,185  Several proteins involved in the signaling pathways of 
PDAC have been considered as therapeutic targets, such as epidermal growth 
factor receptor (EGFR), mammalian target of rapamycin (mTOR), 




therapeutic agents against PDAC, numerous small-molecule inhibitors189-192 as 
well as therapeutic nanoparticles193-196 have been developed and tested in 
various in vitro and in vivo models.   
 
 
Figure A.1. FDA approved drugs for treatment of pancreatic cancer.   
 
Most of the chemotherapeutic agents in clinical use are non-specific to 
cancer cells and have potentially high risk of side effects to normal tissue and 
organs.  A specific strategy that enables selective interaction between the 
chemical agent and the receptors on the cancer cell surfaces, or “active 
targeting”, will be beneficial.6  Naturally occurring small molecules (e.g. biotin, 
folate, androgen)32,35 and monoclonal antibodies (mAbs)193,196 are commonly 




tissue.  Relatively few synthetic small molecules have been reported for active 
targeting compared with mAbs.40,197,198   
To develop novel small molecules with active targeting properties, our 
group developed a combinatorial solution-phase synthesis of a small molecule 
library mimicking bivalent β-turn structures.41,81,199,200  The library contained 
commonly found amino acid side chains at protein-protein interfaces;201 it was 
hypothesized that these would have a higher chance of interaction with the cell 
surface proteins.  Two compounds based on this strategy have been applied in 
active targeting and agent delivery to metastatic breast and melanoma 
tissues.73,74  These successes inspired a further investigation of other out-
standing compounds from the library. Compound A (KB1005) was identified as 
a specific probe that binds unknown cell surface receptors on PANC-1 cells via a 







A dipyrrometheneboron difluoride (BODIPY) dye was conjugated with the 
targeting moiety of compound A, that has two symmetric dipeptide mimics with 
isoleucine (I) and arginine (R) (abbreviated as IR-IR), to form the “first 
generation” targeted compound 1-F.  The tumor accumulation was checked via 
optical imaging to confirm its potential in labeling pancreatic cancer cells as 
diagnostic probe.  A simple derivative 1-PDT was generated with similar strategy 
by conjugating the IR-IR targeting moiety with a BODIPY-based photodynamic 
therapy (PDT) sensitizer;203,204 and its toxicity on pancreatic cancer cells (PANC-
1) was tested to evaluate the targeted therapeutic potency.   
In PDT, cells are damaged when the sensitizer is irradiated at specific 
wavelength of light (~530 nm for diiodo-BODIPY applied in this case).30  Briefly, 
the PDT sensitizer transfers energy to 3O2 generating 
1O2 (singlet oxygen) 
through a series of photochemical reactions.205,206  Singlet oxygen damages 
tumor tissue and the microenvironment around it, promoting immune 
response.207  Since singlet oxygen has very limited half-life,208 the PDT effect is 
highly localized, and can be applied as a highly focused therapy to the targeted 







Α.2 Results and Discussion 
Α.2.1 In vitro cytotoxicity of “first generation” targeted probes 1-F and 1-PDT 
Compound 1-F and 1-PDT were prepared by the protocol described 
below. (Scheme A.1)  General cytotoxicity and PDT effect of compound 1-PDT 
was tested against PANC-1 cells in vitro. (Figure A.2)  The results 
unambiguously showed that compound 1-PDT was uptaken by the PANC-1 cells, 
and was only toxic to the cells when exposed to light.  It can suppress the cell 
proliferation efficiently at sub-micromolar level in vitro, that implied its potential 






Figure A.2. Light and dark cytotoxicity of compound 1-PDT.  Data was averaged 
from 12 independent parallel experiments. (n = 12, mean ± SD)   
 
Α.2.2 Preparation and cytotoxicity check of gemcitabine conjugate 22 
To further investigate the potential of targeted delivery via the IR-IR 
fragment, gemcitabine, an FDA approved drug for pancreatic cancer, was 
chosen as the therapeutic cargo.  After modification of the linker between the 
targeting moiety and gemcitabine, compound 22 was prepared. (Scheme A.2)  A 
pair of targeted and non-targeted probe with a different linker was also prepared 
as back-up. (Scheme A.8 and 9)   
The cytotoxicity test of 22 on PANC-1 cells was carried out in a similar 
procedure with two modifications: (i) a larger dose range was used and (ii) no 
light treatment involved.  Free gemcitabine was used as a positive control to 
measure the efficiency of the conjugated drug.  Interestingly, compound 22 
seemed to be as effective as the free gemcitabine on the PANC-1 cells as tested, 






Figure A.3. Cytotoxicity comparison between compound 22 and gemcitabine.  
Data was averaged from 12 independent parallel experiments. (n = 12, mean ± 
SD)   
 
Α.2.3 Fluorescence tissue histology of compound 1-F and 1-R 
The selectivity of the designed molecule 1 can be determined in three 
ways: (i) comparison of the cytotoxicity between targeted the control (non-




cytotoxicity of the targeted compound on PANC-1 versus normal pancreas cells; 
(iii) comparison of the fluorescence intensity of tumor and normal pancreas 
tissues sampled from patients.  Compared to the first two methods, the third 
method offered an inexpensive way to exam more diverse cases, and also may 
provide some hints for the cell surface target the designed molecule possibly 
bound to.   
The fixed tumor and adjacent normal tissues sampled from PDAC 
patients were stained with 2 μM 1-F for 1 h, and confocal images were taken 
after a thorough wash. (Figure A.4)  To our surprise, 1-F did not show any 
fluorescence contrast on staining the tumor against adjacent normal tissues.  
Instead, in some cases, the normal tissues were stained brighter than the tumor.   
 
 
Figure A.4. Featured confocal fluorescence images of 1-F on fixed tumorous 
and normal pancreas tissues.  DAPI stained the nuclei of pancreas cells with 







Figure A.5. Featured confocal fluorescence images of 1-R on fixed tumorous 
and normal pancreas tissue.  1-R stained cells with red fluorescence.   
 
To further confirm that the results were not biased because of the auto-
fluorescence from the tissue (cellular components are also fluorescent in green 
light region), a red fluorescence probe 1-R was prepared. (Scheme A.3)  
Unfortunately, the red fluorescence signals from 1-R did not distinguish between 




of compound 1-F and 1-PDT was not selective in patient tissues, thus the 
investigation of their application came to a dead end.   
 
Α.2.4 Design and preparation of “second generation” targeted probe 17-F and 
17-PDT 
Although BODIPY is photostable and provides bright fluorescence, and its 
iodinated derivatives serves as a good PDT agent, the absorbance spectrum lies 
in green to yellow region (Amax ~530 nm).  Light in red to near-infrared (NIR) 
region can penetrate deeper through the tissues than the green light.  The low 
absorbance wavelength significantly restricted its potential as in vivo imaging 
and PDT agent for tumors buried deep inside the body.205   
The huge opportunity of NIR light for diagnostic and therapeutic 
applications inspired us to develop a new generation of targeted fluorescence 
molecule based on the core structure of aza-BODIPY (like compound G209 in 
Scheme A.4). By eliminating the extended linker between the targeted moiety 
and the fluorescent dye, compound 17-F and 17-PDT were prepared as the 
“second generation”72 targeted probe.  Compound 18-F and 18-PDT were 
designed to be the non-targeted control.  Control compound synthesis was 
terminated after preparation of the non-targeted ligand 16. (Scheme A.5)  Due to 
the non-selective tissue histology results, no biological experiments were 




        
 
Α.2.5 Design of “first generation” control compound 2-F and 2-PDT 
Along with the targeted molecule design, a set of non-targeted compound 
2-F and 2-PDT with reversed sequence of isoleucine and arginine was proposed 
as negative control.  The very original design of the non-targeted fragment was 
shown as molecule C in Figure A.6.  Since the accessibility of the chiral alkyne 
(red fragment in C) was really poor, an isoleucine alkyne derivative was used to 
replace the original design to ease synthesis, while keeping the chemical 
features in the original design.  The synthesis of 2-F and 2-PDT was halted half 
way because of the non-selectivity of 1-F in tissue histology, only the non-







Figure A.6. Alternated design for the original non-targeted fragment C.   
 
Α.3 Conclusions 
A few targeted molecules emerged from our previous studies were 
synthesized, and their theranostic potential was tested on PANC-1 cell line as 
well as tissue histology from pancreatic cancer patients.  Although cytotoxicity of 




between tumor and normal pancreas tissues proved the targeting moiety in 1-F 
and 1-PDT was not suitable for targeted drug delivery to pancreatic cancer 
tissues.   
 
Α.4 Experimental Methods 
A.4.1 Synthesis of the featured compounds 
Synthesis of compound 1-F and 1-PDT 
Compound B, D as well as the BODIPYs were prepared as described in 
previous publications.74,81  The key synthetic step was carried out by mixing 1.0 
equiv. D with 1.0 equiv. cyanuric chloride in acetonitrile (MeCN) on ice, followed 
by adding 1.5 equiv. N,N-diisopropylethylamine (iPr2NEt).  The cooled reaction 
mixture was kept and stirred at 25 oC for 30 min to acquire compound 4 after 
removing the solvent.  Purity of 4 was confirmed via the absorbance trace at 254 
nm on a reverse-phase analytical HPLC column. Without further purification, 1.0 
equiv. 4 and 3.0 equiv. B was dissolved in DMSO and 5.0 equiv. K2CO3 added.  
The mixture was stirred at 25 oC for 3 d to get targeting moiety 5. Compound 5 
was purified through a preparative reverse-phase C18 HPLC column with 
water/acetonitrile (MeCN) system (10 – 90% MeCN in 30 min), and lyophilized. 
A simple Cu(I)-based “click” reaction was then applied to conjugate the targeting 








Scheme A.1. Synthesis of compound 1-F and 1-PDT.   
 
Synthesis of compound 22 
Compound E was prepared as previously described.210  Equal moles of 
gemcitabine hydrochloride and E were dissolved in dichloromethane on ice.  The 
mixture was kept cold on ice, and HOBt, EDCI, NMM were then added in that 
order. The reaction mixture was stirred at 25 oC for 12 h, and compound 23 was 
isolated via flash chromatography (5% MeOH in CH2Cl2).  After Boc deprotection 




were added and the reaction mixture was stirred for one hour at 25 oC to give 
compound 24.  Without further purification, 2.0 equiv. fragment B was added to 
a DMSO solution of 24 with 5.0 equiv. K2CO3.  After 2 d of reaction, compound 
22 was isolated through a preparative reverse-phase C18 HPLC column with 




Scheme A.2. Synthesis of compound 22.   
 
Synthesis of compound 1-R 
Compound F, a gift from Dr. Anyanee Kamkaew (a former graduate 




give 1-R.  The crude compound was purified through a reverse phase 
preparative HPLC column with water/acetonitrile (MeCN) system (10 – 90% 
MeCN in 30 min).   
 
 
Scheme A.3. Synthesis of compound 1-R.   
 
Synthesis of compound 17-F and 17-PDT 
Synthesis of aza-BODIPY G was repeated according to the synthetic 
protocol previously published.209  Isoleucine azide was dissolved in cold N,N- 
dimethyl-formamide (DMF) on ice, and HOAt, EDCI were added in sequence.  
The solution was stirred gently and mixed with compound G and iPr2NEt.  Amide 
coupling reaction was carried out at 25 oC for 12 h before removing the solvent. 
Compound 19 was purified with flash chromatography (1:1 EtOAc:hexane).  A 
Cu(I)-based “click” reaction was applied to conjugate 19 with 12 (synthesis 













Flash chromatography purified (2% MeOH in CH2Cl2) 20-F was 
solubilized in 3:1 CHCl3:acetic acid with 2.5 equiv. N-iodosuccinimide.  The 
reaction took 18 h at 25 oC to acquire 20-PDT.  Boc deprotection (1 d) with 
hydrochloride in 1,4-dioxane will eventually get compound 17-F and 17-PDT 
without further purification.   
 
Synthesis of non-targeted fragment 16 
A Cu(I)-based “click” reaction was applied to conjugate 6 with H to get 14 
via flash chromatography (5% MeOH in CH2Cl2).  After removal of Cbz 
protecting group, the ornithine residue was converted to Boc-protected arginine 









Synthesis of scrambled non-targeted fragment 3 
L-Orn(Z)-OH were converted to its azide derivative 6 followed by the 
similar protocol.81  Compound 7 was acquired by amide coupling between 6 and 
Boc-piperazine.  After a simple 10% citric acid wash followed by a saturated 
NaHCO3 base wash to get pure compound 7 in organic layer, a Cu(I)-based 
“click” reaction was applied to conjugate 7 with H.41  Compound 8 was purified 
via flash chromatography, and the Cbz protecting group was removed by 
common hydrogenation condition to form 9 in quantitative yield.  A simple 
substitute reaction then converted the ornithine residue to Boc-protected 
arginine in compound 10.  The scrambled non-targeted fragment 3 was 










Scheme A.6. Continued.   
 
 
Scheme A.7. Synthesis of compound 12 and 13.   
 
Synthesis of compound 12 and targeted fragment 13 
Alternative synthetic route to get targeted fragment for 17-F and 17-PDT 
was proven success (Scheme A-7).  Compound 11 was converted to 12 using 
the same protocol to convert 9 to 10.  And a Cu(I)-based “click” reaction was 




Synthesis of the alternative design of IR-IR targeted fragment 28 
Isoleucine azide J was coupled with Cbz-protected piperazine K to form 
compound 25.  After routine “click” reaction with compound 12, the Cbz group 
was removed to form fragment 26.  Simple substitution reaction between K and 
cyanuric chloride (1:1 ratio) resulted in 27.  Without further purification, 2.0 equiv. 















Scheme A.9. Synthesis of compound 30.   
 
Synthesis of the alternative design of RI-RI non-targeted fragment 30 
Amide coupling between 16 and K was followed by a hydrogenation to 




reaction between 2.0 equiv. 29 and 1.0 equiv. 27 resulted in compound 30 (RI-
RI, the non-targeted fragment).   
 
A.4.2 Photocytotoxicity test on PANC-1 cells in vitro  
PANC-1 cells were cultured on 75 cm2 tissue culture flasks in Dulbecco’s 
Modified Eagle Medium/nutrient mixture F-12 Ham (DMEM/F12, Millipore Sigma) 
supplement with 10% fetal bovine serum (FBS) in a 37 oC incubator with full 
humidity and 5% CO2.   
To test the PDT effect of 1-PDT, PANC-1 cells were seeded on 96-well 
plates as 5000 cells/well (50 μL) and incubated overnight.  Various 
concentrations of 1-PDT were prepared in 50 μL protein-free hybridoma medium 
(PFHM II) and added to cells to make final concentrations from 0 to 1.0 μM.  For 
the light treatment (PDT) group, cells were illuminated (>480 nm source with 
fluence rate of 12.2 mW/cm2 for 10 min) after 1-PDT was added to induce 
singlet oxygen generation; for dark treatment (control) group, the cells were put 
back to incubator right after adding 1-PDT without light interference. All plates 
were incubated for 72 h, and cell viability was tested with MTT assay.211  Briefly, 
20 μL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, as 5 
mg/mL in Hank’s balanced salt solution) was added to each well, and incubated 
for 3 h in 37 oC incubator with full humidity and 5% CO2.  The medium was then 
removed, and 100 μL of DMSO was added to dissolve the formazan product. 




Synergy 4 Microplate Reader.  Viability data were processed through GraphPad 
Prism® 6.0 software (Figure A.2). 
 
Α.4.3 Fluorescence tissue histology  
Tissue slices (Biomax® #PA241b, 6 cases) were incubated with 2 μM 1-F 
for 1 h after removal of parafilm.  After thorough washing with phosphate saline 
buffers, the tissue was mounted with Vectashield® mounting medium (with DAPI) 
under cover glass.  Confocal fluorescence imaging was taken with Olympus® 
FV-1000 microscope in the Microscopy and Imaging Center in Texas A&M 
University.   
 
Α.5 Compound Characterization 
1-F 
C60H94BF2N25O5  
1H NMR (500 MHz, DMSO-d6) δ 8.08 (s, 1H), 7.83 (s, 2H), 7.58 (s, 1H), 7.27 – 
7.14 (m, 2H), 6.72 (s, 2H), 6.05 (s, 2H), 5.52 (s, 1H), 5.50 (s, 1H), 4.42 (t, J = 6.1 
Hz, 2H), 4.39 (s, 2H), 3.71 – 3.60 (m, 2H), 3.55 – 3.45 (m, 8H), 3.43 – 3.28 (m, 
18H), 3.26 – 3.18 (m, 2H), 2.99 (dd, J = 12.7, 6.4 Hz, 4H), 2.76 (dd, J = 10.8, 
6.3 Hz, 2H), 2.35 (dd, J = 3.4, 1.7 Hz, 4H), 2.23 (s, 6H), 2.18 – 2.09 (m, 2H), 
2.03 (s, 6H), 1.95 – 1.86 (m, 2H), 1.70 – 1.58 (m, 4H), 0.87 – 0.70 (m, 10H), 





13C NMR (126 MHz, DMSO-d6) δ 166.31, 158.45, 158.27, 158.18, 156.83, 
156.78, 153.40, 146.19, 145.03, 144.05, 140.89, 130.63, 124.55, 121.82, 121.01, 
69.79, 69.73, 69.53, 68.96, 68.85, 63.42, 62.32, 49.31, 45.26, 44.58, 43.05, 
42.39, 41.72, 40.23, 37.17, 31.78, 28.25, 25.11, 24.09, 22.13, 21.09, 15.54, 








1H NMR (400 MHz, DMSO-d6) δ 8.44 – 8.29 (m, 4H), 8.28 – 8.20 (m, 2H), 7.64 
– 7.57 (m, 2H), 7.20 (s, 1H), 7.07 (s, 1H), 6.94 (s, 1H), 6.75 – 6.69 (m, 1H), 6.06 
– 5.97 (m, 2H), 4.61 – 4.56 (m, 2H), 4.56 – 4.51 (m, 2H), 4.46 – 4.39 (m, 2H), 
3.84 – 3.39 (m, 28H), 3.18 – 3.09 (m, 3H), 3.06 – 2.99 (m, 2H), 2.71 – 2.62 (m, 
2H), 2.54 (s, 3H), 2.36 – 2.30 (m, 2H), 2.25 (s, 3H), 2.14 – 1.87 (m, 9H), 1.56 – 
1.35 (m, 6H), 1.33 – 1.16 (m, 7H), 1.14 – 0.97 (m, 4H), 0.88 (dt, J = 14.2, 8.5 Hz, 





1H NMR (400 MHz, MeOD) δ 8.15 (s, 1H), 5.91 (t, J = 7.4 Hz, 1H), 4.38 (d, J = 




2H), 2.06 – 1.94 (m, 1H), 1.60 – 1.49 (m, 1H), 1.48 – 1.40 (m, 1H), 1.38 – 1.24 





1H NMR (400 MHz, CDCl3) δ 10.30 (s, 1H), 7.43 – 7.11 (m, 5H), 5.21 – 5.02 (m, 
2H), 4.97 (s, 1H), 3.98 – 3.73 (m, 1H), 3.22 (s, 2H), 1.88 (ddd, J = 13.8, 7.0, 4.0 








1H NMR (400 MHz, MeOD) δ 7.58 – 7.29 (m, 5H), 5.19 (s, 2H), 4.35 (t, J = 6.7 
Hz, 1H), 3.82 – 3.49 (m, 8H), 3.30 (td, J = 6.6, 4.0 Hz, 2H), 1.99 – 1.86 (m, 2H), 








1H NMR (400 MHz, CDCl3) δ 7.59 (s, 1H), 7.38 – 7.26 (m, 5H), 5.79 – 5.66 (m, 
1H), 5.36 – 5.20 (m, 1H), 5.07 (s, 2H), 4.85 (s, 1H), 4.76 – 4.63 (m, 1H), 3.75 – 
3.34 (m, 6H), 3.31 – 2.92 (m, 4H), 2.19 – 1.99 (m, 2H), 1.96 – 1.85 (m, 1H), 1.43 
(s, 9H), 1.39 (s, 9H), 1.36 – 1.16 (m, 3H), 1.13 – 1.00 (m, 1H), 0.88 (t, J = 7.4 Hz, 





1H NMR (400 MHz, CDCl3) δ 7.71 (s, 1H), 5.88 – 5.67 (m, 1H), 5.50 – 5.25 (m, 
1H), 4.81 – 4.59 (m, 1H), 3.60 – 3.40 (m, 6H), 3.22 – 2.82 (m, 4H), 2.31 – 2.08 




1.31 – 1.17 (m, 3H), 1.14 – j0.97 (m, 2H), 0.89 (td, J = 7.5, 4.8 Hz, 3H), 0.79 (d, 





1H NMR (400 MHz, CDCl3) δ 8.50 (s, 1H), 7.61 (s, 1H), 5.79 (t, J = 7.3 Hz, 1H), 
5.29 (s, 1H), 4.73 (s, 1H), 3.85 – 3.32 (m, 8H), 3.32 – 2.83 (m, 2H), 2.28 – 2.13 
(m, 1H), 2.13 – 2.02 (m, 1H), 2.00 – 1.84 (m, 1H), 1.69 – 1.52 (m, 3H), 1.49 (s, 
9H), 1.48 (s, 9H), 1.43 (s, 9H), 1.40 (s, 9H), 1.34 – 1.19 (m, 1H), 1.06 (tt, J = 








1H NMR (400 MHz, CDCl3) δ 8.35 (s, 1H), 3.51 (dd, J = 12.6, 6.9 Hz, 2H), 2.25 
(td, J = 7.1, 2.6 Hz, 2H), 1.95 (t, J = 2.6 Hz, 1H), 1.80 (p, J = 7.1 Hz, 2H), 1.48 (s, 








1H NMR (400 MHz, CDCl3) δ 7.78 (s, 1H), 5.24 – 4.96 (m, 1H), 3.62 – 3.34 (m, 
2H), 2.85 – 2.58 (m, 2H), 2.36 – 2.17 (m, 1H), 2.09 – 1.91 (m, 2H), 1.50 (s, 9H), 
1.49 (s, 9H), 1.28 (dt, J = 14.3, 5.2 Hz, 2H), 1.01 (d, J = 6.6 Hz, 3H), 1.00 – 0.87 





1H NMR (400 MHz, CDCl3) δ 7.80 (s, 1H), 7.65 (s, 1H), 7.30 (s, 5H), 5.79 – 5.54 
(m, 1H), 5.44 – 5.24 (m, 1H), 5.18 – 5.10 (m, 1H), 5.05 (s, 2H), 4.93 – 4.55 (m, 
1H), 3.28 – 3.05 (m, 2H), 2.41 – 1.77 (m, 3H), 1.57 – 1.44 (m, 3H), 1.38 (s, 9H), 





13C NMR (101 MHz, CDCl3) δ 171.72, 156.91, 156.03, 147.55, 136.55, 128.68, 
128.31, 128.22, 121.72, 120.97, 79.93, 66.97, 62.62, 51.61, 40.14, 39.36, 29.93, 








1H NMR (400 MHz, MeOD) δ 7.92 (s, 1H), 5.22 (dd, J = 8.9, 5.4 Hz, 1H), 4.69 (d, 
J = 6.6 Hz, 1H), 2.96 (td, J = 8.2, 3.4 Hz, 2H), 2.44 – 2.15 (m, 2H), 1.96 – 1.80 
(m, 1H), 1.77 – 1.63 (m, 1H), 1.61 – 1.47 (m, 2H), 1.43 (s, 9H), 1.23 – 1.08 (m, 
1H), 0.93 (t, J = 7.4 Hz, 3H), 0.83 (d, J = 6.8 Hz, 3H).  
 
13C NMR (101 MHz, MeOD) δ 173.66, 157.79, 149.27, 123.42, 80.28, 66.01, 








1H NMR (400 MHz, MeOD) δ 7.90 (s, 1H), 7.84 (s, 1H), 5.46 (dd, J = 9.4, 4.3 Hz, 
1H), 4.66 (d, J = 5.5 Hz, 1H), 3.45 – 3.31 (m, 2H), 2.40 – 2.15 (m, 2H), 1.94 – 
1.80 (m, 1H), 1.48 (s, 9H), 1.44 (s, 9H), 1.52 – 1.36 (m, 4H), 1.38 (s, 9H), 1.21 – 





1H NMR (400 MHz, MeOD) δ 8.39 (s, 2H), 8.06 (s, 2H), 7.99 (d, J = 7.5 Hz, 4H), 
7.76 (d, J = 6.7 Hz, 2H), 7.53 (d, J = 5.6 Hz, 2H), 7.18 – 7.08 (m, 2H), 7.04 (s, 




(m, 10H), 3.30 – 3.23 (m, 4H), 2.96 – 2.83 (m, 4H), 2.55 – 2.41 (m, 2H), 2.08 – 





1H NMR (400 MHz, MeOD) δ 8.41 (s, 2H), 8.15 (s, 2H), 8.07 – 7.85 (m, 2H), 
7.82 – 7.59 (m, 4H), 7.42 – 7.22 (m, 2H), 7.21 – 6.90 (m, 4H), 5.47 – 5.30 (m, 
2H), 4.31 – 4.18 (m, 4H), 3.92 – 3.74 (m, 8H), 3.68 (s, 6H), 3.03 – 2.85 (m, 2H), 
2.61 – 2.40 (m, 2H), 2.14 – 1.88 (m, 4H), 1.42 – 1.25 (m, 4H), 1.22 – 1.07 (m, 








1H NMR (400 MHz, CDCl3) δ 8.07 – 8.01 (m, 4H), 8.00 (s, 2H), 7.93 (s, 2H), 7.80 
(d, J = 7.7 Hz, 2H), 7.74 (d, J = 7.7 Hz, 2H), 7.38 (t, J = 7.3 Hz, 2H), 7.04 (s, 2H), 
6.96 (d, J = 7.5 Hz, 4H), 3.95 – 3.88 (m, 2H), 3.84 (s, 6H), 2.03 – 1.89 (m, 2H), 











1H NMR (400 MHz, CDCl3) δ 9.07 (s, 2H), 8.39 (t, J = 5.1 Hz, 2H), 8.03 (d, J = 




(t, J = 7.9 Hz, 2H), 6.96 (d, J = 9.1 Hz, 5H), 5.09 (d, J = 10.1 Hz, 2H), 3.83 (s, 
6H), 3.45 (dd, J = 12.7, 6.5 Hz, 4H), 2.76 (t, J = 7.5 Hz, 4H), 2.46 – 2.31 (m, 2H), 
1.95 (dt, J = 14.5, 7.3 Hz, 4H), 1.47 (s, 18H), 1.46 (s, 18H), 1.30 – 1.12 (m, 4H), 
1.05 (d, J = 6.6 Hz, 6H), 1.00 – 0.90 (m, 4H), 0.82 (t, J = 7.3 Hz, 6H).  
 
13C NMR (101 MHz, CDCl3) δ 166.66, 163.75, 162.19, 158.30, 156.45, 153.44, 
147.57, 145.46, 142.90, 137.31, 133.57, 131.91, 131.86, 129.20, 126.26, 124.14, 
121.80, 121.67, 119.57, 114.41, 83.28, 79.44, 70.19, 55.56, 40.32, 38.49, 28.82, 










1H NMR (400 MHz, MeOD) δ 8.06 (s, 2H), 8.01 (s, 2H), 7.62 (d, J = 8.7 Hz, 4H), 




J = 8.9 Hz, 4H), 5.19 (d, J = 10.7 Hz, 2H), 3.84 (s, 6H), 3.43 – 3.36 (m, 4H), 2.77 
(t, J = 7.5 Hz, 4H), 2.46 – 2.35 (m, 2H), 1.96 – 1.89 (m, 4H), 1.49 (s, 18H), 1.43 
(s, 18H), 1.25 – 1.12 (m, 4H), 1.07 (d, J = 6.7 Hz, 6H), 0.86 (t, J = 7.4 Hz, 6H).  
 









1H NMR (400 MHz, CDCl3) δ 8.09 – 7.97 (m, 2H), 7.93 (d, J = 8.2 Hz, 2H), 7.84 
(d, J = 13.4 Hz, 2H), 7.74 – 7.60 (m, 2H), 7.59 – 7.44 (m, 6H), 7.20 – 7.11 (m, 
2H), 6.97 – 6.78 (m, 4H), 6.76 – 6.48 (m, 2H), 5.55 – 5.30 (m, 2H), 4.89 – 4.66 
(m, 4H), 3.80 (s, 6H), 2.21 – 2.04 (m, 2H), 1.98 – 1.78 (m, 4H), 1.62 – 1.16 (m, 
54H), 1.16 – 1.03 (m, 4H), 0.89 (t, J = 7.2 Hz, 6H), 0.80 (d, J = 6.4 Hz, 6H). 0.89 
– 0.75 (m, 12H).  
 










1H NMR (400 MHz, MeOD) δ 8.33 (d, J = 7.6 Hz, 1H), 7.94 (s, 2H), 7.46 (d, J = 




4.48 – 4.23 (m, 1H), 4.06 – 3.35 (m, 18H), 3.24 (t, J = 7.0 Hz, 4H), 3.04 – 2.85 
(m, 2H), 2.77 (dd, J = 17.4, 9.8 Hz, 4H), 2.62 – 2.50 (m, 2H), 2.48 – 2.33 (m, 2H), 
2.06 – 1.81 (m, 6H), 1.69 – 1.51 (m, 2H), 1.16 – 1.07 (m, 4H), 1.04 (d, J = 6.7 
Hz, 6H), 0.86 (t, J = 7.4 Hz, 6H).  
 
13C NMR (101 MHz, MeOD) δ 178.57, 178.46, 177.49, 168.50, 166.71, 166.33, 
158.81, 157.61, 148.26, 146.07, 122.39, 98.29, 64.87, 60.31, 47.26, 44.54, 
43.89, 43.71, 43.59, 42.46, 41.77, 39.10, 29.52, 29.25, 29.16, 25.72, 23.26, 








1H NMR (400 MHz, MeOD) δ 8.34 (d, J = 7.6 Hz, 1H), 7.48 (d, J = 7.5 Hz, 1H), 
6.34 – 6.14 (m, 1H), 4.59 – 4.43 (m, 2H), 4.30 (td, J = 12.1, 8.2 Hz, 1H), 4.17 – 
4.06 (m, 2H), 4.02 – 3.92 (m, 2H), 3.81 (dd, J = 13.2, 3.6 Hz, 1H), 2.95 – 2.79 
(m, 2H), 2.65 (ddd, J = 14.9, 7.4, 3.8 Hz, 1H), 1.93 – 1.80 (m, 2H), 1.62 (td, J = 





13C NMR (101 MHz, MeOD) δ 177.24, 165.00, 157.63, 156.47, 156.43, 146.06, 








1H NMR (400 MHz, CDCl3) δ 7.39 – 7.28 (m, 5H), 5.13 (s, 2H), 3.77 – 3.65 (m, 
1H), 3.62 – 3.43 (m, 8H), 2.08 – 1.97 (m, 1H), 1.77 – 1.67 (m, 1H), 1.24 (ddq, J 





1H NMR (400 MHz, MeOD) δ 7.92 (s, 1H), 5.57 (d, J = 10.3 Hz, 1H), 3.83 – 3.60 
(m, 3H), 3.49 (ddd, J = 13.1, 7.5, 3.3 Hz, 1H), 3.41 (t, J = 7.0 Hz, 2H), 2.86 – 
2.74 (m, 4H), 2.73 – 2.63 (m, 1H), 2.60 – 2.51 (m, 1H), 2.45 – 2.34 (m, 1H), 2.01 
– 1.89 (m, 2H), 1.53 (s, 9H), 1.47 (s, 9H), 1.10 – 1.03 (m, 2H), 1.02 (d, J = 6.7 








1H NMR (400 MHz, CDCl3) δ 8.53 (s, 2H), 7.67 (s, 2H), 7.42 – 7.28 (m, 5H), 5.41 
(d, J = 10.5 Hz, 2H), 5.16 (s, 2H), 3.96 – 3.34 (m, 30H), 2.78 (t, J = 7.7 Hz, 4H), 
2.45 – 2.30 (m, 2H), 2.07 – 1.91 (m, 4H), 1.50 (s, 18H), 1.49 (s, 18H), 1.13 – 





13C NMR (101 MHz, CDCl3) δ 166.97, 165.15, 155.98, 155.46, 153.27, 147.56, 
136.75, 128.68, 128.25, 128.07, 119.88, 67.47, 63.55, 46.28, 43.81, 43.53, 










1H NMR (400 MHz, CDCl3) δ 8.32 (s, 2H), 7.59 (s, 2H), 7.38 – 7.25 (m, 5H), 5.87 
– 5.65 (m, 2H), 5.12 (s, 2H), 4.86 – 4.61 (m, 2H), 3.92 – 3.16 (m, 34H), 2.31 – 
1.77 (m, 10H), 1.45 (s, 36H), 1.38 (s, 18H), 1.12 – 0.95 (m, 2H), 0.91 – 0.81 (m, 
6H), 0.77 (dd, J = 16.7, 6.9 Hz, 6H).  
 
13C NMR (101 MHz, CDCl3) δ 166.15, 165.24, 156.31, 155.49, 155.41, 153.33, 
136.71, 128.62, 128.19, 128.00, 119.97, 119.80, 83.57, 79.50, 67.39, 58.96, 
53.51, 51.76, 45.93, 43.82, 43.36, 43.06, 42.82, 42.58, 41.14, 39.76, 39.60, 











DESIGN AND MODIFICATION OF ACTIVELY TARGETED, NEAR-IR 




Breast cancer is one of the most commonly diagnosed cancers in US,182 
and targeted therapies have been established based on selective binding with 
several different cell surface receptors {(estrogen receptor (ER), progesterone 
receptor (PR) and human epidermal growth factor receptor 2 (HER2)}.61,212,213 
Metastatic breast cancer, a more aggressive form with poor prognoses, does not 
always have these biomarkers. If none of the three are present on cell surface 
then it is called “triple negative” 54,214).   
Several inhibitors of kinases involved in the cellular signaling pathways 
have been actively studied e.g. Cyclin-dependent kinase (CDK) 4/6, 
Phosphoinositide 3-kinase (PI3K).215,216  Yet, these compounds are not 
designed for active targeting to cancer cells via cell surface receptors. 
Tropomyosin kinase receptor C (TrkC), a member of the receptor tyrosine 
kinase family, along with its selective natural ligand neurotrophin-3 (NT-3) are 
proven to be essential for proliferation and metastasis of metastatic breast and 
other types of cancer.1,2,75,80,176  This provides potential in developing novel 




As discussed in previous chapters, small molecule targeting agents have 
several advantages over mAbs in tumor targeting.217  Previous work in our group 
revealed a synthetic small molecule targeting moiety that preferably binds to 
TrkC on metastatic breast cancer cells.41  A library of 152 fluorescein-labeled 
peptidomimetics was screened through a FACS-based binding assay via flow 
cytometer on cells that were transformed to stably express TrkA, TrkC, or p75.  
Only 10 out of 152 compounds bound significantly and selectively to TrkC+ cells.  
Selected probes were then equipped with biotin tags and subjected to a second 
binding assay. This screening method narrowed the positive hit compounds to 8 
that were tested in further cell-based assay.  Finally, a bivalent IY-IY moiety (I 
stands for isoleucine or Ile, Y for tyrosine or Tyr) gave best binding affinity and 







A “first generation” targeted therapeutic agent A based on the screening 
result showed enhanced killing of TrkC+ cells in vitro, and ablated metastatic 
breast tumors completely in vivo after one dose (10 mg/kg) and one 
illumination.3 The outstanding results encouraged us to develop theranostic 
agents with advance design.  Therefore, a “second generation” targeted agent B 
and C were accomplished by fusing the targeting moiety with a near-IR 
absorbing aza-BODIPY.72,209  These imaging agents had a much longer 
absorbance wavelength and were more compact, thus giving a better chance of 
non-invasive photodynamic therapy with near-IR light ignition.205 Aza-BODIPYs 
can absorb light around 700 nm, but tend to be hydrophobic. Coupling with a 
pair of cysteic acid significantly increased the hydrophilicity of the probe.209  
Histochemistry of agent C on human breast tissue array showed that the agent 
stained on breast cancer tissue brighter than normal breast tissue, and in vivo 
imaging presented enhanced tumor staining compared to its scrambled 
control.72   
 




Previous protocol72 was unable to generate the second-generation 
photosensitizers due to problems with incorporation of iodine.  Specifically, 
iodination reagents react with tyrosine phenol, so iodination must precede 
incorporation of that residue, but the C-I bond in the product was cleaved by 
copper in the “click” reaction (Dr. Kamkaew, Thesis).  Thus, forming the 
proposed second-generation targeting agent 1 and its control 2 was an unsolved 
challenge.  If success, the second-generation agent 1 will have improved ability 
to treat tumors buried in deep tissues, give high signal-to-noise ratio in imaging, 








Evolving the conformational design of the original targeting moiety can 
potentially enhance the affinity of the theranostic agent to the target TrkC protein.  
In this work, a computational strategy created by our group and collaborator, 
exploring key orientations on secondary structures (EKOS),48 was used to 






Figure B.1. Molecular structures of all dipeptide mimics evaluated by EKOS.   
 
EKOS was developed to explore the potential semi-rigid peptide mimics 
with three amino acid residues on ideal secondary structures.  The Cα and Cβ 




coordinates within the peptide secondary structures.  The level of fit is quantified 
in terms of root mean squared deviation (RMSD, Å) for each overlay.  This 
computational approach can guide the development and synthesis of dipeptide 
mimetics by highlighting proposed structures that cannot achieve the desired 
conformations to bind.   
 
 
Figure B.2. List of the overlay RMSD values (Å) of R1 and R2 arms in triazole 
and hydantoin on seven common types of ideal protein secondary structures.  
Average RMSD for triazole I (0.30) was much bigger than that of hydantoin IV 
(0.17), indicating hydantoin backbone was a better fit in mimicking secondary 
structure side chain orientations in general.   
 
Several compact dipeptide mimics (including the triazole core that has 
been used in our actively targeted agent A3), were evaluated by EKOS (Figure 
B-1).  Surprisingly, a simple hydantoin-based dipeptide mimic fit on the 
secondary structures better than the triazole core applied in our actively targeted 
probe (calculation results shown in Figure B-2).  This inspired us to design new 




First generation imaging agents, 3-G and 3-R, were synthesized and their 




Furthermore, while searching for optimal photosensitizers to incorporate 
with our bivalent TrkC-targeted ligand, we became aware that a pH-activatable 
photosensitizer D was reported to show unique properties and high potential for 
modification.218  In the original reference, D was wrapped inside nanoparticles 
for delivery.  The acidic environment of lysosomes in cancer cells activated the 
probe that acted as a theranostic agent with near-IR illumination.  With regional 
modifications, a novel second generation targeted agent 4 was proposed as a 
substitute to agent 1 in treatment of metastatic breast cancer.  Cysteic acid was 





             
 
B.2 Results and discussion 
B.2.1 Second generation agent 1 preparation and cytotoxicity behavior 
Based on preliminary results of iodination and its failure to incorporate in 
the aza-BODIPY core with “click” reaction, the targeted agent 1 was obtained via 
the route shown in Scheme B.1.  The iodination was carried out directly after the 
generation of aza-BODIPY.  A mild condition was used to remove the Boc 
protecting group throughout the procedure to protect iodine from falling off.  
Afterwards, a targeting ligand 8, prepared in advance, was coupled with PDT 







Figure B.3. Light and dark cytotoxicity of targeting (1, a) and non-targeting (2, b) 
agent on TrkC+ or TrkC- cells in vitro.  IC50 (1) = 1.34 ± 0.10 M.  (n = 8, mean ± 
SD)   
 
Cytotoxicity of the targeting agent 1 and the control compound 2 (Scheme 
B-2) was tested with TrkC transfected (TrkC+) and wild-type (TrkC-) NIH3T3 cells 
with and without illumination in vitro for PDT effect and general toxicity 
respectively.  The results (Figure B.3a) showed that 1 was selectively uptaken to 
TrkC+ cells compared with TrkC- cells, and only toxic when illuminated with light.  




argument that targeting effect only exists when the targeting moiety was 
assembled in the correct position.   
 
 
Figure B.4. Light and dark cytotoxicity of targeting (1) and non-targeting (2) 
agent on 4T1 cells in vitro.  IC50 (1) = 1.39 ± 0.05 M.  (n = 8, mean ± SD)   
 
In vitro cytotoxicity tests were then performed on a metastatic breast 
cancer cell line 4T1 (TrkC expression confirmed by literature75) prior to in vivo 
study to check the selectivity of the cell line as tumor model.  The control 
compound 2 also exposed weak light toxicity to 4T1 cells (Figure B.4).   
Furthermore, while exploring the potential to increase reaction yields and 
product purities, compound 5 was found to be unstable in aqueous solution.  
Compound stability in water/acetonitrile was compared between compound 5 
(iodinated) and compound F (non-iodinated).  Although all vials were kept in 
dark, 5 lost its color and decomposed quickly (by 12 h) while solution of F was 
unchanged up to 36 h end point (Figure B.5).  The unexpected short compound 




termination of further study on this compound pair, and one of the opportunities 
to develop the near-IR absorbing therapeutic probe was lost.   
 
         
 
Figure B.5. Stability comparison between 5 (vials 01 – 04) and F (vials 11 – 14).  
Both compounds were prepared as 1 mg/mL at the beginning.  Conditions tested 
in each vial: 01 & 11, pure water/acetonitrile 1:1 mixture; 02 & 12, 0.1% acetic 
acid in water/acetonitrile; 03 & 13, 0.1% TFA in water/acetonitrile; 04 & 14, 0.1% 
TFA in water/CAN with C18 silica gel.  All vials were kept in dark except when 
photos were taken.  Compound 5 was not stable in both neutral and weak acidic 





B.2.2 Hydantoin replacing first generation targeting agent preparation and 
biological affinity check 
Both green and red fluorescence dye were tagged with hydantoin “IY-IY” 
targeting moiety 15 through simple “click” reaction (Scheme B.4).  Other 
synthetic route for the hydantoin fragment synthesis was also successful 
(Scheme B.5).  Non-targeting control fragment was synthesized at the same 
time (Scheme B.6 and 7).   
 
 
Figure B.6. Live cell imaging of 3-G on 4T1 cells.  Top: 2 M 3-G stained for 1 h 
followed by washing, a fluorescence channel; b bright field; c merged.  Bottom: 
blank control with washing, d fluorescence channel; e bright field; f merged.   
 
Live cell imaging with 4T1 breast cancer cells indicated compound 3-G 
was uptaken into the cells within 1 h (Figure B.6), but histochemical staining with 
breast cancer and normal tissues showed contradictory results.  As shown in 
Figure B.7, 3-G stained brighter on malignant cells than normal cells in general, 




3-R did not provide any observable red fluorescence signal for either tumor or 
normal tissue (Figure B.8a, c). Antibody staining (Figure B.8b, d) indicated that 
tumor cells expressed more TrkC on cell surface.  Furthermore, the Kd value 
could not be obtained using Low’s method (detected cell associated 
fluorescence on NIH3T3-TrkC+ cells, excitation/emission at 485/528 nm).85   
 
 
Figure B.7. Histochemical staining of 3-G on tumor (malignant stage III) and 






Figure B.8. 3-R (a, c) and TrkC antibody (b, d) staining on tumor and normal 
tissues (same magnification scale).   
 
 
Figure B.9. Structural comparison between targeting moieties in A (left) and 3 





When comparing the original triazole targeting moiety and the replaced 
hydantoin moiety (Figure B.9), atom distance between Tyr Cα and Ile Cα in 
triazole was one bond extra (four vs. three).  Triazole contains a free primary 
amine in its structure that can be protonated and interact in biological 
environment while hydantoin used the amine during cyclization reaction.  These 
unique structural properties of the original targeting design are critical for the 
binding affinity to TrkC protein.   
 
B.2.3 Preparation and photo-physical property of new aza-BODIPY based 
photosensitizer 
Heavy atom bromine was anchored in the aza-BODIPY core structure at 
the beginning of the scheme (Scheme B.3).  The intermediates were easy to 
purify without flash chromatography till compound 20.  Compound 20 showed 
promising photo-physical property with maximum emission at 829 nm (Figure 
B.10).  Yet, its Boc deprotection product showed poor water solubility.  Coupling 
cysteic acid to the dye core did not make the compound soluble enough in 
aqueous solution for biological assays.  Further attempts, including anchoring 
fixed cation charges in the molecule and coupling with ethylene glycols, did not 





             
Figure B.10. Normalized absorbance and fluorescence spectrum of 20.  
Exmax/Emmax = 774/829 nm.  ε = 5.21×10
4 M-1cm-1 in CHCl3.   
 
B.3 Conclusions 
Although near-IR imaging agent C showed possibility in tumor diagnosis 
with TrkC expressing metastatic breast cancer,72 the iodinated therapeutic probe 
1 was extremely hard to obtain.  Although the targeted compound showed 
therapeutic potential with TrkC-transfected NIH3T3 cells, but not with 4T1 breast 
cancer cell line.  Furthermore, the photosensitizer core was not stable in 
aqueous solution.  Moreover, the use of hydantoin, as a better dipeptide mimic, 
did not help in improving the binding affinity of the original TrkC-targeting moiety, 
with an unmeasurable cell-based Kd value.  Attempts to synthesize a novel near-
IR photosensitizer dye was also hit a dead end. Even though the new 
photosensitizer core was stable and easy to synthesize in a large scale, the poor 
solubility reduced its opportunity.  Unfortunately, the attempts to obtain a 




B.4 Experimental methods 
B.4.1 Synthesis of the featured compounds 
Synthesis of 1 and 2 
Compounds E and F were synthesized following the protocol in our 
previous publication,209 with minor modifications: (i) E was obtained by 
precipitation instead of time-consuming flash chromatography after aqueous 
phase washing.  Briefly, reaction mixture was dissolved in CH2Cl2 and filtered 
through cotton to remove insoluble particles, then 4X volume of hexanes was 
dropwise added to filtered solution with gentle stirring to get E as dark green 
powder (1.72 g, 46% yield).  (ii) 3.0 equiv. N-Boc-Cysteic acid triethyl amine 
salt and corresponding coupling reagents, instead of 5.0 equiv., were used to 
synthesize F with similar yield (1.39 g, 75%).  Iodination was performed before 
Boc deprotection to obtain 5 after reverse phase C18 flash chromatography with 
water-acetonitrile mixture (0.60 g, 45%).  Since BF2 complex can be easily 
damaged under common Boc deprotection conditions (TFA or HCl), a mild 
condition with 10 equiv. iPr2NEt and 15 equiv. BF3OEt2 was applied to get 6 (180 
mg, 90% yield).  Targeting ligand 8 was then coupled to the free amines in 6 
followed by the same mild Boc deprotection to finally acquire 1 (5 mg, 30% yield 
from 6, Scheme B.1).  Compound 8 was prepared separately to avoid C-I bond 























The scrambled control compound 2 was synthesized in a similar way from 
compound 6 by using a non-targeting ligand 9 (21% yield from 6, Scheme B.2).   
 
Synthesis of new photosensitizer core 20 and 23 
4'-(1-Piperazinyl) acetophenone (J, 12.3 g, 60 mmol) was dissolved in 
200 mL CH2Cl2 and cooled down to 0 
oC on ice.  3.0 equiv. Et3N and 1.0 equiv. 
Boc2O was added to reaction solution and mixed well.  Removed ice bath and 
stirred for 6 h, followed by 150 mL 1M HCl wash, sat. NaHCO3 and brine wash.  
After removing the solvents on rotavapor, a light yellow powder was obtained as 
16 (17.9 g, 98% yield).  1.0 equiv. 4-bromobenzaldehyde was then mixed with 
16 and dissolved in 120 mL MeOH.  Nine pellets of KOH was added to the 
solution and stirred vigorously at 25 oC for 12 h.  Solid precipitate was filtered 
out and washed with cold MeOH 200 mL five times to yield 17 as yellow powder 
(12.73 g, 46%).  80 mL MeOH was used to dissolve 17, and 1.2 equiv. KOH and 
20 equiv. nitromethane were added followed by 20 mL of MeOH.  The solution 
was refluxed in 80 oC oil bath for 24 h.  After removal of solvent on rotavapor, 
200 mL EtOAc was used to re-dissolve the solid and washed with 200 mL water.  
Crude compound was extracted from aqueous layer by extra 100 mL EtOAc.  
Combined EtOAc solution was dried to give 12.5 g (87% yield) 18 as sticky 
brownish solid.   Together with 20 equiv. NH4OAc, 18 was dissolved in 200 mL 
n-BuOH and refluxed at 120 oC for 24 h.  Reaction mixture was cooled to 0 oC 




yield) dark green powder 19 was obtained.  0.3 mmol 19 was then dissolved in 6 
mL CH2Cl2 with 10 equiv. BF3OEt2 and 20 equiv. 
iPr2NEt and stirred at 25 
oC for 
24 h to yield 170 mg (55%) dark pink powder 20 via flash chromatography (3% 
EtOAc in CH2Cl2).  Several Boc deprotection conditions were attempted until the 
3rd one (same for deprotection of 5 and 7) gave quantitative yield of 21.  5.0 
equiv. Boc-cysteic acid, 5.5 equiv. EDCI, 5.5 equiv. HOAt and 10 equiv. iPr2NEt 
were mixed with 21 in DMF and stirred for 12 h to obtain 95 mg 22 with 59% 
yield after reverse phase C18 flash chromatography.  Compound 23 was 
obtained with a quick Boc deprotection quantitatively with no further purification 











Scheme B.3. Continued.   
 
Synthesis of 3-G and 3-R 
N-Boc-Tyr(OBn)-OH (20 mmol) was dissolved in 80 mL CH2Cl2 and 
cooled down to 0 oC.  1.1 equiv. HOBt and 1.15 equiv. EDCI was then added in 
sequence and gently stirred for 20 min at 0 oC.  20 mL CH2Cl2 solution of 1.1 
equiv. Cbz-piperazine was poured into the reaction mixture followed by NMM.  
The reaction was finished in 12 h, and washed with 30 mL 2M HCl aqueous 




organic fractions were combined and dried with MgSO4 to yield 11 (10.6 g, 92%).  
Compound 11 was then dissolved in 60 mL TFA:CH2Cl2 (1:1) and stirred for 1 h 
to remove Boc protecting group.  After removal of solvents and washing with sat. 
NaHCO3, the compound was coupled with N
-Boc-Ile-OH that gave 12 (7.17 g, 
57%) as a white powder 12.  Boc deprotection followed by hydantoin formation 
led to formation of compound 13 (2.20 g, 35%).  Briefly, Boc deprotected 12 
(4.17 g, 7.1 mmol) was dissolved in acetonitrile (MeCN), then 1.2 equiv. 
NaHCO3 and 1.3 equiv. 4-nitrophenyl chloroformate were mixed in the solution 
under argon atmosphere.  The reaction was stirred at 25 oC for 6 h (negative 
ninhydrin test) before 1.0 equiv. of Et3N was added.  The white sticky mixture 
turned to bright yellow and reacted 10 h more followed by solvent removal.  13 
was purified through flash chromatography with 1% MeOH in CH2Cl2.  To 
completely remove Bn and Cbz protecting group to get 14 (0.713 g, 91%), 1.23 
g compound 13 was dissolved in 20 mL EtOH mixed with 0.13 equiv. Pd/C 
under H2 atmosphere.  IY-IY-hydantoin targeting moiety 15 (173 mg, 28%) was 
then obtained by substitute reaction between 1.2 mmol 14 and 0.6 mmol N 
(synthesis described in Appendix A) followed by reverse phase HPLC 
purification with water/MeCN system.  3-G (1.7 mg, 13%) and 3-R (1.2 mg, 8%) 
were then synthesized by “click” 15 with either the green fluorescence dye G or 
the red fluorescence dye H and purified by reverse phase HPLC purification with 













Synthesis of targeting (8) and non-targeting (9) ligands 
Synthesis of K and L were described in our previous publication.41  The 
targeting ligand 8 was obtained through a Cu(I) based “click” reaction (1.0 equiv. 
copper powder, 0.1 equiv. CuSO45H2O in 6:1 THF:H2O) followed by flash 
chromatography purification.(3.04 g, 30%, Scheme B.5)   
 
 











Scheme B.6. Continued.   
 
The non-targeting ligand 9 was synthesized in a similar way.  Compound 
24 (17.2 g, 82%) was converted from Nα-Boc-Tyr(OBn)-OH after coupling with 
N,O-dimethylhydroxylamine.  Compounds 25 (5.55 g, 38%) and 26 (5.01 g, 
100%) were obtained following similar protocol as reported earlier.41  A “click” 
reaction followed by general hydrogenation resulted in 9 (2.43 g, 100%) through 
27 (7.22 g, 77%, Scheme B.6).   
 
Attempted synthesis of non-targeting hydantoin ligand 31 
To improve the overall synthesis yield in making the non-targeting 
hydantoin probe 31, benzyl protecting group was added to Nα-Boc-Tyr(OBn)-OH 
at the start of the synthetic route by mixing with 1.0 equiv. benzyl bromide and 
3.0 equiv. K2CO3 in DMF solution to get compound 28 (14.4 g, 63%).  The 
following protocol was similar to the one used for synthesis of 14.  The synthesis 




because no selectivity was observed with the targeting hydantoin probes 





Scheme Β.7. Attempted synthesis of non-targeting hydantoin ligand 31.   
 
Improved synthesis of targeting agent C 
Large scale synthesis of compound C is hampered by the purification of 
the intermediates.  Introduction of side chain protected tyrosine azide M to the 
synthetic route paved way to easier purification of the coupling product 32 (161 
mg, 75%) and the “click” product 33 (63 mg, 70%) by reverse phase C18 flash 




solid was washed thoroughly with MeCN (remove yellow filtrate) to get C without 
further purification (85% yield, Scheme B.8).   
 
 




Β.4.2 Light and dark cytotoxicity assay settings 
4T1 and wild-type NIH3T3 cells were cultured with full culture medium 
(DMEM/F12 medium supplied with 10% FBS), and TrkC-transfected NIH3T3 
cells were cultured with full culture medium containing 0.4 g/L G418 adduct.  
Each type of cells were seeded in a 96-well plate as 5000 cell per well the day 
before the experiment to get cells adhered to plate surface in a single layer.  At 
the beginning of the test, various concentrations of compounds (0 – 2 μM final 
concentration) were added to each well.  Dark control plates were transferred to 
CO2 incubator directly, and light illumination plates were exposed to halogen 
lamp for 10 min before transferring to incubator.  Cell viability in each well was 
tested by a simple MTT assay.  Data was processed with Graph Prism® 6.0 
software.   
 
B.4.3 Live cell imaging protocol 
4T1 cells were (50,000) seeded in one of the 4-well imaging chamber 
(Thermo Scientific® #155383) the day before imaging.  Adhered cells were 
incubated with 2 μM 3-G or protein free medium (as blank control) for 1 h at 37 
oC in a CO2 incubator followed by thorough washing with culture medium without 
phenol red.  Confocal fluorescence images were taken under 20X objective with 
GFP emission filter using Olympus® FV1000 microscope at Microscopy and 





Β.4.4 Tissue histology staining and imaging protocol 
Breast cancer tissue array with matched adjacent healthy breast tissue 
(BR243n, US Biomax) was washed sequentially with xylene, EtOH X 2, 90% 
EtOH, 70% EtOH, pure water, and PBS buffer X 2, 5 min each.  Carefully 
remove the liquid covered on the tissue samples and equilibrate the tissue with 2 
μM fluorescent compound (3-G, 3-R) or TrkC Rabbit monoclonal antibody 
(1:1000 dilution, Cell Signaling Technology® #3376) followed by Alexa Fluor 488 
tagged goat anti-rabbit secondary mAb (1:500 dilution, Jackson 
ImmunoResearch® #111-545-144) for 40 min.  After thorough washing with PBS 
buffer, the tissue array was mounted with Vectashield® medium (with DAPI) with 
cover glass.  Confocal fluorescence images were taken under 20X objective with 
corresponding emission filter (DAPI, GFP, CY5.5) using Olympus® FV1000 
microscope at MIC at Texas A&M University.   
 
Β.5 Compound Characterization 
1 
C72H76BF2I2N15O14S2  
1H NMR (400 MHz, DMSO) δ 10.35 (s, 2H), 8.86 (s, 2H), 8.56 – 8.23 (m, 8H), 
8.22 – 8.09 (m, 4H), 7.97 – 7.84 (m, 1H), 7.77 – 7.56 (m, 2H), 7.47 (dd, J = 19.4, 
8.0 Hz, 2H), 7.40 – 7.27 (m, 2H), 7.20 (d, J = 8.3 Hz, 1H), 7.12 (d, J = 8.4 Hz, 




4.86 – 4.60 (m, 2H), 4.44 – 4.23 (m, 2H), 3.87 (s, 6H), 3.72 – 3.55 (m, 4H), 3.23 
– 2.86 (m, 6H), 2.00 – 1.81 (m, 2H), 1.43 – 1.18 (m, 6H), 1.01 – 0.65 (m, 12H).  
 
13C NMR (101 MHz, DMSO) δ 168.90, 167.20, 161.97, 157.26, 156.05, 144.45, 
142.56, 141.84, 139.36, 132.03, 131.73, 129.83, 126.09, 125.98, 123.12, 119.64, 
119.58, 115.08, 115.01, 114.94, 114.88, 114.45, 64.34, 55.57, 53.37, 51.92, 
50.98, 37.07, 25.05, 17.97, 13.74, 13.64, 11.02, 1.09.  
 










1H NMR (400 MHz, DMSO) δ 10.57 – 10.20 (m, 1H), 9.23 (s, 1H), 8.92 (s, 1H), 
8.57 – 8.28 (m, 4H), 8.23 (s, 2H), 8.20 – 8.01 (m, 2H), 7.96 – 7.81 (m, 2H), 7.74 




5.28 – 5.12 (m, 2H), 4.26 – 4.20 (m, 4H), 3.90 – 3.85 (m, 6H), 3.59 (s, 6H), 3.56 





1H NMR (400 MHz, MeOD) δ 8.05 (s, 2H), 7.64 (d, J = 8.4 Hz, 4H), 7.54 – 7.28 
(m, 8H), 7.00 (d, J = 8.7 Hz, 4H), 4.59 (s, 2H), 3.86 (s, 6H), 3.79 (dd, J = 17.2, 
11.8 Hz, 2H), 3.66 (dd, J = 13.0, 6.5 Hz, 2H), 3.07 – 2.97 (m, 2H), 1.83 – 1.75 





11B NMR (128 MHz, DMSO) δ 0.20, -0.04, -0.27.  
 








1H NMR (400 MHz, DMSO) δ 10.84 (s, 2H), 8.24 (s, 4H), 7.96 (s, 2H), 7.61 (d, J 
= 8.5 Hz, 4H), 7.49 – 7.38 (m, 4H), 7.07 (d, J = 8.8 Hz, 4H), 4.29 (s, 2H), 3.84 (s, 
6H), 3.74 (dd, J = 11.3, 5.6 Hz, 1H), 3.60 (dd, J = 8.4, 4.5 Hz, 1H), 3.12 (dd, J = 





11B NMR (128 MHz, DMSO) δ 0.19, -0.02, -0.25.  
 





1H NMR (400 MHz, MeOD) δ 7.73 (s, 1H), 6.82 (d, J = 8.1 Hz, 2H), 6.56 (t, J = 




= 14.3, 4.6 Hz, 1H), 3.40 – 3.29 (m, 1H), 1.84 – 1.68 (m, 1H), 1.48 – 1.40 (m, 
1H), 1.38 (s, 9H), 1.11 – 0.94 (m, 1H), 0.86 (t, J = 7.4 Hz, 3H), 0.72 (d, J = 6.8 
Hz, 3H).  
 
13C NMR (101 MHz, MeOD) δ 175.16, 171.21, 157.59, 149.19, 131.01, 127.67, 









1H NMR (400 MHz, CDCl3) δ 7.38 (s, 1H), 6.74 (d, J = 8.1 Hz, 2H), 6.69 – 6.56 
(m, 2H), 5.23 – 4.90 (m, 2H), 3.74 (t, J = 6.6 Hz, 1H), 3.21 – 2.79 (m, 2H), 2.27 – 
1.98 (m, 1H), 1.38 (s, 9H), 1.25 – 1.12 (m, 1H), 0.96 (d, J = 6.6 Hz, 3H), 0.92 – 





1H NMR (400 MHz, DMSO) δ 9.10 (s, 2H), 8.18 (s, 2H), 8.04 – 7.85 (m, 6H), 
7.34 – 7.05 (m, 10H), 7.03 – 6.85 (m, 8H), 6.59 (d, J = 6.8 Hz, 4H), 5.29 – 5.06 
(m, 2H), 3.88 (s, 6H), 3.66 – 3.53 (m, 4H), 3.14 – 3.07 (m, 4H), 3.07 – 2.93 (m, 










1H NMR (400 MHz, CDCl3) δ 7.45 – 7.25 (m, 10H), 7.11 (d, J = 8.3 Hz, 2H), 6.90 




= 5.5 Hz, 1H), 3.57 – 3.39 (m, 3H), 3.38 – 3.16 (m, 3H), 3.05 – 2.81 (m, 4H), 
1.45 (s, 9H).  
 
13C NMR (101 MHz, CDCl3) δ 170.77, 158.01, 155.08, 137.07, 136.49, 131.64, 
130.65, 130.59, 129.67, 128.81, 128.72, 128.63, 128.37, 128.19, 128.10, 127.61, 









1H NMR (400 MHz, CDCl3) δ 7.43 – 7.25 (m, 10H), 7.15 – 6.99 (m, 2H), 6.88 – 
6.79 (m, 2H), 5.10 (d, J = 1.8 Hz, 2H), 5.06 – 5.02 (m, 1H), 5.01 (s, 2H), 3.96 (s, 
1H), 3.54 – 3.32 (m, 3H), 3.27 (dt, J = 13.2, 8.1 Hz, 3H), 2.91 (ddd, J = 22.3, 
13.2, 7.3 Hz, 4H), 1.85 (ddd, J = 9.5, 7.9, 5.1 Hz, 2H), 1.43 (s, 9H), 1.06 (ddd, J 





1H NMR (400 MHz, CDCl3) δ 7.69 – 7.51 (m, 10H), 7.40 (d, J = 8.5 Hz, 2H), 7.14 
(d, J = 8.6 Hz, 2H), 5.51 (s, 1H), 5.41 (s, 2H), 5.37 (dd, J = 10.3, 6.0 Hz, 1H), 
5.26 (s, 2H), 4.11 (d, J = 3.7 Hz, 1H), 3.95 – 3.58 (m, 9H), 3.53 (dd, J = 14.3, 5.8 





13C NMR (101 MHz, CDCl3) δ 173.18, 166.96, 157.74, 157.18, 154.90, 136.83, 
136.20, 130.16, 128.72, 128.44, 128.42, 128.09, 127.87, 127.81, 127.30, 114.85, 








1H NMR (400 MHz, MeOD) δ 6.99 (d, J = 8.3 Hz, 2H), 6.63 (d, J = 8.3 Hz, 2H), 
5.09 (dd, J = 10.7, 5.6 Hz, 1H), 3.83 (d, J = 3.7 Hz, 1H), 3.83 (d, J = 3.7 Hz, 1H), 
3.58 – 3.35 (m, 5H), 3.29 – 3.23 (m, 1H), 3.11 (dd, J = 14.2, 5.6 Hz, 1H), 2.80 – 





1H NMR (400 MHz, MeOD) δ 7.10 – 7.00 (m, 4H), 6.68 (dd, J = 8.5, 3.4 Hz, 4H), 
5.17 (dd, J = 10.0, 6.2 Hz, 2H), 4.17 (d, J = 2.3 Hz, 2H), 3.90 (dd, J = 13.7, 3.5 
Hz, 2H), 3.80 – 3.37 (m, 31H), 3.22 (ddd, J = 31.0, 14.3, 5.8 Hz, 2H), 2.83 (t, J = 
2.3 Hz, 1H), 1.83 – 1.74 (m, 1H), 1.71 – 1.61 (m, 1H), 1.42 – 1.30 (m, 1H), 1.26 
– 1.13 (m, 1H), 1.07 – 0.95 (m, 2H), 0.90 (t, J = 7.4 Hz, 3H), 0.82 (dd, J = 16.2, 





13C NMR (101 MHz, MeOD) δ 175.89, 175.38, 169.37, 169.35, 167.66, 166.49, 
159.07, 158.58, 157.47, 157.44, 131.50, 131.39, 128.79, 128.72, 116.32, 116.30, 
80.69, 76.01, 71.57, 71.37, 71.26, 71.03, 70.12, 62.90, 61.63, 59.05, 54.29, 
53.72, 46.65, 44.30, 43.93, 43.63, 41.37, 38.14, 37.84, 34.50, 34.37, 27.10, 









1H NMR (400 MHz, CDCl3) δ 7.82 (d, J = 9.0 Hz, 2H), 6.80 (d, J = 9.0 Hz, 2H), 
3.67 – 3.40 (m, 4H), 3.37 – 3.08 (m, 4H), 2.45 (s, 3H), 1.43 (s, 9H).  
 
13C NMR (101 MHz, CDCl3) δ 196.55, 154.78, 154.12, 130.53, 128.25, 113.88, 








1H NMR (400 MHz, CDCl3) δ 7.97 (d, J = 8.8 Hz, 2H), 7.69 (d, J = 15.6 Hz, 1H), 
7.55 – 7.42 (m, 5H), 6.88 (d, J = 8.9 Hz, 2H), 3.65 – 3.49 (m, 4H), 3.42 – 3.27 
(m, 4H), 1.47 (s, 9H).  
 
13C NMR (101 MHz, CDCl3) δ 187.82, 154.77, 154.12, 141.92, 134.40, 132.25, 








1H NMR (400 MHz, CDCl3) δ 7.80 (d, J = 9.0 Hz, 2H), 7.42 (d, J = 8.4 Hz, 2H), 
7.14 (d, J = 8.4 Hz, 2H), 6.81 (d, J = 9.0 Hz, 2H), 4.79 (dd, J = 12.6, 6.3 Hz, 1H), 
4.62 (dd, J = 12.6, 8.3 Hz, 1H), 4.21 – 4.07 (m, 1H), 3.60 – 3.52 (m, 4H), 3.36 – 





13C NMR (101 MHz, CDCl3) δ 194.57, 154.78, 154.38, 138.62, 132.28, 130.34, 








1H NMR (400 MHz, CDCl3) δ 7.84 (d, J = 8.3 Hz, 4H), 7.74 (d, J = 8.5 Hz, 4H), 
7.46 (d, J = 8.3 Hz, 4H), 7.01 (s, 2H), 6.94 (d, J = 8.5 Hz, 4H), 3.62 (s, 8H), 3.32 
(s, 8H), 1.49 (s, 18H).  
 
13C NMR (101 MHz, CDCl3) δ 154.86, 154.09, 152.22, 149.55, 140.30, 133.13, 









1H NMR (400 MHz, CDCl3) δ 8.03 (d, J = 9.0 Hz, 4H), 7.83 (d, J = 8.6 Hz, 4H), 
7.49 (d, J = 8.6 Hz, 4H), 6.97 (s, 2H), 6.86 (d, J = 9.1 Hz, 4H), 3.62 – 3.47 (m, 
8H), 3.37 – 3.21 (m, 8H), 1.48 (s, 18H).  
 
13C NMR (101 MHz, CDCl3) δ 156.79, 154.80, 152.30, 145.18, 140.23, 131.79, 






11B NMR (128 MHz, CDCl3) δ 1.35, 1.10, 0.85.  
 








1H NMR (400 MHz, DMSO) δ 9.29 (s, 4H), 8.17 (d, J = 8.8 Hz, 4H), 8.06 (d, J = 
8.4 Hz, 4H), 7.72 (d, J = 8.5 Hz, 4H), 7.63 (s, 2H), 7.12 (d, J = 9.1 Hz, 4H), 3.70 
(t, J = 9.1 Hz, 8H), 3.48 – 3.25 (m, 8H).  
 










1H NMR (400 MHz, MeOD) δ 8.09 (d, J = 8.9 Hz, 4H), 7.83 (d, J = 8.4 Hz, 4H), 




2H), 4.02 – 3.87 (m, 4H), 3.80 – 3.73 (m, 4H), 3.62 – 3.55 (m, 2H), 3.53 – 3.35 
(m, 8H), 3.11 – 3.02 (m, 2H), 1.46 (s, 18H).  
 








1H NMR (400 MHz, DMSO) δ 8.17 (d, J = 9.0 Hz, 4H), 8.12 – 7.98 (m, 10H), 
7.73 (d, J = 8.6 Hz, 4H), 7.64 (s, 2H), 7.11 (d, J = 9.1 Hz, 4H), 4.56 (d, J = 7.5 
Hz, 2H), 3.79 – 3.48 (m, 16H), 2.98 (d, J = 14.4 Hz, 2H), 2.82 (dd, J = 14.3, 10.0 
Hz, 2H).  
 
13C NMR (101 MHz, DMSO) δ 165.87, 155.22, 151.69, 144.14, 138.37, 131.75, 
131.59, 131.32, 131.16, 130.49, 122.59, 119.68, 119.33, 113.85, 49.72, 48.42, 





11B NMR (128 MHz, DMSO) δ 1.37, 1.11, 0.85.  
 





1H NMR (400 MHz, CDCl3) δ 7.43 – 7.24 (m, 5H), 7.06 (d, J = 8.5 Hz, 2H), 6.87 




(s, 3H), 3.13 (s, 3H), 2.97 (dd, J = 13.6, 6.1 Hz, 1H), 2.81 (dd, J = 12.7, 6.5 Hz, 





1H NMR (400 MHz, CDCl3) δ 7.45 – 7.27 (m, 5H), 7.17 (d, J = 8.5 Hz, 2H), 6.91 
(d, J = 8.6 Hz, 2H), 5.03 (s, 2H), 4.71 – 4.51 (m, 2H), 2.89 (qd, J = 13.5, 6.1 Hz, 








1H NMR (400 MHz, CDCl3) δ 7.41 – 7.29 (m, 5H), 5.23 (d, J = 12.2 Hz, 1H), 5.18 
(d, J = 12.2 Hz, 1H), 3.72 (d, J = 6.4 Hz, 1H), 2.03 – 1.88 (m, 1H), 1.48 (dtt, J = 
15.0, 7.5, 3.8 Hz, 1H), 1.29 – 1.14 (m, 1H), 0.92 (d, J = 6.8 Hz, 3H), 0.86 (t, J = 





13C NMR (101 MHz, CDCl3) δ 170.22, 135.29, 128.80, 128.73, 128.64, 67.45, 





1H NMR (400 MHz, CDCl3) δ 7.45 – 7.20 (m, 11H), 6.97 – 6.86 (m, 2H), 6.86 – 
6.71 (m, 2H), 5.20 – 5.09 (m, 3H), 4.97 – 4.87 (m, 2H), 3.07 (ddd, J = 38.5, 31.4, 
10.3 Hz, 2H), 2.20 – 1.94 (m, 1H), 1.39 (s, 9H), 1.15 – 1.05 (m, 1H), 0.87 (dd, J 





13C NMR (101 MHz, CDCl3) δ 168.51, 157.76, 155.27, 137.29, 134.86, 130.77, 
128.88, 128.85, 128.69, 128.60, 128.06, 127.55, 70.19, 67.87, 41.02, 38.47, 








1H NMR (400 MHz, CDCl3) δ 7.44 – 7.26 (m, 10H), 6.94 (d, J = 8.3 Hz, 2H), 6.82 
(d, J = 8.5 Hz, 2H), 5.12 (q, J = 12.2 Hz, 2H), 5.01 (s, 2H), 4.96 (d, J = 7.1 Hz, 





1H NMR (400 MHz, CDCl3) δ 7.43 – 7.25 (m, 10H), 6.91 (d, J = 8.6 Hz, 2H), 6.80 
(d, J = 8.6 Hz, 2H), 6.26 (d, J = 6.7 Hz, 1H), 5.14 (d, J = 12.1 Hz, 1H), 5.08 (d, J 
= 12.1 Hz, 1H), 4.99 (s, 3H), 4.86 (dd, J = 13.6, 5.9 Hz, 1H), 3.97 – 3.84 (m, 1H), 
3.03 (d, J = 5.8 Hz, 2H), 1.86 – 1.74 (m, 1H), 1.42 (s, 9H), 1.11 – 0.99 (m, 1H), 





13C NMR (101 MHz, CDCl3) δ 171.26, 158.14, 137.18, 135.22, 130.52, 128.75, 
128.73, 128.68, 128.11, 127.92, 127.61, 115.12, 79.72, 70.15, 67.38, 59.44, 








1H NMR (400 MHz, CDCl3) δ 7.43 – 7.19 (m, 10H), 6.97 (d, J = 8.6 Hz, 2H), 6.80 
(d, J = 8.6 Hz, 2H), 5.13 (d, J = 12.2 Hz, 1H), 5.06 (d, J = 12.0 Hz, 1H), 4.97 (s, 
2H), 4.89 – 4.80 (m, 1H), 3.47 – 3.32 (m, 1H), 3.03 (dd, J = 6.3, 3.0 Hz, 2H), 
2.15 (s, 2H), 1.95 – 1.79 (m, 1H), 1.29 – 1.15 (m, 1H), 1.09 – 0.95 (m, 1H), 0.87 
(d, J = 6.9 Hz, 3H), 0.81 (t, J = 7.4 Hz, 3H).  
 
13C NMR (101 MHz, CDCl3) δ 171.74, 158.06, 137.20, 135.40, 130.48, 128.71, 
128.62, 128.56, 128.36, 128.09, 127.60, 115.04, 70.14, 67.24, 59.62, 53.38, 








1H NMR (400 MHz, DMSO) δ 10.26 (s, 2H), 8.63 – 8.49 (m, 2H), 8.20 (s, 2H), 
8.16 (d, J = 8.7 Hz, 4H), 7.92 (d, J = 7.7 Hz, 2H), 7.67 (d, J = 7.9 Hz, 2H), 7.48 
(ddd, J = 11.1, 8.3, 3.8 Hz, 2H), 7.37 (s, 2H), 7.20 (dd, J = 8.1, 5.6 Hz, 4H), 7.13 
(d, J = 8.9 Hz, 4H), 6.87 (dd, J = 14.2, 8.4 Hz, 4H), 4.65 (dd, J = 12.6, 6.4 Hz, 
2H), 4.15 (ddd, J = 24.8, 9.5, 4.4 Hz, 2H), 3.88 (s, 6H), 3.65 – 3.52 (m, 2H), 3.20 





13C NMR (101 MHz, MeOD) δ 170.44, 163.61, 159.01, 157.53, 155.59, 146.26, 
139.55, 134.10, 133.06, 131.57, 131.11, 130.90, 130.08, 127.14, 125.40, 125.00, 
122.81, 120.32, 116.48, 115.23, 79.59, 65.07, 56.06, 54.70, 44.13, 29.20, 27.22.  
 










1H NMR (400 MHz, DMSO) δ 8.20 – 8.13 (m, 4H), 8.10 (d, J = 9.2 Hz, 2H), 7.93 
(d, J = 9.6 Hz, 2H), 7.66 (dd, J = 13.8, 7.9 Hz, 2H), 7.51 – 7.43 (m, 2H), 7.38 (s, 




6.71 (dd, J = 16.3, 8.4 Hz, 4H), 5.75 – 5.37 (m, 2H), 4.67 (dd, J = 36.5, 30.5 Hz, 
4H), 3.88 (s, 6H), 3.14 – 2.92 (m, 8H), 2.89 (dd, J = 13.7, 6.6 Hz, 2H), 2.73 (t, J 
= 17.4 Hz, 4H), 1.70 (dd, J = 18.7, 11.2 Hz, 4H), 1.35 (s, 18H), 1.20 (s, 9H), 1.16 
(s, 9H), 0.98 (t, J = 7.2 Hz, 4H), 0.78 (dd, J = 12.3, 7.3 Hz, 6H), 0.60 (t, J = 6.2 
Hz, 6H).  
 
13C NMR (101 MHz, DMSO) δ 168.94, 167.39, 167.32, 161.95, 157.40, 155.01, 
153.66, 144.47, 139.45, 139.31, 132.04, 131.72, 130.79, 130.53, 129.40, 129.06, 
124.78, 123.36, 123.17, 121.85, 120.91, 119.51, 114.44, 77.71, 77.57, 63.76, 





11B NMR (128 MHz, MeOD) δ 1.14, 0.88, 0.63.  
 











TRK TRANSFECTED CELLS GENERATION FOR OBOC LIBRARY 
SCREENING OF NOVEL TRK TARGETING LIGAND 
 
C.1 Introduction 
Tropomyosin receptor kinase (Trk) family plays an important role in 
signaling pathways related to cell proliferation and survival.  Trk receptors are 
overexpressed in several different types of cancer and are strongly correlated 
with tumor progression and metastasis.219-221  Non-specific synthetic Trk 
inhibitors are reported in literature that successfully reduced tumor growth.222,223   
It would be beneficial to develop a unique binder to a specific Trk receptor 
for tumor treatment because it can potentially increase the therapeutic output 
and reduce the risk of side effect in chemotherapy.  Preference of neurotrophin 
interactions on cell surface indicates the distinguishable extracellular domains 
among TrkA – C, making it possible to develop small organic molecules that 
selectively bind to one type of Trk receptor.   
Cancer cellular membranes usually contain varied amounts of Trk 
receptors and other proteins, which poses a significant challenge in identifying a 
selective Trk ligand via a cell-based assay.  Hence, it is desirable to overexpress 
a single Trk gene in a transfected cell line.  Unfortunately, it is extremely hard to 




ideal when comparing the ligand affinity to different Trk receptors.  Thus, the aim 
of this project was to obtain uniform Trk transfected cells.   
Several factors need to be considered when performing gene 
transfections.  First, a proper host cell line is required for the transfected 
mammalian gene to be translated and folded correctly.  Human embryonic 
kidney 293 (HEK293) and Chinese hamster ovary (CHO) cells are most typical 
for mammalian gene transfection.  NIH3T3 and some other cell lines are also 
used as host cells in transfection.224-227  Second, the design of the DNA plasmid 
or gene construct is crucial for gene expression that is generally beyond our 
knowledge.  Luckily, Addgene has several plasmids deposited by Dr. Moses 
Chao’s research group that showed Trk receptor expression in their previous 
work.224  In their design, CMV and SV40 promoters were used to improve the 
expression efficiency of the inserted genes.  Third, a proper method to perform 
the plasmid transfection into the host cells is important.  In general, the plasmid 
can be transfected by chemical, physical or biological methods.226,228,229  
Phosphate precipitation and liposome complexation are the widely applied 
chemical methods and suitable for most of the cell types,226,230 while 
electroporation is the most common physical way to introduce foreign 
gene.231,232  Furthermore, a suitable way for selecting cell population with high 
transfected protein expression is another key factor to improve the transfection 
efficacy.  Usually, a fluorescence tag or an antibiotic resistant selection marker is 




antibiotic pressure (in culture medium) is applied to remove the population with 
low transfection rate.225,226   
In this chapter, the general protocol of Trk gene transfection and results 
are summarized for future reference.   
 
C.2 Results and Discussion 
C.2.1 Sequencing and quality check of the plasmids 
 
Plasmids containing TrkA, B and C genes were extracted from single 
colonies of E. coli. and sequenced briefly to confirm the correct gene insert was 
obtained from Addgene (Figure C.1a).  As a sample study, a list of primers was 
designed with primer-BLAST tool233 in order to confirm the whole sequence of 
the inserted TrkC gene on pcDNA-TrkC plasmid (Table C-1).   
 

























Figure C.1. General protocol to prepare DNA plasmid for mammalian cell 
transfection.  Detailed plasmid extraction protocol can be obtained from Zymo 
Research website.   
 
reverse primers












When designing the primers, several factors were taken into 
consideration.  (i) Length of the primer was between 15 to 25 nucleotides.  (ii) 
Estimated melting temperature (Tm) of the primer was 60 ± 5 
oC {estimated by 
equation Tm (
oC) = 4(C + G) + 2(A + T), primer-BLAST also provide an estimate 
value listed in Table C.1}.  (iii) No homo-dimer or hairpin structure was formed 
for a single primer; each primer was unique for the plasmid sequence region it 
was designed to bind to (no match with other positions on the whole plasmid).  
(iv) The distance between two primers on the same sequencing direction was 
less than 700 nucleotides.  More detailed discussion has been presented in 
literature.234   
 
C.2.2 TrkC plasmid transfection into mammalian cells 
NIH3T3 and HEK 293 cell lines are well characterized in our group that it 
does not express notable amount of Trk receptors (via flow cytometry and 
western blots, as negative controls in Figure C.2).  Thus it was applied as the 
parent cell line for the gene transfection.  TrkC plasmids were transfected into 
NIH3T3 and HEK293 cells by using Lipofectamine 3000 transfection kit.  0.8 g/L 
G418 were added in the culture medium to eliminate the untransfected cells.  
Expression of TrkC protein was checked when the growth rate of the transfected 






C.2.3 TrkC protein expression check after transfection 
Western blotting result (Figure C.2a) provided positive feedback proving 
the TrkC proteins were expressed in the transfected NIH3T3 cells; yet further 
test with flow cytometry (Figure C.2b) showed negative respond (no difference 
among all four samples) indicating TrkC proteins were not correctly located on 
cellular membrane.   
Similar protocols were applied to HEK293 cells, and obtained same 
results as mentioned above (Figure C.2c, d).  A higher loading of pcDNA-TrkC 




Figure C.2. TrkC protein expression confirmation after mammalian cell 
transfection.  a Western blot (lysate of TrkC+ cell was used as reference) and b 
flow cytometry result for pcDNA-TrkC transfected NIH3T3 cells.  c Western blot 




lines in b and d represented transfected cells with anti-TrkC and corresponding 
2nd antibody staining. 
 
C.3 Conclusions 
Correct Trk DNA plasmids were obtained from Addgene and successfully 
extracted from host E. coli.  The extracted plasmids were also successfully 
transfected into mammalian cells (NIH3T3 and HEK293) and fully translated into 
corresponding proteins.  But due to unknown reason, the Trk protein did not 
localize on cell surface that stopped its application in our research.   
 
C.4 Experimental Methods 
E. coli. samples with TrkA-RFP (Addgene® # 24093), pcDNA-TrkB 
(Addgene® #24088), and pcDNA-TrkC (Addgene® #24089) plasmids, which all 
contain CMV promoter and were encoded with antibiotic resistance genes 
(Kanamycin/Neomycin resistance for TrkA and Ampicillin/Neomycin resistance 
for TrkB and C), were obtained from Addgene (deposited by Dr. Moses Chao224).   
 
C.4.1 Plasmid extraction and sequencing protocol 
Before preparing larger amount of DNA plasmid for transfection in 
mammalian cells, the plasmid quality was tested.  E. coli. with TrkA, B, or C 
plasmid were seeded on lysogeny broth (LB) argar plate with antibiotics and 
kept at 37 oC for growth for 12 h.  Random single colonies were picked and 




of plasmids.  Each colonies were numbered and the colony on the gel were kept 
in 4 oC refrigerator while the E. coli. samples cultured in buffer were centrifuged 
down.  Plasmids from each sample were extracted via a commercial kit (Zymo 
Research® #D4209).  Two Primers (CMV-Forward, sequence: CGCAAATGGG-
CGGTAGGCGTG; DsRed1-N, sequence: GTACTGGAACTGGGGGGACAG) at 
5’ and 3’ end of the inserted genes were applied for a partial sequencing to 
confirm the correct gene was implanted into the plasmid we received.  Most of 
the samples (sequenced by McLab) showed perfect alignment with the Trk 
genes logged within the gene databank as well as the references from Addgene. 
(Figure C.1a)  One colony for each Trk gene was selected and cultured for 
larger amount of plasmids which was extracted by Zymo maxi-prep kit (Zymo 
Research® #D4202).  Extracted pcDNA-TrkC plasmids were concentrated and 
confirmed DNA concentration as 2.1 mg/mL (concentration = A260 on a Take3
® 
micro-volume plate with a path length of 0.5 mm).   
 
C.4.2Trk plasmid transfection protocol 
NIH3T3 cells are relative vulnerable for antibiotic G418 (killing curve 
shown in Figure C.3), as 0.8 mg/mL G418 in culture medium almost killed all 
cells after 6 d (medium refreshed every 3 d).  Same concentration of G418 was 
applied to select out the proper transfected populations in NIH3T3 cells.   
NIH3T3 cells were cultured with full culture medium (DMEM-F12 with 10% 




μg) were then transfected into NIH3T3 cells using Lipofectamine 3000 
transfection kit (Life Technologies® #L3000-001).  The transfected cells were 
then incubated with the plasmids for 48 h, and then detached and reseeded into 
a T25 tissue culture flask with 0.8 g/L antibiotic G418 in the full culture medium.  
The cells were kept under constant antibiotic pressure while culturing.  Two 
weeks after transfection, growth rate of the transfected NIH3T3 cells recovered, 
and enough number of cells were harvested to check the TrkC protein 
expression.   
 
 
Figure C.3. Killing curve of NIH3T3 wild type cells with G418 after 6 d.  Data 
was averaged from 8 independent parallel experiments. (n = 8, mean ± SD)   
 
C.4.3 Western blotting protocol for checking TrkC expression after transfection 
The pcDNA-TrkC transfected NIH3T3 cells were seeded on a T75 tissue 
culture flask and cultured in DMEM/F12 medium containing 0.8 g/L G418 till 80% 
confluency.  After washing with cold PBS buffer twice, 1.0 mL RIPA lysis and 




phosphatase inhibitor cocktail (Thermo Scientific® #78440) was added and kept 
on ice for 30 min.  The mixture was scratched and transferred to a 1.5 mL 
Eppendorf tube.  After centrifuging at 12500 x g at 4 oC for 20 min, the 
supernatant was collected as cell lysates.  Total protein concentration was 
confirmed by BCA protein assay kit (Thermo Scientific® #23225), and 30 μg of 
protein was loaded into each lane of the 15% SDS-PAGE protein gel.  After 
electrophoresis with 180 V for 70 min, the gel was washed and protein got 
transferred to a PVDF membrane (Thermo Scientific® #LC2005) and stained 
with primary anti-TrkC antibody (1:1000 dilution, Cell Signaling Technology® 
#3376S) followed by corresponding secondary antibody conjugated with 
Horseradish Peroxidase (HRP) (1:5000 dilution, Jackson ImmunoResearch® 
#111-035-144).  Western blotting image was taken after treatment with blotting 
substrate (Thermo Scientific® #32106).   
 
C.4.4 Flow cytometry protocol for checking TrkC expression after transfection 
To check the TrkC protein expression level on cellular membrane, 
cultured transfected NIH3T3 cells were detached from the tissue culture flask 
with enzyme-free dissociation buffer (Thermo Scientific® #13151014).  Cells 
were collected in each sample vial 1 – 4 (0.5 million each), and incubated with 
either blank control buffer or primary antibody (1 & 2 blank buffer, 3 anti-TrkB 
(Cell Signaling Technology® #4603), 4 anti-TrkC) 30 min.  After washing with 




3 & 4 anti-rabbit IgG with red fluorescence label (Thermo Scientific® #A21245)} 
was used to resuspend cell pellets.  Thorough washed and resuspended with 
PBS, the samples in vials 1 – 4 were analyzed with flow cytometer (gated with 
live cells, check fluorescence counts in FL4 red channel).  If TrkC was detected 
on cell surface, sample vial 4 (in red) should present significantly stronger 





SUPPORTING INFORMATION FOR CHAPTER II* 
 
D.1 General Experimental Procedures 
All reactions were carried out under an inert atmosphere (nitrogen, or 
argon where stated) with dry solvents under anhydrous conditions.  Glassware 
for anhydrous reactions was dried in an oven at 140 oC for minimum 6 h prior to 
use.  Dry solvents were obtained by passing the previously degassed solvents 
through activated alumina columns.  Reagents were purchased at a high 
commercial quality (typically 97% or higher) and used without further purification, 
unless otherwise stated.   
Flash chromatography was performed using silica gel (230 - 400 mesh).  
Analytical thin layer chromatography (TLC) was carried out on Silicycle® silica 
gel plates and visualized by UV, ninhydrin, para-methoxybenzaldehyde and/or 
potassium permanganate stains. A reversed phase column on preparation high 
performance liquid chromatography (prepHPLC) was also applied to purify 
compounds in 10 – 90% MeCN/water gradient with 0.1% trifluoroacetic acid over 
20 minutes.   
 
*Reprinted with permission from Jiang, Z.;  Yang, Z.;  Li, F.;  Li, Z.;  Fishkin, N.; 
Burgess, K., Targeted Maytansinoid Conjugate Improves Therapeutic Index for 
Metastatic Breast Cancer Cells. Bioconjugate Chem. 2018, 29, 2920-2926. 




High field NMR spectra were recorded with Bruker Avance III at 400 MHz 
for 1H, and 101 MHz for 13C for all compounds except 1 and 2. NMR spectra of 1 
and 2 were taken with Bruker Avance 500 at 500 MHz for 1H, and 126 MHz for 
13C. All spectra were calibrated using residual non-deuterated solvent as an 
internal reference (CDCl3: 
1H NMR = 7.24, 13C NMR = 77.0, MeOD-d4: 
1H NMR 
= 3.30, 13C NMR = 49.0, DMSO-d6: 
1H NMR = 2.50, 13C NMR = 39.5).  The 
following abbreviations were used to explain the multiplicities: s = singlet, d = 
doublet, t = triplet, q = quartet, quint = quintet, dd = double doublet, dt = double 
triplet, dq = double quartet, m = multiplet, br = broad.  Electrospray ionization 
mass spectrometry (ESI-MS) data were collected on triple-stage quadrupole 
instrument in a positive mode.  All statistical analyses were carried out by 
GraphPad Prism® 6.0 Software.  Results are represented as means ± SD.   
Cell Culture. Hs578t (ATCC®) and MCF-7 cells were cultured on 75 cm2 
tissue culture flasks in Dulbecco’s Modified Eagle Medium/nutrient mixture F-12 
Ham (DMEM/F12, Millipore Sigma) supplement with 10% fetal bovine serum 
(FBS). NIH3T3-TrkC cells, NIH3T3 cells transfected with tropomyosin receptor 
kinase C (TrkC), were cultured on 75 cm2 tissue culture flasks in DMEM/F12 
supplement with 10% FBS including 0.4 g/L G418 (GIBCO®).  4T1 cells were 
cultured on 75 cm2 tissue culture flasks in RPMI-1640 medium (ATCC®) with 10% 
FBS. All cells were cultured in a humidified incubator at 37 °C with 5% CO2 and 





D.2 Compound Synthesis and Characterization 
D.2.1 Preparation and Characterization of Compound B   
Compounds C, D and E were prepared following the protocol previously 
described.41,81 Compound B was first published by our group.3  Briefly, 
compound C (2.4 equiv.) and E (1.0 equiv.) were dissolved in DMSO (0.02 M), 
K2CO3 (5.0 equiv.) was then added to the reaction mixture, and stirred at room 
temperature for 36 h. Product was purified via reversed phase column on 
prepHPLC, with 25 – 35% yield.   
 
 
Scheme D.1. Synthesis of targeting moiety B.  Reprinted with permission from 
[217].   
 
B (IY-IY-TEG)  




1H NMR (400 MHz, DMSO-d6) δ 8.28 (s, 2H), 6.99 (d, 4H), 6.61 (d, 4H), 6.16 (s, 
2H), 4.38 (s, 2H), 4.13 (s, 2H), 3.49 – 3.00 (m, 31H), 2.54 (s, 2H), 1.91 (s, 2H), 
1.33 (d, 2H), 1.05 – 0.94 (m, 2H), 0.93 – 0.84 (m, 6H), 0.75 (d, 6H);   
 
 
13C NMR (101 MHz, DMSO-d6) δ 165.86, 158.14, 157.80, 156.27, 141.51, 
130.23, 125.37, 123.47, 115.03, 80.28, 77.00, 69.70, 69.46, 68.94, 68.48, 60.28, 






D.2.2 Synthesis and Characterization of Targeted and Non-targeted 
Maytansinoid DM4 Conjugates (3, 4, 1, 5, 2) 
Preparation of 4,6-dichloro-N-(2-(pyridin-2-yldisulfanyl)ethyl)-1,3,5-triazin-
2-amine (3) 
2-(pyridin-2-yldisulfanyl)ethanamine (336 mg, 2.0 mmol), Cyanuric 
chloride (369 mg, 2.0 mmol) were dissolved in 20 mL 1,4-dioxane. K2CO3 (552 
mg, 4.0 mmol) was added to reaction mixture and stirred at room temperature 
for 12 h. Solvent was removed in vacuum, and compound was used without 




methylbutyl)-1H-1,2,3-triazol-1-yl)-3-(4-hydroxyphenyl)propan-1-one)  (4) 
Compound 3 (334 mg, 1.0 mmol) and C (773 mg, 2.0 mmol) were 
dissolved in 10 mL DMSO. K2CO3 (1.38 g, 10.0 mmol) was added to reaction 
mixture and stirred at room temperature for 24 h. Solvent was removed in 
vacuum, compound was purified via flash chromatography on Biotage® Isolera 
purification system with 10 g reversed phase silica gels column (200 – 400 
mesh). Column was flushed at 12 mL/min, 10% water / 90% MeCN for 1 column 
volume (1 CV), then changed to 100% MeCN gradually in 10 CV, followed by 
MeCN wash in 2 CV. Fractions containing 4 were collected, and solvent was 





C50H67N17O4S2   
1H NMR (400 MHz, MeOD-d4) δ 8.41 (d, 1H), 7.99 (s, 2H), 7.80 (d, 1H), 7.73 (t, 
1H), 7.17 (t, 1H), 6.99 (d, 4H), 6.67 (d, 4H), 6.04 (t, 2H), 3.96 (d, 2H), 3.34-3.70 
(m, 22H), 2.95 (t, 2H), 1.74 (m, 2H), 1.42 (m, 2H), 1.06 (m, 2H), 0.90 (t, 6H), 






13C NMR (101 MHz, MeOD-d4) δ 168.15, 167.44, 166.29, 161.52, 157.95, 
151.50, 150.49, 139.01, 131.57, 127.14, 122.85, 122.29, 121.25, 116.55, 74.32, 







HRMS (ESI) m/z calculated for C50H68N17O4S2







Characterization of maytansinoid DM4   
DM4 
C38H54ClN3O10S 
1H NMR (400 MHz, CDCl3) δ 6.82 (s, 1H), 6.73 (d, 1H), 6.66 (s, 1H), 6.42 (dd, 
1H), 6.20 (s, 1H), 5.68 (dd, 1H), 5.42 (q, 1H), 4.79 (d, 1H), 4.27 (t, 1H), 3.98 (s, 
3H), 3.64 (d, 1H), 3.50 (d, 1H), 3.35 (s, 3H), 3.28 (s, 1H), 3.23 (s, 3H), 3.11 (d, 
1H), 3.03 (d, 1H), 2.88 (s, 3H), 2.67 – 2.39 (m, 3H), 2.18 (d, 1H), 2.03 – 1.75 (m, 
2H), 1.64 (s, 3H), 1.52 – 1.39 (m, 2H), 1.33 (d, 6H), 1.29 (d, 6H), 1.21 (d, 1H), 
0.80 (s, 3H);   
042518-1h #52-84 RT: 0.23-0.37 AV: 33 NL: 8.21E8
T: FTMS + p ESI Full ms [300.0000-1800.0000]

































13C NMR (101 MHz, CDCl3) δ 172.38, 171.06, 168.85, 156.13, 152.27, 142.42, 
141.07, 139.22, 133.44, 127.87, 125.61, 122.36, 119.05, 113.26, 88.66, 81.06, 
78.29, 74.26, 67.33, 60.10, 56.75, 52.49, 46.78, 44.14, 41.35, 39.04, 36.31, 







Synthesis of targeted DM4 maytansinoid conjugate 1   
Compound 4 (8.3 mg, 0.008 mmol) and maytansinoid DM4 (9.3 mg, 
0.012 mmol) were dissolved in 0.5 mL DMF, and stirred at room temperature for 




1 (IY-DM4)   
C83H116ClN19O14S2   
1H NMR (500 MHz, MeOD-d4) δ 8.22 (s, 2H), 7.07 (d, 4H), 6.71 (d, 4H), 6.67 (d, 
2H), 6.59 (m, 1H), 6.19 (t, 2H), 5.69 (dd, 1H), 5.46 (d, 1H), 4.66 (dd, 1H), 4.45 (d, 
2H), 4.19 (m, 1H), 3.93 (s, 3H), 3.79 – 3.42 (m, 20H), 3.39 – 3.34 (m, 5H), 3.25 
– 3.15 (m, 4H), 2.94 (d, 1H), 2.84 (s, 3H), 2.82 – 2.63 (m, 4H), 2.59 – 2.38 (m, 
2H), 2.15 (dd, 1H), 2.07 – 1.89 (m, 5H), 1.67 (s, 3H), 1.58 – 1.43 (m, 5H), 1.32 – 
1.27 (m, 6H), 1.27 – 1.20 (m, 6H), 1.19 – 1.10 (m, 2H), 1.05 (d, 1H), 0.99 (t, 6H), 






13C NMR (126 MHz, MeOD-d4) δ 174.33, 172.30, 171.27, 168.38, 162.69, 
162.41, 158.12, 157.60, 155.28, 143.17, 142.90, 140.39, 134.50, 131.63, 129.70, 
126.76, 126.72, 124.65, 123.18, 119.38, 119.11, 116.64, 115.12, 89.84, 81.74, 
79.50, 75.71, 68.86, 61.95, 61.38, 57.31, 56.97, 53.82, 52.99, 51.29, 47.31, 
44.50, 44.26, 40.58, 40.12, 39.67, 39.13, 37.87, 37.16, 36.56, 33.51, 31.17, 










HRMS (ESI) m/z calculated for C83H118ClN19O14S2
2+ 851.9113; found (M+2H)2+  
851.9129   
 
 
05092017_IY-DM4 #1-92 RT: 0.02-1.79 AV: 92 NL: 3.10E5
T: FTMS + p ESI Full ms [250.0000-2000.0000]














































































































Scheme D.2. Synthesis of non-targeted DM4 maytansinoid conjugate 2.  
Reprinted with permission from [217].   
 
Synthesis of (S,2S,2'S,3S,3'S)-1,1'-(4,4'-(6-(2-(pyridin-2-yldisulfanyl) 
ethylamino) -1,3,5-triazine-2,4-diyl) bis (piperazine-4,1-diyl)) bis (2-(4-((S)-1-
amino-2-(4-hydroxyphenyl)ethyl)-1H-1,2,3-triazol-1-yl)-3-methylpentan-1-
one) (5) 
Compounds 3 (30 mg, 0.09 mmol) and D (69.6 mg, 0.18 mmol) were 
dissolved in 1.0 mL DMSO. K2CO3 (124 mg, 0.9 mmol) was added to reaction 
mixture and stirred at room temperature for 48 h. Solvent was removed in 
vacuum, compound was purified through reversed phase column on prepHPLC 
(10.0 mg, 0.01 mmol, 11% yield).   
5 




1H NMR (400 MHz, MeOD-d4) δ 8.45 (s, 1H), 7.96 (s, 2H), 7.85 (d, 1H), 7.80 (d, 
1H), 7.22 (br, 1H), 6.93 (d, 4H), 6.63 (d, 4H), 5.66 (d, 2H), 4.76 – 4.66 (m, 2H), 
4.09 – 3.41 (m, 18H), 3.29 – 3.10 (m, 4H), 3.02 (m, 2H), 2.36 (br, 2H), 1.01 (m, 






13C NMR (101 MHz, MeOD-d4) δ 168.09, 161.25, 157.86, 150.55, 144.71, 
139.18, 131.48, 131.43, 126.91, 126.85, 124.04, 122.48, 121.22, 116.58, 64.96, 







HRMS (ESI) m/z calculated for C50H68N17O4S2
+ 1034.5076; found (M+H)+  
1034.5067   
 
 
Synthesis of non-targeted DM4 maytansinoid conjugate 2 
5 (9.8 mg, 0.0095 mmol) and maytansinoid DM4 (9.1 mg, 0.0117 mmol) 
were dissolved in 0.5 mL DMF, and stirred at room temperature for 12 h.  2 was 
purified through reversed phase column on prepHPLC (6.2 mg, 0.0036mmol, 38% 
yield).   
042518-2h #88-123 RT: 0.39-0.55 AV: 36 NL: 3.21E8
T: FTMS + p ESI Full ms [300.0000-1800.0000]































2 (YI-DM4)  
C83H116ClN19O14S2   
1H NMR (500 MHz, MeOD-d4) δ 7.97 (s, 2H), 7.08 (d, 2H), 6.92 (m, 4H), 6.72 – 
6.55 (m, 7H), 5.69 (m, 3H), 5.46 (dd, 1H), 4.74 (dd, 1H), 4.66 (d, 2H), 4.30 – 
4.13 (m, 2H), 4.07 – 3.49 (m, 20H), 3.37 (s, 3H), 3.29 – 3.10 (m, 8H), 2.96 – 
2.71 (m, 7H), 2.66 (t, 2H), 2.60 – 2.30 (m, 5H), 2.14 (d, 1H), 1.93 (m, 2H), 1.68 
(s, 3H), 1.58 – 1.46 (m, 3H), 1.35 – 1.18 (m, 12H), 1.05 – 0.90 (m, 9H), 0.88 – 






13C NMR (126 MHz, MeOD-d4) δ 174.35, 172.29, 171.25, 168.11, 157.88, 
157.60, 155.27, 144.73, 143.20, 142.90, 140.38, 134.49, 131.50, 131.45, 129.70, 
126.84, 126.71, 124.02, 123.17, 119.37, 116.59, 116.55, 115.12, 89.84, 81.74, 
79.49, 75.70, 68.83, 64.95, 61.37, 57.31, 56.97, 53.82, 51.32, 50.03, 47.29, 
45.07, 40.64, 39.81, 39.66, 39.53, 39.07, 37.87, 37.19, 36.56, 33.49, 31.17, 










HRMS (ESI) m/z calculated for C83H118ClN19O14S2
2+ 851.9113; found (M+2H)2+  
851.9100   
 
 
D.2.3 1D NMR Spectra Comparison between DM4 and Compound 1 
Stacking 1D NMR spectra of DM4 and 1 shows no significant chemical 
shifts for most protons or carbons from DM4, newly appeared peaks in 1 come 
from the targeting moiety in 4. (Figure D.1) Thus the core structure of DM4 is not 
disrupted during the disulfide exchange.   
042518-3h #52-87 RT: 0.23-0.39 AV: 36 NL: 3.63E8
T: FTMS + p ESI Full ms [500.0000-2000.0000]
































Figure D.1. Comparison of NMR spectra of DM4 (red) and 1 (blue).  a 1H NMR. 
b 13C NMR.  Reprinted with permission from [217].   
 
D.3 Compound Property Check 
D.3.1 Cell-based Assay for Dissociation Constant Measurement 
Dissociation constant of our TrkC targeting moiety was determined via a 
cell-based assay.85 NIH3T3-TrkC cells were seeded in 24-well plate with 2 x 104 
cells/well and incubated overnight.  For total binding test, culture medium in 






incubated for 2 h.  Fluorescent probe A was dissolved in DMEM/F12 containing 
1% BSA with various concentrations, 250 μL was added to each well to make 
final concentrations from 0 to 300 nM (as shown in Figure II.2).  For non-specific 
binding test, medium containing 200x concentrations of B (relative to A to be 
added in each well) was applied for the first 2 h incubation.   
After 1 h incubation, the medium was removed and cells were washed 
carefully twice with 500 μL PBS containing 0.5% Cremophor EL.  Then washing 
buffer was replaced by 500 μL 1% SDS aqueous solutions, fluorescence 
intensity (Ex/Em 485/528 nm) was scanned with BioTek® Synergy H4 hybrid 
microplate reader.  Results were analyzed with GraphPad Prism® 6.0 software 
using one site-total and non-specific binding model.   
 
D.3.2 Protocol for Solubility Measurement 
Compound solubility was measured by UV absorbance following the 
literature.88,209 Briefly, stock solution (50 mM) of 1 was prepared in DMSO.  Then 
various concentrations (0 – 500 μM, Figure II.3a) were prepared in pH 7.40 PBS 
with 9% ethanol, 1% DMSO and 0.5% CrEL on 24-well plate (500 μL per 
concentration).  The plate was shaken on a horizontal orbital shaker in dark for 6 
h at room temperature, and kept steady overnight for equilibrium.  Then the plate 
was centrifuged at 600x g for 10 min.  3 x 100 μL supernatant was transferred 




Transparent Microplate) and read compound absorbance at 254 nm against 
blank using microplate reader (BioTek® Synergy H4).   
 
D.3.3 Determination of Conjugate Stability 
Compound 1 was prepared as 20 μM stock in pH 7.40 PBS, or 
DMEM/F12 with 10% FBS, containing 0.5% CrEL, and kept at 37 oC.  Boc-L-
tyrosine was prepared as 6 mM separate stock in pH 7.40 PBS, kept at 4 oC, 
and used as internal standard for analytical HPLC trace analysis.  300 μL 
solution of 1 and 100 μL solution of Boc-L-tyrosine were taken out from stock 
and mixed after certain time of incubation (0 – 196 h).  Mixed samples were 
injected to analytical HPLC column (0.75 mL/min flow rate, 10% MeCN / 90% 
water to 95% MeCN / 5% water gradient with 0.1% trifluoroacetic acid in 20 min), 
and traces of absorbance at 254 nm were collected (Figure D.2a, b; retention 
time 9.5 min for Boc-L-tyrosine, 12.4 min for 1).  Area under curves for 1 was 
normalized and plotted in GraphPad Prism® 6.0 software.   
Conjugate stability in mouse serum is tested in a similar way.  1 was 
prepared as 20 μM stock in mouse serum:PBS (1:1, pH 7.40), containing 0.5% 
CrEL, and kept at 37 oC.  Boc-L-tyrosine was prepared as 3 mM separate stock 
in pH 7.40 PBS, kept at 4 oC, and used as internal standard for analytical HPLC 
trace analysis.  40 μL solution of 1 and 10 μL solution of Boc-L-tyrosine were 
taken out from stock and mixed after certain time of incubation (0 – 24 h).  Mixed 




MeCN / 90% water to 95% MeCN / 5% water gradient with 0.1% trifluoroacetic 
acid in 20 min), and traces of absorbance at 254 nm were collected (Figure D.2c. 
retention time 8.6 min for Boc-L-tyrosine, 13.3 min for 1).   
Based on the HPLC-UV traces, there was no other significant peak 
except the internal standard (Boc-Tyrosine) and conjugate 1 even after 24 h of 
incubation, which means the conjugate was relatively stable, and free DM4 is 
not released at detectable level (Figure D.2).  Previous studies also indicated 
that hindered disulfide bond was resistant to thiol exchange reactions.61   
 
         
 
Figure D.2. Normalized HPLC traces for conjugate 1 stability in a PBS, b DMEM 
with 10% FBS, c mouse serum:PBS (1:1) (IS: internal standard Boc-L-tyrosine, 





D.4 Biological Studies 
D.4.1 TrkC Expression Confirmation of Cells involved 
Western Blots were applied to check TrkC expression level on Hs578t 
and MCF-7 cells.   
Cell lysates were prepared from cells cultured in a 75 cm2 tissue culture 
flask by adding 1 mL of RIPA buffer  (Thermo Scientific® #89901) with 1% 
protease inhibitor cocktail (Thermo Scientific® #78440). After 30 min incubation 
on ice, the mixtures were transferred to 1.5 mL Eppendorf tube and spin down at 
14,000X g for 20 min at 4 oC. Supernatant was transferred out carefully as 
lysates, and the protein concentration was measured out by BCA protein assay 
kit (Thermo Scientific® #23227).   
20 μg of each cell lysate was loaded onto 10% SDS-PAGE protein gels, 
and added 180V/80mA electric current for 75 min to separate the proteins in the 
lysate. Separated proteins were then transferred to PVDF membrane 
(Invitrogen® #LC2005), blocked with blocking buffer in PBS (Thermo Scientific® 
#37515) for 1 h, and incubated with anti-TrkC rabbit mAb (Cell Signaling 
Technology® #3376) overnight at 4 oC. After thorough wash with tris-buffered 
saline (TBS) containing 0.05% Tween 20, the membrane was incubated with 
1:5000 dilution of goat anti-rabbit IgG secondary antibody with HRP tag 
(Invitrogen® #31460), and imaged after reacting with ECL western blotting 





Figure D.3. Western Blot imaging result with anti-TrkC mAb on Hs578t and 
MCF-7.  Reprinted with permission from [217].   
 
The Western Blotting result clearly showed that TrkC protein is expressed 
in Hs578t (TrkC+) cells but not MCF-7 (TrkC-) cells, which is consistent with 
other studies.75 76   
Immunohistochemistry staining using anti-TrkC rabbit mAb (Cell Signaling 
Technology® #3376) demonstrated TrkC overexpression in 4T1 tumor tissue. 
Previous studies also reported that 4T1 tumor overexpresses TrkC, and TrkC 
plays an essential role in breast tumor growth and metastasis.75   
 
 
Figure D.4. Immunohistochemistry staining of 4T1 tumor using anti-TrkC 









D.4.2 In vitro Cytotoxicity Assay 
Hs578t (TrkC+) or MCF-7 (TrkC-) cells were seeded on 96-well plates as 
5000 cells/well (50 μL) and incubated in the incubator overnight. Various 
concentrations of DM4, 1 and 2 were prepared in 50 μL protein-free hybridoma 
medium (PFHM II) and added to cells to make final concentrations from 0.03 nM 
to 10 μM. All plates were incubated for 72 h, and cell viability was tested with 
AlamarBlue assay (Invitrogen). Briefly, in a well containing 100 μL medium, 10 
μL of AlamarBlue reagent was added, and incubated for 2 h. Fluorescence 
intensity (Ex/Em 560/590 nm) was measured on a microplate reader (BioTek® 
Synergy H4). Results are processed through GraphPad Prism® 6.0 software.   
Cytotoxicities (IC50) of all compounds are listed as:   
With Hs578t cells (TrkC+): DM4, 1.10 ± 0.11 nM; 1, 28.1 ± 1.9 nM; 2, 23.0 
± 2.5 nM.  
With MCF-7 cells (TrkC-): DM4, 1.86 ± 0.63 nM; 1, 137 ± 14 nM; 2, 50.2 ± 
6.6 nM.   
Cellular therapeutic indexes were calculated based on the following 
equation:   
cellular therapeutic index = IC50 with TrkC
- cells / IC50 with Trk
+ cells  
Cytotoxicity of conjugate 1 against 4T1 cells was tested with the same 






Figure D.5. Cytotoxicity of conjugate 1 on 4T1 cells. IC50 = 401 ± 38 nM.  
Reprinted with permission from [217].   
 
D.4.3 In vivo therapeutic study 
Breast tumor model was created by inoculating 4T1 cells on BALB/c 
mouse (Charles River®).  Briefly, 4T1 cells were cultured under recommended 
condition of DMEM media supplemented with 10% FBS at 37 oC and 5% CO2.  
Upon reaching ~70% confluence, cells were harvested and mixed with 10 
mg/mL Corning® Matrigel® matrix, and then inoculated into BALB/c mice at total 
number of 1 x 106 cells per mouse.  10 days was waited after tumor implantation 
to allow tumor growth reach to 2~3 mm (long side).  To start therapy, tumor-
implanted mice were randomly assigned into two study groups with 5 mice per 
group. For therapy group, 30 nmol 1 in 100 μL solution cocktail (5% DMSO, 5% 
Cremophor EL surfactant, and 90% PBS) was intravenously injected into mouse 
every other day for seven shots. Similarly, 2 was injected as control group.  




CrEL-contained PBS to yield 30 nmol per 100 μL solution for each shot of i.v. 
injection.  From the start of therapy, tumor size was measured as length of short 
side and long side, and weight of mouse was monitored on a daily basis until the 
end of study.  Tumor size was calculated by the formula of (short side)2 x (long 
side)/2. The study was ended after three-week therapy by scarifying the mice as 
described in animal protocol.  Lastly, 4T1 tumors were harvested and ex vivo 
measured of the size.  All animal experiments were performed under approved 
protocols in compliance with the guidelines established by the Institutional 
Animal Care and Use Committee (IACUC) of the Houston Methodist Research 









SUPPORTING INFORMATION OF CHAPTER III 
 
E.1 General Experimental Procedures 
General reaction and purification methods are the same as Appendix D.  
High field NMR spectra were recorded with Bruker Avance III at 400 MHz 
for 1H, and 101 MHz for 13C for all compounds except for compound 5.  NMR 
spectra of 5 were taken with Bruker Avance 500 at 500 MHz for 1H, and 126 
MHz for 13C.   
Electrospray ionization mass spectrometry (ESI-MS) data were collected 
on triple-stage quadrupole instrument in a positive mode.  Paper spray mass 
spectrometry data were obtained with LTQ XL mass spectrometer (Thermo 
Scientific®, San Jose, CA).  Instrumental conditions used for the positive-mode 
mass spectrometry is specified as following: paper spray voltage: 3.5 kV; 
heated-capillary temperature: 275 °C; heated-capillary voltage: 33 V; tube lens 
voltage: 65 V.  Both the full-scan and tandem mass spectra were acquired, and 
the corresponding m/z values confirmed the structure of each species.  The 
qualitative filter paper (VWR® #8310-026) was cut into an isosceles triangle 
shape with 10 mm height and 5 mm base.  A copper clip was employed as both 
the paper holder and the spray voltage conductor.  The distance from the paper 




Cell Culture. U87 cells were cultured on 75 cm2 tissue culture flasks in 
Dulbecco’s Modified Eagle Medium/nutrient mixture F-12 Ham (DMEM/F12, 
Millipore Sigma) supplement with 10% fetal bovine serum (FBS). All cells were 
cultured in a humidified incubator at 37 °C with 5% CO2 and 95% air.   
 
E.2 Compound Synthesis and Characterization 
E.2.1 Preparation and Characterization of Compound F 
Compound F was prepared via the protocol previous published.108  Briefly, 
2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (TBTU, 
1.2 g, 1.2 equiv.) and compound H108 (1.1 g, 3.0 mmol, 1.0 equiv.) were 
dissolved in N,N-dimethylformamide (DMF, 0.3 M) in an ice bath, gemcitabine 
hydrochloride ( 0.90 g, 3.0 mmol, 1.0 equiv.) and N,N-diisopropylethylamine 
(iPr2NEt, 1.1 mL, 2.0 equiv.) were then added to the reaction mixture, and stirred 
at room temperature for 18 h.  Product was purified via flash chromatography (2 
– 5% MeOH in CH2Cl2) with 63% yield (1.1 g).  Protecting group of the thiol in 
the product (0.59 g, 1.0 mmol) was then removed under acidic conditions in 1:3 
(v/v) trifluoroacetic acid (TFA):CH2Cl2 (0.2 M) on ice for 1 h, with triethylsilane 
(Et3SiH, 0.39 mL, 2.4 equiv.) as scavenger.  After removing solvents, reaction 
was washed with diethyl ether 5 mL X 2 to get compound F (0.36 g as 1.0 equiv. 









1H NMR (400 MHz, MeOD) δ 8.17 (d, J = 7.9 Hz, 1H), 6.28 (t, J = 8.1 Hz, 1H), 
6.16 (d, J = 7.9 Hz, 1H), 5.50 (dt, J = 13.5, 6.9 Hz, 1H), 4.27 (dd, J = 6.7, 3.1 Hz, 












































13C NMR (101 MHz, MeOD) δ 171.66, 145.40, 130.47, 129.25, 127.29, 122.73, 
95.82, 81.80, 71.07 (dd, J = 31.8, 16.8 Hz), 60.57, 38.94, 20.00.   
 
162.29, 85.88 (dd, J = 40.0, 22.0 Hz) from TFA, 66.87, 15.41 from Et2O. 
 
E.2.2 Synthesis and Characterization of Targeted (1a – d), Control Cyanine-
Gemcitabine Conjugates (2a, b, d) and Compound 3 – 5 
Synthesis of 1a – d   
Compounds B (Sigma Aldrich® #543292) and D (abcr GmbH® 
#AB332015) were commercially available, and compounds A and C were 
prepared by the protocol previously described.235  As shown in Scheme III.1, 
equal equiv. of compound F and representative free heptamethine dye A – D 
were dissolved in DMF (0.06 M), followed by 2.0 equiv. of triethylamine (Et3N) 
and stirred at 25 °C for 6 h.  Solvent was removed in vacuum, and compound 






1H NMR (400 MHz, DMSO) δ 8.66 (s, 2H), 8.24 (d, J = 7.6 Hz, 1H), 7.56 (d, J = 
7.4 Hz, 2H), 7.46 – 7.37 (m, 6H), 7.30 – 7.20 (m, 3H), 6.34 – 6.23 (m, 1H), 6.19 
– 6.08 (m, 1H), 4.23 – 4.10 (m, 6H), 3.95 – 3.85 (m, 1H), 3.85 – 3.71 (m, 1H), 
3.71 – 3.59 (m, 1H), 3.10 – 3.02 (m, 2H), 2.78 (t, J = 6.5 Hz, 2H), 2.70 – 2.59 (m, 
4H), 2.30 (t, J = 7.3 Hz, 1H), 2.21 (t, J = 7.3 Hz, 4H), 1.92 – 1.80 (m, 2H), 1.77 – 
1.51 (m, 22H), 1.46 – 1.35 (m, 4H).   
 
13C NMR (101 MHz, DMSO) δ 174.22, 171.69, 171.64, 162.65, 154.87, 154.01, 
144.53, 142.13, 140.83, 132.92, 128.51, 124.80, 122.34, 111.16, 95.93, 94.56, 
81.09, 58.87, 58.78, 48.70, 43.48, 36.70, 33.45, 33.05, 31.72, 27.41, 27.36, 






+) (m/z): 998.4531 Calculated M+: 998.4544 (1.3 





1H NMR (400 MHz, DMSO) δ 9.99 (s, 1H), 8.99 (s, 1H), 8.74 – 8.62 (m, 2H), 
8.26 (d, J = 7.6 Hz, 1H), 8.16 (d, J = 7.9 Hz, 1H), 7.72 – 7.61 (m, 1H), 7.57 (dd, 
J = 15.2, 7.3 Hz, 2H), 7.47 – 7.35 (m, 3H), 7.32 – 7.20 (m, 2H), 6.34 (dd, J = 
09121806 #791-926 RT: 1.00-1.17 AV: 136 SB: 158 0.09-0.29 NL: 3.68E6
T: FTMS + p ESI Full ms [450.0000-1100.0000]
























































14.2, 6.2 Hz, 2H), 6.26 (d, J = 7.9 Hz, 1H), 6.18 – 6.03 (m, 1H), 4.27 – 4.12 (m, 
5H), 3.96 – 3.85 (m, 1H), 3.80 (d, J = 12.7 Hz, 1H), 3.65 (dd, J = 12.8, 3.3 Hz, 
1H), 3.17 (s, 1H), 3.08 (t, J = 6.4 Hz, 1H), 2.99 (t, J = 6.8 Hz, 1H), 2.78 (t, J = 6.5 
Hz, 1H), 2.72 – 2.52 (m, 8H), 1.89 – 1.71 (m, 12H), 1.71 – 1.55 (m, 12H).   
 
13C NMR (101 MHz, DMSO) δ 172.22, 171.72, 171.65, 162.66, 159.27, 154.89, 
154.00, 146.77, 144.78, 142.18, 140.91, 140.85, 133.09, 128.51, 124.74, 122.28, 
111.29, 101.32, 95.99, 94.76, 58.78, 58.71, 50.68, 48.74, 48.71, 48.56, 43.58, 






+) (m/z): 1042.3564 Calculated M+: 1042.3571 




C52H64ClF2N5O10S2   
1H NMR (400 MHz, DMSO) δ 8.70 (d, J = 14.2 Hz, 1H), 8.63 (d, J = 14.0 Hz, 1H), 
8.24 (d, J = 7.6 Hz, 1H), 7.55 (dd, J = 10.2, 7.6 Hz, 2H), 7.49 – 7.33 (m, 5H), 
7.29 – 7.20 (m, 4H), 6.38 (d, J = 14.3 Hz, 1H), 6.25 (d, J = 14.1 Hz, 1H), 6.14 (t, 
02281901b #589-617 RT: 0.75-0.78 AV: 29 SB: 48 0.48-0.54 NL: 1.44E5
T: FTMS + p ESI Full ms [500.0000-1200.0000]


















































J = 7.5 Hz, 1H), 4.25 – 4.10 (m, 5H), 3.91 – 3.86 (m, 1H), 3.80 (d, J = 11.4 Hz, 
2H), 3.67 (d, J = 3.5 Hz, 1H), 3.64 (d, J = 3.5 Hz, 1H), 3.08 (t, J = 6.5 Hz, 2H), 
2.78 (t, J = 6.5 Hz, 2H), 2.70 – 2.60 (m, 4H), 2.54 (d, J = 7.2 Hz, 2H), 2.21 (t, J = 
7.3 Hz, 2H), 2.06 (s, 1H), 1.90 – 1.79 (m, 4H), 1.79 – 1.68 (m, 4H), 1.67 – 1.62 
(m, 12H), 1.62 – 1.53 (m, 2H), 1.45 – 1.35 (m, 2H).   
 
13C NMR (101 MHz, DMSO) δ 174.31, 172.32, 171.71, 171.12, 162.73, 154.94, 
154.11, 145.28, 144.86, 144.07, 142.27, 142.10, 141.01, 140.75, 133.52, 132.69, 
128.61, 128.52, 125.47, 125.06, 124.57, 122.90, 122.34, 118.01, 117.22, 111.53, 
110.96, 101.87, 100.75, 96.05, 81.14, 68.45, 58.83, 50.65, 48.92, 48.60, 43.80, 
43.38, 36.83, 33.51, 31.77, 27.54, 27.49, 27.42, 27.37, 26.57, 26.05, 25.79, 






+) (m/z): 1020.4040 Calculated M+: 1020.4057 





1H NMR (400 MHz, DMSO) δ 8.71 – 8.63 (m, 2H), 8.24 (d, J = 7.6 Hz, 1H), 7.57 
(d, J = 7.4 Hz, 2H), 7.47 – 7.37 (m, 4H), 7.31 – 7.20 (m, 3H), 6.39 – 6.25 (m, 2H), 
6.14 (t, J = 7.5 Hz, 1H), 4.24 – 4.10 (m, 6H), 3.94 – 3.60 (m, 4H), 3.07 (t, J = 6.6 
02251909 #975-1060 RT: 1.23-1.33 AV: 86 SB: 91 0.78-0.89 NL: 7.01E7
T: FTMS + p ESI Full ms [400.0000-1200.0000]























































Hz, 2H), 2.77 (t, J = 6.5 Hz, 2H), 2.64 (t, J = 5.6 Hz, 4H), 1.89 – 1.60 (m, 19H), 
1.00 – 0.92 (m, 6H).   
 
13C NMR (101 MHz, DMSO) δ 171.91, 171.88, 171.62, 162.65, 154.83, 154.01, 
144.83, 144.59, 142.27, 140.80, 132.93, 128.49, 124.78, 122.83, 122.34, 111.24, 
101.24, 95.91, 81.12, 68.44, 58.78, 48.74, 44.93, 36.70, 31.63, 27.46, 27.40, 






 +) (m/z): 854.4091 Calculated M+: 854.4121 (3.5 
ppm).   
 
 
Synthesis of 2a, b, d   
Compounds 2 were prepared in the same way as for compounds 1 
described above (Scheme E.2).  Briefly, TBTU (3.86 g, 1.2 equiv.) and 
compound H (3.49 g, 1.0 equiv.) were dissolved in DMF (0.3 M) in an ice bath, 
2’-deoxycytidine (2dC, 2.27 g, 10.0 mmol, 1.0 equiv.) and iPr2NEt (2.10 mL, 1.2 
equiv.) were then added to the reaction mixture, and stirred at room temperature 
for 18 h. Product compound 3 was purified via flash chromatography (2 – 4% 
MeOH in CH2Cl2) with 22% yield (1.20 g). Protecting group of the thiol in 3 was 
then removed under acidic conditions in 1:3 (v/v) TFA:CH2Cl2 (0.2 M) on ice for 
1 h, with Et3SiH (2.4 equiv.) as scavenger. After removing solvents, reaction was 
washed with diethyl ether 5 mL X 2 to get compound 4 (quantitative).   
Then equal equiv. of compound 4 and representative free heptamethine 
dye A, B or D were dissolved in DMF (0.06 M), followed by 2.0 equiv. of Et3N 
02251904 #858-878 RT: 1.08-1.10 AV: 21 SB: 92 0.88-0.99 NL: 6.91E7
T: FTMS + p ESI Full ms [400.0000-1200.0000]

















































and stirred at 25 °C for 6 h. Solvent was removed in vacuum, and compound 








1H NMR (400 MHz, DMSO) δ 8.31 (d, J = 7.4 Hz, 1H), 7.40 – 7.28 (m, 12H), 
7.28 – 7.21 (m, 3H), 7.15 (d, J = 7.5 Hz, 1H), 6.10 (t, J = 6.3 Hz, 1H), 5.20 (d, J 
= 15.2 Hz, 1H), 5.05 – 4.96 (m, 1H), 4.27 – 4.15 (m, 1H), 4.09 – 3.96 (m, 1H), 
3.86 (q, J = 3.7 Hz, 1H), 3.66 – 3.50 (m, 2H), 3.28 (d, J = 9.5 Hz, 1H), 2.38 – 

































A, B or D
Et3N, DMF, 25 
oC, 6 h
4





13C NMR (101 MHz, DMSO) δ 171.68, 161.89, 154.31, 145.01, 144.29, 129.01, 





1H NMR (400 MHz, DMSO) δ 8.33 (d, J = 7.4 Hz, 1H), 7.84 (d, J = 7.0 Hz, 1H), 




4.15 (m, 1H), 3.86 (d, J = 3.5 Hz, 1H), 3.59 (qd, J = 11.9, 3.8 Hz, 2H), 2.86 – 
2.62 (m, 5H), 2.38 (m, 1H), 2.34 – 2.22 (m, 1H), 2.08 – 1.90 (m, 1H).   
 
13C NMR (101 MHz, DMSO) δ 172.01, 162.04, 154.30, 145.04, 95.25, 87.89, 
86.15, 69.89, 60.91, 40.86, 40.35, 18.90.   
 








1H NMR (400 MHz, DMSO) δ 8.67 (d, J = 14.0 Hz, 2H), 8.37 (d, J = 7.5 Hz, 1H), 
7.57 (d, J = 7.4 Hz, 2H), 7.46 – 7.36 (m, 5H), 7.31 – 7.21 (m, 2H), 7.18 (d, J = 
7.5 Hz, 1H), 6.29 (d, J = 14.2 Hz, 2H), 6.07 (t, J = 6.3 Hz, 1H), 4.27 – 4.10 (m, 
5H), 3.90 – 3.82 (m, 1H), 3.58 (qd, J = 12.0, 3.8 Hz, 1H), 3.06 (t, J = 6.4 Hz, 2H), 
2.76 (t, J = 6.2 Hz, 2H), 2.69 – 2.59 (m, 4H), 2.31 – 2.15 (m, 5H), 1.99 – 1.80 (m, 
3H), 1.78 – 1.35 (m, 28H), 1.27 – 1.18 (m, 1H).   
 
02251905a #5-84 RT: 0.01-0.11 AV: 80 NL: 2.23E8
T: FTMS + p ESI Full ms [50.0000-700.0000]
















































13C NMR (101 MHz, DMSO) δ 174.20, 171.74, 171.43, 161.93, 154.85, 154.09, 
145.18, 144.62, 142.13, 140.85, 133.01, 128.51, 124.79, 122.37, 111.18, 101.23, 
95.34, 87.99, 86.20, 69.92, 60.87, 48.75, 43.51, 40.89, 36.63, 33.51, 31.84, 
27.42, 26.60, 25.73, 25.68, 24.15, 20.40.   
 
Measured M+ (C54H68N5O9S
+) (m/z): 962.4721 Calculated M+: 962.4732 (1.1 




09121805a #833-989 RT: 1.06-1.25 AV: 157 SB: 144 0.25-0.43 NL: 1.99E6
T: FTMS + p ESI Full ms [450.0000-1100.0000]
























































1H NMR (400 MHz, DMSO) δ 9.73 – 9.54 (m, 1H), 8.89 – 8.67 (m, 4H), 8.23 (d, 
J = 7.9 Hz, 1H), 8.11 – 7.75 (m, 3H), 7.70 – 7.55 (m, 3H), 7.49 – 7.36 (m, 3H), 
7.25 (t, J = 7.3 Hz, 2H), 6.35 (d, J = 14.2 Hz, 1H), 6.16 (d, J = 7.9 Hz, 1H), 6.10 
– 5.98 (m, 1H), 4.29 – 4.13 (m, 4H), 3.85 (q, J = 3.4 Hz, 1H), 3.59 (dd, J = 9.5, 
3.6 Hz, 1H), 2.99 (t, J = 6.8 Hz, 1H), 2.70 – 2.62 (m, 4H), 2.60 – 2.51 (m, 6H), 
2.28 – 2.02 (m, 3H), 1.90 – 1.63 (m, 24H).   
 
13C NMR (101 MHz, DMSO) δ 172.22, 171.73, 159.23, 154.82, 147.59, 146.87, 
144.77, 144.41, 142.20, 140.90, 133.11, 128.51, 124.75, 122.34, 111.29, 101.39, 
99.49, 93.75, 88.05, 85.82, 69.74, 60.74, 50.71, 48.74, 43.57, 40.43, 34.48, 






+) 1006.3757 (m/z): Calculated M+: 1006.3759 





1H NMR (400 MHz, DMSO) δ 8.98 (d, J = 16.3 Hz, 1H), 8.74 – 8.66 (m, 2H), 
8.26 (d, J = 7.8 Hz, 1H), 7.73 – 7.66 (m, 1H), 7.60 (d, J = 7.4 Hz, 2H), 7.47 – 
7.37 (m, 4H), 7.29 – 7.22 (m, 1H), 6.39 – 6.27 (m, 1H), 6.23 (d, J = 7.8 Hz, 1H), 
03091901b #904-968 RT: 1.14-1.22 AV: 65 NL: 1.93E6
T: FTMS + p ESI Full ms [500.0000-1500.0000]
















































944.2439758.2200605.4426 654.3296 1044.3250 1117.4212
1233.4631968.3408




6.07 (dd, J = 13.7, 6.9 Hz, 1H), 4.29 – 4.12 (m, 5H), 3.85 (dd, J = 7.1, 3.5 Hz, 
1H), 3.59 (ddd, J = 21.8, 12.0, 3.7 Hz, 2H), 3.03 – 2.94 (m, 2H), 2.69 – 2.60 (m, 
3H), 2.58 – 2.51 (m, 2H), 2.31 – 2.09 (m, 2H), 2.08 (s, 2H), 1.89 – 1.72 (m, 8H), 
1.70 – 1.64 (m, 12H), 1.08 – 1.02 (m, 1H), 0.99 – 0.93 (m, 5H).   
 
13C NMR (101 MHz, DMSO) δ 172.18, 171.99, 159.55, 154.82, 147.33, 146.69, 
144.70, 142.30, 140.88, 132.94, 128.50, 124.80, 122.41, 111.28, 101.34, 93.69, 
88.07, 85.82, 69.70, 60.68, 52.61, 48.80, 44.97, 34.49, 32.35, 30.63, 27.45, 






+) (m/z): 818.4293 Calculated M+: 818.4310 (2.1 
ppm).   
 
 
Preparation of 5 
2.0 equiv. of 3-mercaptopropionic acid and 1.0 equiv. of heptamethine 
dye A were dissolved in DMF (0.1 M), followed by 3.0 equiv. of Et3N and stirred 
at 25 °C for 6 h. Solvent was removed in vacuum, and compound was purified 
via prepHPLC and lyophilized to get 5 (4.0 mg, 20% yield).   
02251903 #1133-1191 RT: 1.43-1.50 AV: 59 NL: 6.41E7
T: FTMS + p ESI Full ms [400.0000-1200.0000]



















































1H NMR (500 MHz, DMSO) δ 8.71 (d, J = 14.1 Hz, 2H), 7.60 (d, J = 7.3 Hz, 2H), 
7.45 – 7.38 (m, 4H), 7.29 – 7.23 (m, 2H), 6.30 (d, J = 14.2 Hz, 2H), 4.18 (t, J = 
7.2 Hz, 4H), 2.99 (t, J = 6.9 Hz, 2H), 2.64 (t, J = 5.9 Hz, 4H), 2.55 – 2.51 (m, 2H), 
2.24 – 2.13 (m, 4H), 1.88 – 1.80 (m, 2H), 1.77 – 1.71 (m, 4H), 1.70 (s, 12H), 










Et3N, DMF, 25 





13C NMR (126 MHz, DMSO) δ 174.29, 172.33, 171.86, 154.94, 144.75, 142.18, 
141.58, 140.92, 135.35, 132.99, 128.55, 124.84, 122.44, 111.21, 101.29, 48.80, 
43.50, 43.29, 33.52, 27.41, 26.64, 25.70, 24.18, 20.49.   
 
Measured M+ (C45H57N2O6S +) (m/z): 753.3922 Calculated M
+: 753.3932 (1.3 





03271908a #117-133 RT: 0.52-0.59 AV: 17 SB: 27 0.25-0.37 NL: 5.61E8
T: FTMS + p ESI Full ms [300.0000-900.0000]












































E.3. Compound properties in vitro 
E.3.1 Photo-physical Properties of Compounds 1 
Compounds 1 were solubilized as DMSO stock solutions before diluting 
to 1 μM in PBS buffer.  Absorbance and fluorescence spectrum of each 
compound were measured at the same concentration first (Figure E.1a). 
Absorbance spectrum was taken with Cary 100 Bio UV-Visible 
Spectrophotometer (absorbance region 500 – 900 nm, blank solvent as 
baseline), and fluorescence spectrum was taken by Cary Eclipse Fluorescence 
Spectrophotometer (excited with 750 nm light and emission region 780 – 900 nm, 
blank solvent as baseline).  Extinction coefficient (ε) of compounds 1 were 
calculated based on Lambert-Beer’s Law (Table E.1).   
 
Table Ε.1. Photo-physical properties of compounds 1a – d.   
 
ε(cm-1M-1) Ex/Em (nm) Φ(ex750) brightness 
1a 1.62 x 105 799/817 0.071 1.15 x 104 
1b 1.56 x 105 795/816 0.076 1.19 x 104 
1c 1.99 x 105 798/817 0.078 1.55 x 104 
1d 1.75 x 105 795/811 0.098 1.72 x 104 
 
Different concentrations of each compound were then prepared with A750 
lies in the range between 0.01 and 0.1 (X axis in Figure E.1b), and 
corresponding fluorescence spectrum was taken with area under curve 




of each compound was then calculated based on the equation shown in Figure 
E.1.236  Brightness of each conjugate equals ε ×  Φ.   
 
 
Figure Ε.1. Photo-physical properties of compounds 1a – d.  a UV-vis (solid 
lines) and fluorescence (dashed lines) spectrum of each compound. b plot of 
area of fluorescence curve vs. absorbance for calculation of fluorescence 
quantum yield of each compound, slope kx = 39389 (1a), 42405 (1b), 43045 (1c), 
54309 (1d). Indocyanine Green (ICG) was applied as standard, with Φs = 0.17.  
Φ𝑥 =  Φ𝑠  ×  
𝑘𝑥
𝑘𝑠




2   
 
E.3.2 Subcellular Localization of Conjugates 1 and free dyes A – D 
U87 cells were seeded in a 4-well imaging chamber (Thermo Scientific® 
#155383) as 10,000 per well, and incubated at 37 °C overnight.  20 μM of the 
test compound (conjugates 1 or free dyes A – D) were prepared in FluoroBrite 
DMEM medium (Thermo Scientific® #A1896701) and added to the imaging 
chamber after removing original culture medium and incubated at 37 °C for 45 
min.  Medium was removed and cells were washed with Hank's Balanced Salt 





LysoTracker (1:10,000 dilution, Invitrogen® #L5726) or MitoTracker (1:15,000 
dilution, Invitrogen® #M5714) for 15 min at 37 °C before HBSS wash.  0.5 mL 
FluoroBrite DMEM medium was then added to imaging chamber followed by 1 
drop of NucBlue Live Cell Stain ReadyProbes reagent (Invitrogen® #R37605).  5 
min after incubation, medium was removed and washed with HBSS buffer once, 




Figure E.2. Subcellular localization in U87 cells of compounds 1b – d.  PCC 
value between red (1) and green (organelle stain) fluorescence were shown as 
“mitochondria (Rm)” and “lysosomes (Rl)”.  a 1b was localized in both 




(0.40), but not mitochondria (0.17); c 1d was localized in both mitochondria 
(0.79) and lysosomes (0.73).   
 
 
Figure E.2. Continued.   
 
All images were taken by a confocal fluorescence microscope (Olympus® 
FV-1000) with 60X (water immerse, NA 1.20) objective, excitation laser applied: 
405 nm for nuclei stain, 488 nm for Lyso- or Mito-tracker, 633 nm for tested near 
infrared dye or conjugate in the Microscopy and Imaging Center at Texas A & M 
University.  Pearson’s correlation coefficient (PCC) was used to quantify 
colocalization of the tested fluorescent compound and stained organelle.237,238  
PCC for the region of interest in each set of image was calculated by the Coloc 2 








Figure E.3. Subcellular localization in U87 cells of compounds A – D.  a A was 
localized in both mitochondria (0.83) and lysosomes (0.53); b B was localized in 




mitochondria (0.75) and lysosomes (0.52); d D was localized in both 
mitochondria (0.69) and lysosomes (0.62).   
 
 
Figure E.3. Continued.   
 
E.3.3 Determination of Conjugate 1a Stability 
U87 cell lysate as well as tumor homogenate were prepared to check the 
conjugate 1a stability.  ~2 g of U87 tumor tissue from a mouse model was cut 
into small pieces and incubated with 2 mL RIPA buffer (Thermo Scientific® 
#89901) on ice for 15 min before blended.  Blended mixture was then 
centrifuged down and supernatant was taken out and filtered through a 0.2 μm 
mesh filter as the tumor homogenate.  To generate U87 cell lysate, U87 cells 
were cultured in a 75 cm2 tissue culture flask to 80% confluency.  After removing 
culture medium, cells were washed with 8 mL cold PBS buffer twice and then 
incubated with 1 mL RIPA buffer on ice for 25 min.  Mixtures were scratched and 




20 min) to collet supernatant as cell lysate.  1a was prepared as 50 μM in U87 
tumor homogenate or cell lysate and incubated at 37 °C, for up to 72 h. At 
designed incubation time, 5 μL samples were injected to analytical C4 HPLC 
column (0.50 mL/min flow rate, 5% MeCN / 95% water to 90% MeCN / 10% 
water gradient with 0.1% TFA in 15 min), and traces of absorbance at 780 nm 
were collected (Figure E.4).  Area under curves for 1a was normalized and 
plotted in GraphPad Prism® 6.0 software (Figure III.2).   
 
 
Figure Ε.4. Absorbance traces of conjugate 1a in different solutions on 
analytical HPLC.  a U87 tumor homogenate; b U87 cell lysate.   
 
Stability of 1a in mouse serum was also tested in the same way by 
solubilizing 1a in commercial mouse serum and checked traces of absorbance 
at 780 nm (Figure E.5a).  Conjugate 1a was metabolized generating a new 
compound with longer retention time.  When Protease and Phosphatase 





in serum), metabolism of 1a was inhibited; incubating 1a in serum at low 




Figure Ε.5. Conjugate stability of 1a in mouse serum.  a conjugate 1a was 
metabolized to a new compound in ~3 h (re-presentation of Figure III.2b); b 
protease and phosphatase inhibitor cocktail (10% in serum), and c low 










Figure Ε.6. Paper spray mass spectrometric and HPLC analysis of metabolic 
product of 1a in mouse serum.  a mass spectrum of compound 1a (calculated 
M+ = 998.45) as standard; b mass spectrum of 1a-metabolite in mouse serum, 
compound 5 (calculated M+ = 753.39) was possibly the key product;  c adding 
equivalent amount of compound 5 into 1a-metabolite in mouse serum resulted in 
an analytical HPLC trace with a single peak at higher intensity, which indicates 5 










E.3.4 In vitro Cytotoxicity Tests 
U87 cells were seeded on 96-well plates as 5000 cells/well (50 μL) and 
incubated in the incubator overnight.  Various concentrations of gemcitabine, its 
derivative F, conjugates 1, 2 as well as free heptamethine dyes A – D were 
prepared in 50 μL protein-free hybridoma medium (PFHM II) and added to cells 
to make final concentrations from 0.001 to 10 μM.  All plates were incubated for 
72 h, and cell viability was tested with AlamarBlue assay (Invitrogen).  Briefly, in 
a well containing 100 μL medium, 10 μL of AlamarBlue reagent was added, and 
incubated for 2 h.  Fluorescence intensity (Ex/Em 560/590 nm) was measured 
on a microplate reader (BioTek® Synergy H4).  Results are processed through 
GraphPad Prism® 6.0 software.  Cytotoxicity of dye D was also observed in 
other’s work.239   
 
 
Figure Ε.7. Compounds cytotoxicity comparison. a gemcitabine and its 






IC50 values of each compound are listed as:  gemcitabine, 8.2 ± 1.7; F, 
11.0 ± 1.4; 1a, 20.9 ± 5.0; 1b, 20.7 ± 3.2; D, 7.1 ± 1.7 nM; IC50 of 1d is 
ambiguous.   
 
E.4 In vivo Tumor Model Studies 
Ε.4.1 In vivo Imaging for conjugate localization 
Mice were anesthetized with isoflurane and then imaged for fluorescence 
or luminescence on an IVIS Spectrum (in vivo imaging system; Perkin Elmer®).  
For luminescence imaging, mice were subcutaneously injected with D-luciferin 
(15 mg/mL, Perkin Elmer® #122796) in μL at 10x the mouse weight.  During 
imaging mice remained anesthetized by isoflurane.  Fluorescence was 
measured by radiant efficiency and luminescence was measured by counts.  
Red Fluorescence Protein (RFP) from the U87 cells was captured at an 
excitation wavelength of 570 nm and an emission wavelength of 620 nm.  The 
near IR dye fluorescence was capture at an excitation wavelength of 745 nm 
and an emission wavelength of 840 nm.  Images were captured and data were 






Figure Ε.8. Fluorescence imaging of 1a can be detected up to 6 days after 
intravenous injection (before normalization).  a – e Fluorescence of 1a-injected 
mice after intravenous injection (mice 1 – 4) compared to an uninjected control 
(mouse C).  f Fluorescence of 1a-injected mice (mice 1 – 5).  Fluorescence is 
normalized to an uninjected control mouse (not shown).   
 
 
Figure Ε.9. 1a localizes to tumors.  a RFP signal from a GBM subcutaneous 
tumor 2 h post intravenous injection of 1a.  b RFP signal from GBM 
subcutaneous tumors 2 d after intravenous injection of gem, vehicle, or 1a.  c 
Fluorescence  of 1a in 3 different tumor-bearing mice 2 d after intravenous 
injection.  Compound 1a remained in the blood and localized to the intestines, 




































Figure E.9. Continued.   
 
Ε.4.2 In vivo therapeutic study 
Seven-week-old Foxn1 nu females were ordered from Jackson Lab.  
U87-RFP-LUC cells (5 x 105) were injected subcutaneously into the right flank of 
the mice.  Four days later (day 4) intravenous injections of the drugs and vehicle 
were administered through retro orbital injections.  The mice were injected again 
4 days later (day 8), and the injections were subsequently administered once 
weekly.  Compounds were administered at a concentration of 10 mg/kg for 5 
weeks.  Tumor growth was monitored by luminescence and fluorescence (RFP; 
570 – 620 nm) imaging and drug clearance/localization of 1a was monitored by 
the fluorescence imaging (745 – 840 nm).   
A cocktail vehicle (2% DMSO, 9% ethanol, 9% BSA in PBS buffer) was 
applied to solubilize 1a and gem for retro orbital injections.  Compound 1a was 










































(< 100 L) of each compound administered was calculated based on the body 
weight of each mouse to deliver 10 mg/kg dose.   
 
      
Figure Ε.10. Mouse weights show no significant reduction between treatments 
and control.  a Average of mouse weights in grams by treatment group over five 
weeks with SEM (n = 3).  Two-way ANOVA with Bonferroni posttest shows no 
statistically significant differences between groups.  b Average of mouse weights 
in grams by treatment group with SEM.  Points represent average mouse weight 
by week within a treatment group (n = 3).  Two-way ANOVA with Bonferroni 
posttest shows no statistically significant differences between groups.   
 
All animal experiments were performed under approved protocols in 
compliance with the guidelines established by the Institutional Animal Care and 
Use Committee (IACUC).   
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